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ABSTRACT 
 
 
Transcription Factor Specificity Protein 1 (Sp1) Regulates the Centrochromatin  
Landscape and Centromeric Transcription During Mitosis 
 
 
Aislinn Rebecca Sowash Molinari 
 
Jane Azizkhan-Clifford, Ph.D. 
 
 
 
 
Chromosomal instability (CIN) is a dynamic and continual gain or loss of whole 
chromosomes, or parts of chromosomes, during cell division. It is associated with poor 
patient outcome in multiple cancer types, as well as tumor heterogeneity and resistance 
to multiple chemotherapeutics, underscoring its clinical importance. Despite its 
prevalence and clinical significance, the exact mechanisms that lead to CIN remain to be 
determined. 
The transcription factor Specificity Protein 1 (Sp1) regulates the transcription of 
genes involved with many cellular processes, including differentiation, cell cycle 
progression, DNA repair, apoptosis, and senescence. Sp1 binds to specific GC-rich 
elements through its highly conserved carboxy-terminal zinc-finger, DNA-binding 
domain, and recruits various factors to chromatin to influence transcription. Our previous 
work shows that Sp1 is important for maintaining chromosomal stability during mitosis. 
We have shown that loss of Sp1 results in abnormal chromosome alignment along the 
metaphase plate, creation of micronuclei, and aneuploidy, as well as lagging 
chromosomes and anaphase bridges, all of which are phenotypes consistent with CIN. 
xiv 
 
We now show that Sp1 localizes and binds to centromeres during mitosis. Rapid 
localization is dependent on ATM (ataxia telangiectasia mutated) activity, and does not 
require the Sp1 DNA-binding domain. Loss of Sp1 results in disrupted centrochromatin, 
including changes in histone modifications and transcription of α-satellite arrays. Further, 
loss of Sp1 results in defects in centromeric cohesion, as well as a decrease in 
Centromeric Protein C (CENP-C) and Centromeric Protein A (CENP-A) binding at 
centromeres. These data suggest that Sp1 is an important factor for maintaining the 
structure, function, and identity of centromeres, thereby maintaining chromosomal 
stability.  
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Chapter 1: Whole Chromosomal Instability  
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Introduction 
A fundamental process important for the health and survival of an organism is the 
ability of the cells to accurately replicate their genome, and to pass a complete and intact 
copy of their genome on to daughter cells. There are several surveillance systems within 
the cell to ensure that this occurs with little genomic variation. DNA replication is 
monitored to ensure minimal errors during DNA synthesis, and the DNA damage 
response marks and repairs areas of damaged DNA. Additionally, the cell employs cell 
cycle checkpoints to respond to errors in DNA replication and/or DNA damage, and 
stalls the cell cycle to allow for repair. Finally, a checkpoint during mitosis ensures that 
chromosomes are divided evenly between the two daughter cells. When these governing 
mechanisms break down, a cell can acquire a variety of genomic abnormalities, 
collectively classified as genomic instability. The consequences of genomic instability 
can be devastating to the health of the organism, and can result in pathological disease, 
including cancer. 
Genomic instability is described as an increased tendency for the genome to 
acquire mutations [1], and is a characteristic of almost all human cancers [2, 3]. When all 
cellular surveillance systems are functioning, the frequency of normal genetic variation is 
extremely low, at 10-8 bases per generation [4]. However, an increased mutation 
frequency results when one or more of these mechanisms becomes dysfunctional [1]. 
Genomic instability provides a cell with the opportunity to acquire the “Hallmarks of 
Cancer” as described by Hanahan and Weinberg [5], a collection of characteristics that 
allows a normal cell to transform into a cancerous cell (Figure 1.1). The defective 
surveillance mechanism will dictate the type of mutation that results, and can include (a) 
changes on the nucleotide level, such as point mutations and microsatellite instability, 
(b) changes in chromosome structure, including gross chromosomal rearrangements 
and copy number variations, and (c) changes in the number of whole chromosomes in 
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the nucleus [6]. The latter two types of mutation are classified as chromosomal instability 
(CIN), including structural/segmental CIN (S-CIN) and numerical/whole CIN (W-CIN), 
respectively (Figure 1.2).  
We have previously shown that Specificity Protein 1 (Sp1, discussed in detail in 
Chapter 3) is required for maintaining chromosomal stability. In this study, depletion of 
Sp1 resulted in several phenotypes consistent with W-CIN, including the formation of 
micronucleated cells, mis-alignment of chromosomes along the metaphase plate, and 
aneuploidy [7]. Although this study identified supernumerary centrosomes and a multi-
polar mitotic spindle as a likely contributing factor to the generation of W-CIN in Sp1-
depleted cells, my work described in Chapters 4 and 5 suggests that Sp1 is also 
involved with maintaining centromere identity and function, which is the foundation upon 
which the mechanisms for preventing W-CIN are built. To bring these recent findings into 
context and to appreciate the importance of this function for Sp1, this chapter will focus 
on the significance of W-CIN, including a description of this phenomenon, its clinical 
relevance, current understanding of the mechanisms that may generate W-CIN in 
cancers, and its potential as an anti-cancer therapeutic target.        
 
What is Numerical/Whole CIN (W-CIN)? 
W-CIN is the dynamic and continual gain or loss of whole chromosomes at an 
elevated rate during cell division [8]. This continuous chromosome mis-segregation is a 
major cause for aneuploidy, defined as a deviation from an exact multiple of the normal 
haploid number of chromosomes in a cell [9]. Over 100 years ago, German zoologist 
Theodor Boveri discovered while studying sea urchin embryos that aneuploidy can have 
a detrimental effect on cell physiology, and proposed that abnormal chromosome 
content may promote cancer development [10]. Aneuploidy is now known to be a 
common characteristic of human cancers [11]. While W-CIN always results in 
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aneuploidy, it is important to note that W-CIN and aneuploidy are not synonymous. By 
definition, W-CIN is dynamic and continual. Therefore, a population of cells that has 
stably acquired or lost whole chromosomes can be aneuploid, but not necessarily 
chromosomally unstable. Examples of this include hyperdiploid acute lymphoblastic 
leukemia and near-triploid neuroblastoma, both of which have stable aneuploid 
karyotypes [12, 13].  
There are several different mechanisms that govern proper chromosome 
segregation during mitosis (discussed in detail below), and it is clear that when these 
mechanisms are experimentally disrupted, chromosomes can mis-segregate, resulting in 
W-CIN. Whether these mechanisms become defective and are a driving force for cancer 
development, or simply a consequence or side effect of cell transformation, remains a 
hotly debated topic. Some contest that W-CIN is an initiating event [14], with 
mathematical modeling in support of this theory [15]. The resulting karyotype from the 
initial event sets the stage for further W-CIN, generating an increasingly abnormal and 
eventually cancer-causing combination of chromosomes. Others believe that the 
expression of oncogenes and/or the loss of tumor suppressor genes are responsible for 
cell transformation, with W-CIN developing as a consequence [16]. It has been 
challenging to determine scientifically if W-CIN is an initiating event, in part because W-
CIN creates highly heterogeneous tumors, making identifying an original mis-segregated 
chromosome difficult. Further, tumors with W-CIN often have other chromosomal 
abnormalities, including S-CIN. In these cases, it is less likely assumed that W-CIN is 
responsible, as many specific S-CIN rearrangements have been directly implicated in 
malignancy. Large scale sequencing of cancer genomes has started to provide 
additional information as to what mutations are commonly associated with W-CIN. These 
studies have identified specific “CIN genes”. However, the question remains whether 
mutations or changes in expression levels of these CIN genes actually drive 
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tumorigenesis, or if these changes are simply a consequence. The gene products 
identified as being involved with CIN are summarized in Table 1.1 [36]. Thus, although 
W-CIN is a characteristic of almost all cancers, a consistent basis for how W-CIN 
develops in tumors is still not clear. Further, as discussed below, W-CIN is associated 
with poor patient prognosis. Therefore, there is much to be gained from elucidating the 
cause(s) for W-CIN, with great potential for therapeutic applications.        
 
Causes for Generation of W-CIN 
Within the W-CIN field, most researchers agree that there are four main 
mechanisms that govern proper chromosome segregation, and when these mechanisms 
are disrupted, chromosome mis-segregate, leading to W-CIN. These disruptions include 
centrosome amplification, sister chromatid cohesion defects, improper kinetochore-
microtubule attachment, and weakening of the mitotic checkpoint. The research 
presented in Chapters 4 and 5 identify Sp1 as an important factor for maintaining the 
architecture of centromeres (centromeres are discussed in detail in Chapter 2). Each of 
the mechanisms governing chromosome segregation relies heavily on active 
centromeres for function, suggesting that Sp1 may be a vital upstream factor for 
preventing chromosome mis-segregation and W-CIN. To bring our findings into context, 
this section summarizes each of the mechanisms that ensure faithful chromosome 
segregation, as well as how disruption of these mechanisms contributes to W-CIN.   
Centrosome Amplification:  
Centrosomes are the microtubule organizing centers (MTOC) of the cell. These 
organelles are composed of a pair of centrioles, surrounded by a matrix of hundreds of 
proteins called the pericentriolar material (PCM). The PCM consists of proteins that are 
important for many cellular processes, and include cell cycle regulators and signaling 
molecules, as well as proteins that are important for the nucleation, growth, and 
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organization of microtubules [17]. As the MTOC, centrosomes are central in 
orchestrating several cellular processes through the nucleation and anchoring of 
microtubules. These processes include cell motility, cell signaling, adhesion, protein 
trafficking, cell polarity, and the division of chromosomes during mitosis [18].   
When a cell enters mitosis, it should contain two centrosomes that migrate to 
opposite ends of the cell with the assistance of microtubule-anchored motor proteins, to 
create a bipolar mitotic spindle. At each pole, centrosomes nucleate a radial array of 
dynamic astral microtubules, which stochastically probe the cytoplasm with their plus 
ends in search of a kinetochore. Once the plus end of a microtubule comes into contact 
with a kinetochore, the microtubule is “captured” and stabilized [19]. Each chromosome 
must attach to microtubules emanating from both centrosomes, as these attachments 
create the tension necessary to align the chromosomes along the metaphase plate. 
Once all chromosomes are correctly attached and aligned, the spindle assembly 
checkpoint (SAC) is satisfied (reviewed in detail below), and sister chromatids are pulled 
in opposite directions (anaphase), towards the centrosomes at the poles of the cell. This 
is followed by cytokinesis, generating two daughter cells with symmetrically segregated 
chromosomes.   
The bipolarity of the mitotic spindle is necessary for ensuring that each daughter 
cell receives one of each pair of sister chromatids. Cancer cells frequently have more 
than two centrosomes, creating the potential for a multipolar spindle [20]. For example, 
nearly 80% of invasive breast tumor cells have an amplified number of centrosomes 
[20]. Additionally, centrosome amplification was shown to be a characteristic of 
pancreatic, prostate, colorectal, lung, and gall bladder cancers, among others [21-25]. A 
multipolar spindle created from more than two centrosomes during mitosis can result in 
the segregation of chromosomes into more than two daughter cells, generating severe 
aneuploidy in those cells. Studies have shown that such a severe aneuploidy produces 
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daughter cells that are inviable, and therefore do not pose a threat to the health of the 
organism [26]. In order to survive, cancer cells cluster their extra centrosomes into a 
pseudo-bipolar configuration, allowing for segregation into two viable daughter cells. 
However, this clustering process often creates improper kinetochore-microtubule 
attachments (reviewed in detail below), which promotes chromosome mis-segregation 
and W-CIN. As such, numerical centrosome amplification has emerged as an important 
mechanism for the generation of W-CIN.  
Upon the completion of cytokinesis, each daughter cell must receive one 
centrosome, and that centrosome must only duplicate once in the subsequent cell cycle. 
The centrosome duplication cycle consists of four stages, including disengagement in 
late mitosis and early G1, procentriolar formation in later G1 and S phases, elongation in 
later S and G2 phases, and finally disjunction or maturation as the cell enters mitosis 
[27].  
Disengagement:  
In early G1, the centrosome contains two centrioles, tightly orthogonally oriented 
to one another and attached by electron dense fibers [28]. Disengagement, the first 
stage of the duplication cycle, is the so-called licensing step, and describes the cleavage 
of the fibrous material connecting the two centrioles so that the distance between the 
centrioles increases. Some studies have suggested that the connecting material consists 
of sister-chromatid-cohesin (SCC) complexes, and that separase, the same protease 
that cleaves centromeric SCC molecules during anaphase, acts at the centrosome. 
Shockel, et al. showed that disengagement was suppressed by replacing endogenous 
Scc1 (cohesin subunit) with non-cleavable Scc1. Additionally, when a cleavage-inducible 
form of Scc1 was used, disengagement could be artificially triggered [29]. However, 
other experiments, including those in Drosophila, have challenged this theory, where 
centriolar disengagement could not be triggered by cleavage-inducible Rad21, the 
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Drosophila Scc1 ortholog [30].  More recently, additional separase targets involved with 
centriolar disengagement have been identified, including kendrin [31]. Thus, a complete 
understanding of the centriolar disengagement process is still lacking. Once centrioles 
have disengaged, they begin the process of duplication. 
Procentriolar formation:  
The recently disengaged centrioles are known as the “mother” centrioles. One 
new centriole (a procentriole or daughter centriole) begins to grow in an orthogonal 
angle at the proximal end of each licensed mother centriole, maintaining a tight ‘side-to-
base’ connection between the mother and daughter centriole [32]. The location of the 
daughter centriole in relation to the mother centriole is known as the origin, and once the 
origin is established, the cartwheel, a ninefold symmetric template structure inside of the 
proximal end of the daughter centriole, begins to form. Although how the origin is 
established is not fully understood, three proteins appear to play a vital role, and include 
PLK4, SAS-6, and STIL. These proteins localize to the origin in later G1 and S phases 
during the time of procentriole initiation. Although there is currently no direct link 
between PLK4 kinase activity and centriole initiation, it’s believed that PLK4 
phosphorylation of downstream proteins in centriole assembly initiates the assembly 
process [33].               
    Elongation: 
 Daughter centriole elongation begins during S phase, and centrioles reach ∼80% 
the length of the maternal centriole in late G2 [34]. Centrioles reach a maximum length of 
about 500 nanometers, and a width of about 200 nanometers through the addition of 
heterodimers consisting of α-tubulin and β-tubulin [35]. The mechanisms that control 
centriole elongation and length determination are still relatively unclear. In recent years, 
two proteins have been shown to be important regulators of elongation, including the 
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centriolar protein CPAP and the distal end-capping protein CP110. Overexpression of 
CPAP results in elongated centriolar structures, as does depletion of CP110 [36].     
Disjunction/Maturation and Movement: 
 During late G2 and early mitosis, the two sister centrosomes separate from each 
other in a process called disjunction or maturation, then migrate to opposite poles of the 
cell. During the process of centrosome duplication, two linker proteins, C-Nap1 and 
rootletin, join the centrosomes together. At the beginning of mitosis, these two proteins 
are phosphorylated by Nek2A kinase, displacing C-Nap1 and rootletin from 
centrosomes, a process necessary for their subsequent migration. Nek2A is regulated 
upstream by PLK1 [37]. Centrosomes are then pushed apart by the force of microtubule-
dependent motor proteins. This occurs at the very beginning of mitosis, simultaneously 
with nuclear envelope breakdown. One motor protein that appears to be essential for 
this process is the plus end directed motor Eg5 [38].  
 Causes for Centrosome Amplification: 
 Centrosome amplification can result from a variety of abnormalities, including 
cytokinesis failure, mitotic slippage, cell–cell fusion, overduplication of centrioles, and de 
novo centriole assembly. However, the major cause for centrosome amplification is 
disruption in the regulation of the duplication cycle. The duplication cycle is regulated at 
each of the different stages, with PLK4 as the “master regulator” of centrosome 
duplication. PLK4 plays a major role in procentriolar formation, and it is clear that the 
cellular levels of PLK4 must be tightly controlled to ensure proper centrosome number. 
When PLK4 is experimentally decreased, centrosome number decreases as well [39]. 
Likewise, when PLK4 is increased, centrosome numbers increase [40]. PLK4 regulation 
is achieved through several different mechanisms. First, the SCF/Slimb ubiquitin ligase 
binds to and facilitates the degradation of PLK4 to prevent unintended duplication. When 
this ubiquitin ligase is absent, PLK4 protein accumulates, and the resulting phenotype 
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includes an increase in daughter centrioles [41]. Further, PLK4 mRNA levels are 
negatively regulated by p53 through recruitment of HDAC (histone deacetylases) 
repressors to the PLK4 promoter [42]. In mouse cells, loss of p53 has been associated 
with an increase in centrosome number [43]. Increased levels of CP110, the distal end-
capping protein important for regulating centriole elongation, has also been shown to 
result in centrosome amplification [44]. Finally, over-expression of protein components of 
the PCM, the matrix of hundreds of proteins surrounding the centrioles, can also result in 
centrosome amplification. For example, over-expression of pericentrin results in 
centrosome amplification [45], as well as increased levels of γ-tubulin within the PCM 
[46].        
 Centrosome Amplification and Chromosomal Instability: 
 Centrosome amplification is frequently detected in W-CIN positive cancers, 
including breast, prostate, colon, ovarian, and pancreatic cancers [21, 47-49]. In addition 
to these solid tumors, centrosome amplification has been described in hematological 
malignancies, including multiple myeloma, non-Hodgkin's and Hodgkin's lymphomas, 
and acute and chronic myeloid leukemia  [50, 51]. Studies suggest that centrosome 
amplification may be a major player in the progression from early to advanced stages of 
carcinogenesis, as this phenotype has been characterized in both pre-neoplastic lesions 
and tissue that presents as histopathologically normal. One mechanism by which 
centrosome amplification may contribute to W-CIN is by increasing the frequency of 
merotelic attachments (discussed below) [52]. A recent review summarizes in great 
detail the existing clinical data for centrosome abnormalities and cancer (refer to 
reference [53]). 
Sister Chromatid Cohesion Defects: 
 During prometaphase, spindle microtubules probe the cytoplasm of the cell in 
search of kinetochores, which function to connect each set of sister chromatids to the 
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bipolar mitotic spindle. The sisters must connect to microtubules emanating from 
opposite poles of the cell, which serves two purposes. First, the tension created from the 
bipolar connections allows the sister chromatids to align along the metaphase plate. 
Second, when the mitotic checkpoint is satisfied and the cell proceeds into anaphase, 
the sister chromatids are pulled in opposite directions, ensuring faithful segregation. This 
mechanism of chromosome segregation critically depends on sister chromatids 
remaining physically connected to each other from the time of DNA replication, until the 
onset of anaphase. This is achieved by a complex of proteins called the sister-
chromatid-cohesin (SCC) complex. If sister chromatid cohesion fails, sister chromatids 
can separate prematurely, resulting in W-CIN.  
 Sister-Chromatid-Cohesin Complexes: 
 The somatic mammalian SCC complex consists of three main proteins that form 
a ring-like structure, including Smc1, Smc3, and Scc1. Smc1 and Smc3 are part of the 
structural maintenance of chromosome family (Smc), a family of proteins characterized 
by a distinct domain organization. Proteins in the Smc family contain a hinge domain, 
allowing for the proteins to fold back on themselves at this region, resulting in an anti-
parallel coiled-coil structure between the hinge domain, and the N- and C-termini of the 
proteins [54]. The N- and C-termini of the proteins come together to form an ATPase 
“head”. The hinge domains from Smc1 and Smc3 bind to each other, and the ATPase 
heads from each of these proteins bind the third component of the ring structure, Scc1 
[55]. When assembled, the outer diameter of the cohesin ring structure is approximately 
50 nanometers [56]. A fourth subunit of the SCC complex is the SA1 (stromalin antigen 
1) or SA2 protein, which associates with Scc1. Interestingly, complexes either contain 
SA1 or SA2, but never both [57]. It is predicted that in vertebrate somatic cells, there are 
three fold more complexes containing SA2 than complexes containing SA1, but the 
functional difference between these two associated proteins is not yet clear [58].  
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 Meiotic cells contain cohesin complexes that are distinct from those found in 
somatic cells. This is likely because during meiosis I, kinetochores on sister chromatids 
must attach to the same spindle pole for separation of homologous chromosomes, thus 
giving meiotic SCC complexes a slightly different function. These complexes consist of 
Smc1β in place of Smc1, Rec8 in place of Scc1, and STAG3 in place of SA1 or SA2 [59, 
60].           
 Loading and Establishment of Sister Chromatid Cohesion: 
 In most eukaryotes, SCC complexes are loaded onto DNA prior to DNA 
replication. Although it has been demonstrated that no specific DNA sequence is 
required for cohesin complex loading, the density of SCC complexes is highest around 
centromeres, as well as in regions called cohesin-associated regions (CARs). CARs 
span about 1 kilobase of DNA, and tend to be adenine and thymine rich [61, 62]. SCC 
complexes appear to be loaded onto DNA by the Scc2/Scc4 complex, as this complex is 
required for cohesin association with chromatin, and also requires the activity of the 
acetyltransferase Ctf7/Eco1, but much about how the complexes are loaded remains 
unclear [63]. This process likely involves transient opening of the Smc1 and Smc3 hinge, 
as tethering of these regions together abolishes loading [64]. 
 There are four main models for how SCC complexes associate with DNA and 
maintain cohesion between sisters, including the one-ring model, the two-ring model, the 
bracelet model, and the handcuff model. The one-ring model is most simple, and 
predicts that Smc1, Smc3, and Scc1 form a ring around DNA prior to DNA replication, 
and sister chromatid cohesion is established when the replication fork passes through 
the ring. This model is largely supported by the fact that it has been difficult to identify 
protein-protein interactions between cohesin complexes. However, the size of the ring is 
thought to be too small to accommodate two chromatids [65]. The two ring model 
suggests that each sister chromatid is bound by the Smc1-Smc3 heterodimer, and 
13 
 
cohesion is formed by a single Scc1 molecule during DNA replication [66]. The bracelet 
model is similar to the two ring model, with the added feature that Scc1 connects several 
SCC complexes together to form extended filaments [67]. Finally, in the handcuff model, 
each chromatid is embraced by a single SCC complex, and the Scc1 and SA1/2 proteins 
on the respective complexes bind in order to pair the sisters together [68].          
 Removal of Sister-Chromatid-Cohesin Complexes: 
 SCC complexes are removed from chromatin through two separate mechanisms. 
First, arm complexes are removed at the beginning of mitosis, during prophase. Here, 
the SA1/2 subunits are phosphorylated by kinases Plk1 (polo-like kinase 1) and Aurora 
B. This results in the destabilization of the complexes, and their subsequent removal. In 
cells containing SA1/2 that could not be phosphorylated, cohesin complexes failed to 
dissociate from chromosome arms [69]. Cohesin is maintained at centromeres until the 
mitotic checkpoint is satisfied. Once the mitotic checkpoint is satisfied, the protease 
separase is activated, and subsequently cleaves Scc1 to release centromere cohesion 
and allow sister chromatids to be pulled to opposite poles of the cell. Centromeric 
cohesion is protected from Plk1 and Aurora B-mediated dissociation through the 
activities of Sgo1 (Shugoshin 1) and PP2A (protein phosphatase 2A). Sgo1 is thought to 
recruit PP2A to centromeres, and together, these proteins function to continuously 
dephosphorylate SA1/2 at this specific region, protecting centromeric SCC complexes 
from dissociating prematurely [70].    
 Sister Chromatid Cohesion Defects and Chromosomal Instability:  
 Defects in sister chromatid cohesion resulting in precocious separation of sister 
chromatids has been described in a variety of diseases. For example, Smc1, Smc3 and 
SA1/2, as well as the cohesin loading complex component Scc2, have all been found to 
be mutated in colon cancers. In a 2008 study, DNA from 132 W-CIN positive colorectal 
tumors were sequenced and compared to matched normal DNA from the same patients 
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to eliminate the possibility of germ line polymorphisms. Results showed four tumors with 
mutations in Smc1, one tumor with mutated Smc3, one tumor with mutated SA2, and 
four tumors with mutated Scc2. To confirm their hypothesis that W-CIN likely resulted 
from reduced activity of the gene products that were found to be mutated, the authors 
used RNAi to decrease the expression of each protein in the W-CIN negative colorectal 
carcinoma cell line HTC 116, and subsequently analyzed cells for W-CIN by flow 
cytometry and evaluation of metaphase spreads. Flow cytometry results suggested a 
heterogeneous population of cells with extra chromosomes, and metaphase spread 
analysis confirmed these results [71]. In addition to colorectal cancers, an increased 
distance between the primary constriction site in Giemsa stained chromosome spreads, 
as well as aneuploidy, was observed in Wilms tumors in several infant patients, 
implicating sister chromatid cohesion defects [72-74]. In one of these studies, one 
patient also presented with rhabdomyosarcoma, a rare malignant tumor of striated 
muscle tissue, while two other patients also presented with acute leukemia [74]. Another 
study examined the relevance of cohesion defects and subsequent aneuploidy in 
lymphocyte cultures from individuals at high risk for familial breast cancer. This study 
found that a significant proportion of breast cancer patients, patients with benign breast 
lesions, and unaffected members from breast cancer families presented with cohesion 
defects and aneuploidy [75]. Premature separation of sister chromatids has also been 
described in Roberts syndrome [76], Fanconi Anemia, Ataxia Teleangiectasia [77], 
Alzheimer disease [78, 79], and Tuberous Sclerosis [80].  
Improper Kinetochore-Microtubule Attachment: 
 Live cell imaging has demonstrated that one of the most common causes of W-
CIN is the persistence of errors in the attachment of spindle microtubules to 
chromosomes [81]. In order for chromosomes to become bi-oriented on the metaphase 
plate, sister kinetochores must attach to microtubules emanating from opposite poles of 
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the cell. Further, the kinetochore on one sister chromatid must attach to microtubules 
originating from a single spindle pole. This type of correct attachment is called amphitelic 
[82]. Because the spindle microtubules probe the cytoplasm at random in search for 
kinetochore attachment sites, errors in the orientation of microtubule attachment can 
occur, particularly in the early stages of mitosis. One prominent error is when the 
kinetochore on a single chromosome attaches to microtubules from both spindle poles. 
This type of attachment error is called merotelic [82, 83], and has the potential to be the 
most devastating for maintaining genomic integrity for two reasons. First, merotelic 
attachments can fail to activate the spindle assembly checkpoint (SAC, discussed in 
more detail below), a signaling cascade employed by the cell to identify and remove 
improperly attached microtubules. Rather, studies show that cells possessing merotelic 
attachments proceed into anaphase without significant delay [84, 85]. As such, this type 
of mal-attachment is the most likely defect to escape detection and persist into 
anaphase. Further, this type of attachment, if not corrected, will pull chromosomes 
towards both poles of the cell during anaphase, resulting in lagging chromosomes and 
anaphase bridges. Then, the cleavage furrow can push that lagging chromosome into 
either daughter cell, resulting in chromosome mis-segregation in 50% of cases, thus 
contributing to W-CIN [86]. Other types of incorrect microtubule attachments include 
monotelic and syntelic attachments. Monotelic describes when one sister kinetochore is 
attached to one spindle pole and the other sister kinetochore remains unattached, while 
syntelic describes when both sister kinetochores are attached to microtubules from the 
same spindle pole [82]. A monoletic attachment will activate the SAC, which will delay 
mitotic progression so that the error can be corrected. Syntelic attachments are likely to 
be destabilized by the Chromosomal Passenger Complex (CPC, discussed below), 
which in turn also activates the SAC.    
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 Aurora B Kinase and the Chromosomal Passenger Complex for Attachment 
Correction: 
 The CPC is a complex of proteins consisting of Aurora B kinase, INCENP (inner 
centromere protein), Borealin, and Survivin, and is thought to have multiple roles during 
mitosis. During early stages of mitosis, the CPC localizes to chromosome arms and 
centromeres, as Aurora B kinase together with Plk1 phosphorylates arm SCC 
complexes to allow for their dissociation from chromosomes. As the cell progresses into 
metaphase, localization is restricted to centromeres, where the CPC is thought to assist 
in recruiting other centromere-associated proteins (such as SAC proteins [87] the Sgo1 
[88]), and to assist in destabilizing incorrectly attached microtubules. 
 Studies have shown that when CPC function is compromised, a cell fails to 
detach incorrectly attached microtubules, resulting in an increased persistence of 
merotelic and syntelic attachments. For example, in Saccharomyces cerevisiae, both 
Ipl1 and Sli15 mutant strains (the Aurora kinase and INCENP orthologs, respectively) 
showed an increase in syntelic attachments as compared to control strains [89]. Further, 
in Ptk1 cells (female rat kangaroo kidney epithelial cells), partial Aurora kinase inhibition 
using the specific inhibitor ZM447439 increased the frequency of merotelic kinetochores 
in late metaphase. In this study, immunofluorescence analysis showed that treatment 
with the Aurora kinase inhibitor suppressed kinetochore-microtubule turnover in 
prometaphase [90]. By slowly removing reversible small-molecule Aurora B kinase 
inhibitors to carefully control Aurora B kinase activation in Ptk2 cells (male rat kangaroo 
kidney epithelial cells), another group confirmed that upon Aurora B activation, mal-
oriented microtubules were selectively disassembled [91]. As such, the CPC is most 
abundant at kinetochores in early stages of mitosis when incorrect attachments are likely 
to occur, and becomes enriched at kinetochores showing merotelic and syntelic 
attachments [92]. 
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 How a cell detects improper microtubule attachment, and how Aurora B kinase 
destabilizes those incorrect attachments is not completely understood. The most widely 
accepted model proposes that the physical distance between Aurora B kinase and its 
substrate determines whether the microtubule connections are maintained. The Ndc80 
complex, a component of the outer kinetochore KMN Network and a major attachment 
module for microtubules, is a target substrate for Aurora B kinase for this process. 
Ndc80 phosphorylation by Aurora B kinase decreases its ability to bind microtubules. 
When a kinetochore makes an attachment to a microtubule emanating from the correct 
spindle pole, tension is created across the kinetochore complex, much like a spring that 
is being stretched. Because Aurora B kinase is located at centromeres, the tension 
created by a correct attachment pulls the Ndc80 complex away from centromeres, and 
out of the kinase’s reach. Thus, Aurora B kinase is not able to phosphorylate the Ndc80 
complex, and correct microtubule attachments are stabilized. However, when a 
kinetochore makes an attachment to a microtubule from the opposite spindle pole, the 
kinetochore “spring” is not stretched, and this lack of tension places the Ndc80 complex 
within the reach of Aurora B kinase, resulting in Aurora B kinase-dependent 
phosphorylation and microtubule destabilization [82]. This theory is supported by studies 
showing that in mammalian cells, a difference of about 1 to 3 micrometers is observed 
between a kinetochore that is under tension as compared to a kinetochore in a relaxed 
state [93]. The CPC is about 45 nanometers in length, allowing for the possibility that 
tension can physically separate the CPC and Ndc80 [94].                    
 Improper Kinetochore-Microtubule Attachment and Chromosomal Instability: 
 Centrosome amplification, discussed above, can cause increased incidences of 
merotelic attachments and a resulting increase in lagging chromosomes and 
subsequently W-CIN [52]. However, in some cancers, lagging chromosomes occur in a 
larger percentage of cells than does centrosome amplification, suggesting that 
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centrosome amplification isn’t the only cause for merotelic attachments. For example, in 
oral cancer cells, 5.5–23% exhibit multipolar spindles from centrosome amplification, but 
lagging chromosomes occur in as many as 20-40% of cells [95, 96]. Further, 8% of the 
human breast cancer cell line MX-1 contained anaphase bridges with no evidence of 
centrosome amplification [97]. In a panel of W-CIN positive cancer cell lines, one study 
examined the stability of kinetochore-microtubule attachments, and found that the 
attachments are significantly more stable in the W-CIN positive cancer cell lines as 
compared to non-transformed control cells. Because merotelic attachments do not 
significantly delay anaphase onset, an increase in kinetochore-microtubule attachment 
stability results in reduced correction efficiency. As such, this increased stability 
correlated with elevated frequencies of lagging chromosomes in anaphase [98]. This 
same group also showed that over-expressing proteins required for kinetochore-
microtubule detachment could decrease the incidence of merotelic attachments in W-
CIN positive cancer cells, regardless of the upstream cause for the mal-attachments. In 
this study, they over-expressed the microtubule-depolymerizing kinesins Kif2b and 
MCAK, and then tested the impact of over-expression on chromosome segregation and 
W-CIN. They found that over-expression of either kinesin significantly suppressed the 
incidence of lagging chromosomes in two W-CIN positive cancer cells lines, U2OS and 
MCF-7 cell. Using fluorescence in situ hybridization (FISH) with chromosome-specific 
AS DNA probes, they also quantified chromosome mis-segregation events in cells over-
expressing Kif2b and MCAK, and found that mis-segregation events were significantly 
reduced in over-expressing cells as compared to controls [99].   
Weakening of the Spindle Assembly Checkpoint:           
 The spindle assembly checkpoint (SAC), also known as the mitotic or metaphase 
checkpoint, functions to prevent mitotic cells from transitioning from metaphase to 
anaphase with kinetochores that lack microtubule attachment, or have incorrectly 
19 
 
attached microtubules. If a kinetochore is unattached or improperly attached, the SAC 
halts progression and thus safeguards the cell against chromosome mis-segregation 
and W-CIN by inhibiting the APC/C (anaphase promoting complex/cyclosome). The 
APC/C is an E3 ubiquitin ligase that drives centromeric SCC complex cleavage and thus 
mitotic exit though two mechanisms. First, it polyubiquitinates and targets the protein 
securin for proteasomal degradation by the 26S proteasome. Securin binds to and 
inhibits separase, the protease that cleaves SCC complexes at centromeres. 
Additionally, the APC/C also polyubiquitinates and targets cyclin B for degradation, and 
the resulting drop in cyclin B levels inactivates CDK1, driving mitotic exit. The SAC 
inhibits the APC/C by binding to the APC/C coactivator protein Cdc20, blocking the 
Cdc20 substrate binding sites, thereby repositioning Cdc20 away from the APC/C thus 
blocking its activation [100]. As long as the SAC is active, the ACP/C remains inactive, 
SCC complexes remain intact, and cyclin B levels remain elevated, collectively 
preventing mitotic exit. The complex of proteins that functions to inhibit the APC/C is 
known as the mitotic checkpoint complex (MCC).  
The Mitotic Checkpoint Complex:  
 The MCC is a complex of proteins consisting of Mad2, the kinase BubR1, and 
Bub3, as well as Cdc20, all of which are present at unattached kinetochores during 
mitosis. Whether these proteins exist as a complex at kinetochores, as they do in the 
cytosol, or are associated independently of each other remains unclear. The MCC 
proteins are recruited to unattached kinetochores through Aurora B and Msp1 kinase 
signaling, and bind to Cdc20 to prevent ACP/C activation. Models for how the MCC is 
recruited to unattached kinetochores are complex, and the mechanism by which the 
MCC activates the SAC is still slightly controversial. As mentioned previously, Aurora B 
kinase localizes to centromeres as a component of the CPC to facilitate the release of 
mal-attached microtubules by phosphorylating the KMN Network component Ndc80. 
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Aurora B kinase activity is also required for recruitment of Mps1 kinase to kinetochores. 
Once at kinetochores, Mps1 kinase phosphorylates the KMN Network component Knl1 
at several Met-Glu-Leu-Thr (MELT) motifs, which creates a docking site for recruitment 
of additional SAC proteins [101, 102]. Bub1 kinase and its binding partner Bub3 
(Bub1:Bub3 complex) recognize and bind to phosphorylated Knl1, which is followed by 
recruitment and binding of the BubR1:Bub3 complex. Interestingly, both Bub1 and 
BubR1 bind to Bub3 through the same Bub3-binding or GLEBS domain. This is followed 
by Bub1-dependent recruitment of the Mad1:C-Mad2 complex, which catalyzes the 
formation of the Cdc20:C-Mad2 complex, thereby inhibiting Cdc20 [103].    
Mad2 adopts two different conformational states. O-Mad2, or “open”-Mad2, is the 
unbound, cytosolic open conformation of the protein. When Mad2 binds to Mad1 or 
Cdc20, two β-sheets move across the face of the protein to create the closed 
conformation (C-Mad2), with Mad1 or Cdc20 trapped within this fold. This creates either 
the Mad1:C-Mad2 complex or the Cdc20:C-Mad2 complex [103]. The process of binding 
to and inhibiting Cdc20 begins with the Bub1-dependent recruitment of a Mad1:C-Mad2 
complex to kinetochores. Mad2 is able to dimerize, and as such, kinetochore-bound 
Mad1:C-Mad2 recruits more O-Mad2 to kinetochores. When O-Mad2 dimerizes with the 
Mad1:C-Mad2 complex, it is able to capture Cdc20, at which point it converts to C-Mad2 
and subsequently forms the Cdc20:C-Mad2 complex [104-106]. Cdc20:C-Mad2 then 
recruits more O-Mad2, and catalyzes the formation of more Cdc20:C-Mad2 complexes, 
thereby amplifying the SAC signal [107].  
 Silencing the SAC: 
 As long as O-Mad2 is being recruited to kinetochores, the SAC signal will be 
maintained. As such, loss of Mad1:C-Mad2 from kinetochores halts Mad2 conversion 
and thus MCC formation, thereby extinguishing the checkpoint signal [104]. Two 
mechanisms contribute to dissociation of Mad1:C-Mad2 from kinetochores. The first is 
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mediated by dynein, a minus-end directed motor protein. Dynein localizes to 
kinetochores, and when microtubules make attachments, dynein is able to strip Mad1:C-
Mad2 from kinetochores by walking the complex towards the spindle poles. BubR1 is 
also removed by this mechanism [108, 109]. Interestingly, dynein does not localize to 
kinetochores in all eukaryotes, suggesting alternative mechanisms for SAC silencing 
[110]. It is attractive to suggest that microtubule binding alone displaces the Mad1:C-
Mad2 complex. However, Mad1 can be recruited to attached kinetochores by Mps1 
targeting, arguing against this hypothesis [111]. The second mechanism that contributes 
to the dissociation of Mad1:C-Mad2 from kinetochores is the most widely conserved, and 
involves the dephosphorylation of checkpoint proteins by PP1 (protein phosphatase 1) 
[112]. PP1 associates with kinetochores through Knl1, and preventing this interaction 
results in sustained checkpoint signaling [113]. PP1 functions to remove the Bub1:Bub3 
complex, and as a result Mad1:C-Mad2 [102].  
 Weakening of the SAC and Chromosomal Instability: 
 Complete loss of the SAC causes massive chromosome mis-segregation and 
cell death. However, weakening of the checkpoint can result in the mis-segregation of a 
few chromosome, and thus W-CIN. Many studies have been carried out to establish a 
causal relationship between mutations in genes encoding SAC proteins, and W-CIN. For 
example, several studies have linked mutations in the BubR1 gene to mosaic variegated 
aneuploidy, a condition that is characterized by a strong predisposition to cancer [114-
117]. One study identified mutations in the Bub1 and BubR1 genes in a panel of 19 
aneuploid colorectal cancer cell lines [118], and in a screen of 49 W-CIN positive gastric 
cancer tissues and five gastric cancer cell lines, another study found that the Mad2 gene 
was mutated in 44.9% of the gastric tissues, as well as in one of the cell lines. Here, 
over-expression of mutated Mad2 in HeLa cells resulted in chromosome mis-
segregation, implicating Mad2 in W-CIN development [119]. Further, a study 
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demonstrated that deletion of one Mad2 allele resulted in W-CIN in the human colon 
carcinoma cell line Hct-116 [120]. Despite these findings, many other attempts have 
failed to identify mutations in SAC proteins. For example, very few mutations were 
identified in Bub3, BubR1 and Bub1 genes in glioblastoma, breast, lung, bladder and 
thyroid cancers [121, 122]. Bub1 gene mutations are also rare in hematological cancers, 
head and neck cancers, and renal tumors [123-125]. Rather than gene mutation, what 
appears to be more common in cells with impaired SAC activity is over-expression of 
SAC proteins. For example, in 181 gastric cancer samples examined, 50.3% showed 
BubR1 over-expression, which correlated with aneuploidy, tumor invasiveness, 
metastasis likelihood and poor prognosis [126]. It was also found to be associated with 
W-CIN in bladder cancer and clear cell kidney carcinomas [127, 128]. Similarly, Bub1 
over-expression was found in breast tumor samples, salivary gland tumors, and gastric 
cancers [129-131]. Mad2 over-expression has been found in a number of cancers, 
including Familial Adenomatous Polyposis colorectal adenomas, advanced differentiated 
thyroid carcinomas, salivary duct carcinomas, and lung cancers [132-135].  
 
Clinical Significance of W-CIN 
Not only is W-CIN a characteristic of almost all cancers, it is also associated with 
poor patient prognosis [8], and thus has clinical relevance. The negative association 
between W-CIN and patient prognosis is likely driven by the tumor hererogeneity that 
results from W-CIN. This heterogeneity provides tumor cells with the opportunity to 
adapt to environmental stresses like chemotherapeutics, and thus may facilitate multi-
drug resistance, making treatment challenging. For these reasons, identifying the 
molecular mechanisms that most consistently generate W-CIN in cancers is paramount. 
Once identified, this information may be exploited, and W-CIN can be used as a target 
for anti-cancer therapuetics. To highlight the importance of studying W-CIN with the goal 
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of identifying ways to exploit this common characteristic, this section focuses on the 
functional and clinical consequences of W-CIN, as well as current methods for 
diagnosing W-CIN in clinical settings, and how W-CIN may be utilized for anti-cancer 
therapeutics.       
Functional Consequences of W-CIN: 
 The loss or gain of a whole chromosome can have profound effects on the 
genome of a cell, and can contribute to tumorigenesis through changes in gene dosage, 
including loss of heterozygosity (LOH) of tumor suppressor genes and/or amplification of 
oncogenes. Further, W-CIN results in tumor heterogeneity, which provides the tumor 
with the opportunity to adapt to environmental pressures such as chemotherapeutics, 
facilitating drug resistance. 
The two-hit hypothesis, which was developed from studies of retinoblastoma in 
children [136], proposed that two “hits” to the retinoblastoma gene were required for 
cancer development. For the inherited form of this cancer, the first hit is a mutation in 
one of the two alleles in the germ line, and the second hit emerges in the other allele 
sometime during somatic cell division. For the sporadic form of retinoblastoma, 
mutations in both alleles arise during somatic cell division [15]. Tumor suppressor genes 
negatively regulate cell growth, thereby preventing uncontrolled proliferation. Inactivation 
of the first allele of a tumor suppressor gene often does not change the phenotype of the 
cell, whereas inactivation of the second allele can confer a growth advantage, 
contributing to tumorigenesis. LOH of tumor suppressor genes, defined as the loss of an 
entire gene and the surrounding region, can occur if the chromosome mis-segregation 
event results in the loss of a chromosome containing these genes. Thus, one functional 
consequence of W-CIN is an elevated rate of LOH, or the first hit of the two-hit 
hypothesis, which accelerates the potential for tumor suppressor gene inactivation [15]. 
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 Gaining a whole chromosome during chromosome mis-segregation can also 
result in increased expression of genes that promote tumorigenesis, or amplification of 
oncogenes. One example of this is in certain breast and ovarian cancers. Here, 
chromosome mis-segregation events can result in the loss of the heterochromatic X 
chromosome and a subsequent gain of the active X chromosome. The X chromosome 
contains both tumor suppressor and cancer-promoting genes, and studies have reported 
over-expression of these cancer-promoting genes in tumors, including BRCA1-
associated ovarian tumors [137-139]. Further, in another study, a significant proportion 
of sporadic basal-like tumors and BRCA1 null tumors showed a complete loss of the 
heterochromatic X chromosome and the gain of several active X chromosomes, 
accompanied by the overexpression of a small, distinct subset of X-linked genes, 
suggesting that dysregulated X chromosomal genes contribute to tumor development 
[140]. Thus, gaining whole chromosomes through W-CIN can amplify the expression of 
tumor-promoting or oncogenes, thereby contributing to tumorigenesis.  
 In addition to promoting tumorigenesis through LOH and/or gene amplification, 
W-CIN also provides tumors with the opportunity to adapt to environmental stresses, 
including chemotherapeutics, allowing for the possibility of drug resistance and 
subsequently cancer reoccurrence. Several studies have confirmed this phenomenon. 
For example, one study treated a panel of 18 W-CIN positive and 9 W-CIN negative 
colorectal cancer cell lines with a small molecule library of 160 kinase inhibitors, and 
found that the W-CIN positive cell lines were significantly more resistant to the inhibitors 
[141]. Additionally, another study showed that in the OV01 ovarian cancer clinical trial, a 
high level of W-CIN was associated with taxane resistance [142]. In a study where 
puromycin resistant subclones were isolated from three human colon and breast cancer 
cell lines (MDA 231, SW 480, and HT 29 cell lines), a comparison of the karyotype of the 
subclones to the parental line showed that the drug-resistant subclones differed from the 
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parental line by six chromosomal alterations, whereas the average random subclone 
differed from the parental line by only 0.45 chromosomal alterations [143], suggesting 
that W-CIN was responsible for the development of drug resistance. Finally, in 
untransformed human mammary epithelial cells, cells surviving paclitaxel treatment 
showed higher basal and paclitaxel-induced chromosome mis-segregation as compared 
to controls, indicating that paclitaxel resistance is related to increased W-CIN in these 
cells [144]. Taken together, W-CIN has several functional consequences, including 
initiating changes in gene dosage, that likely contribute to tumorigenesis, as well as have 
a negative impact on patient outcome through the facilitation of chemotherapeutic 
resistance.    
Clinical Consequences: 
 Table 1.2 summarizes the clinical outcome of several W-CIN positive cancers. 
The most thoroughly studied cancers include lung cancer, colon cancer, and breast 
cancer.  
 In a study analyzing the prognostic importance of W-CIN in adenocarcinoma of 
the lung, 39.7% of the specimens studied were W-CIN positive, and the overall disease-
free 5 year survival rate was 46.9% for W-CIN positive patients as compared to 71.0% 
for W-CIN negative patients. The difference in the 5 year overall survival rate was even 
more striking, at only 68.7% for W-CIN positive patients as compared to 93.5% for W-
CIN negative patients [145]. Several other studies have also correlated W-CIN with 
additional poor prognostic factors, like metastasis [146-148]. 
 W-CIN is present in about 65-70% of colorectal cancers, and in a meta-analysis 
aimed at estimating the prognostic significance of W-CIN, the authors found that W-CIN 
is associated with poorer prognosis in terms of overall survival and progression-free 
survival, and could actually stratify colorectal cancer patients further after standard 
pathological staging. This study used both flow cytometry and image cytometry to 
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quantify aneuploidy status as a measure for W-CIN, and found that poorer survival was 
consistent, regardless of the patients’ ethnic background, location, or whether or not the 
patient received an adjuvant treatment [148]. 
 In breast cancer, quantification of W-CIN by a variety of techniques, including 
FISH, flow and image cytometry, similarly correlated with poor patient prognosis. In one 
study, W-CIN and prognostic factors were analyzed using 31 breast cancers and 5 
benign breast lesions, and W-CIN was significantly higher in the breast cancers as 
compared to the benign lesions. Further, W-CIN showed a significant correlation with 
lymph node metastasis, as well as estrogen receptor negativity, suggesting that W-CIN 
status may be useful for predicting the aggressiveness of breast cancers [149]. In 
another study that used three independent measures for W-CIN, increased W-CIN was 
also correlated with poor prognosis in estrogen receptor positive breast cancers [150].  
Clinical Diagnosis of W-CIN: 
Studies in colon cancer demonstrated that W-CIN is capable of predicting 
whether or not a patient would relapse, independently of the information gained from the 
stage of the tumor [151]. This indicates that measuring W-CIN status in the clinic could 
provide valuable prognostic information. However, the methods used to measure W-CIN 
are inconsistent, sometimes technically difficult, and overall fall short of truly measuring 
chromosome mis-segregation events. A true measure of W-CIN involves evaluating 
chromosome mis-segregation by determining cell-to-cell variability in chromosome 
number, as well as assessing the rate at which chromosomes are gained and lost. 
Currently, determination of W-CIN is based upon only one component of the 
phenomenon, such as aneuploidy status or tumor heterogeneity status, from which W-
CIN is inferred. Evaluating tumors for a change in chromosome number as well as for 
the rate at which that change occurs is often neither time nor cost effective. Measuring 
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only one aspect of W-CIN, however, has the potential to mask a more complex 
relationship between W-CIN and patient prognosis [8].    
One method used for evaluating both changes in chromosome number as well as 
the rate at which that change occurs is by fixing tumor cells during anaphase, and 
evaluating each cell for evidence of chromosome mis-segregation, thereby capturing the 
dynamic nature of W-CIN. Experimental evidence shows that the most common 
indicators of chromosome mis-segregation are lagging chromosome and chromatin 
bridges [52]. This method has been used to assess the specific contribution of W-CIN to 
the prognosis of patients with diffuse large B-cell lymphoma (DLBCL). Here, 54 samples 
from cases of de novo DLBCL were formalin-fixed, paraffin-embedded, and stained with 
hematoxylin and eosin, and all anaphase cells were scored for evidence of chromosome 
mis-segregation. Further, radiologic imaging and bone marrow biopsy were used to 
score patients based on overall survival, progression-free survival, and requirement for 
treatment. Using these methods, they found that a two-fold increase in the frequency of 
chromosome mis-segregation led to a 24% decrease in overall survival and 48% 
decrease in relapse-free survival after treatment, concluding that increased rates of 
chromosome mis-segregation in DLBCL correlate with inferior outcome and poor patient 
prognosis [152]. This method for evaluating W-CIN is useful in cancers with a high 
mitotic index; however, this method may be challenging for slower growing tumors in 
which isolating and scoring anaphase-stage cells may be difficult.  
Fluorescence in situ hybridization (FISH) is a common method for assessing W-
CIN status in tumors. This method uses fluorescently labeled DNA probes to quantify 
variations in chromosome copy number per cell, and can assess the chromosomal state 
of hundreds of cells at a time, but does not allow for evaluation of the rate of 
chromosome mis-segregation. This method has proven effective for analysis of W-CIN in 
lung cancer [145-147], breast cancer [149], and oral squamous cell carcinomas [153], 
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among others. However, this method has some limitations, including that tumors must 
be fixed, sectioned, and stained for evaluation. Thus, FISH is labor intensive, and 
therefore has limited clinical potential.  
Another commonly used method for assessing W-CIN is flow cytometry. Here, 
cells must be labeled with a fluorochrome that is expected to stain DNA 
stoichiometrically, and cellular DNA content is reported using a laser-based electronic 
detection apparatus. This method can rapidly and accurately estimate the DNA content 
of single cells that are part of a larger population of cells, such as a tumor. The W-CIN 
status can be determined from both the aneuploidy status and heterogeneity of the 
population evaluated. Once again, this method is limited by the fact that it does not 
measure the rate of change of chromosome content [154]. A method similar to flow 
cytometery is DNA image cytometry, whereby cells are stained with a fluorochrome and 
evaluated by microscopy for increased DNA content. Like FISH, this method is labor 
intensive and thus has limited clinical potential.  
More recently, a technique called comparative genomic hybridization (CGH) has 
been used, and allows for the detection of genomic variations as small as 5 to 10 
megabases in individual cells as compared to control cells. Here, the DNA content of an 
individual sample cell and a control cell must be amplified, labeled with fluorophores of 
different colors, denatured, then hybridized at a one-to-one ratio to a metaphase spread 
originating from the same material as the control cell. The DNA samples will bind to the 
location from which they originated. Areas that show a higher intensity for the sample 
DNA indicate a gain of material in the sample at that region, and vice versa [155]. 
Numerical chromosomal aberrations can be quantified, and heterogeneity can be 
determined by comparing CGH results from multiple cells. However, this method is 
expensive, time consuming, and cannot be easily used for high-throughput analysis. 
Taken together, there are several methods currently available for assessing W-CIN 
29 
 
status in the clinic, each with its own set of limitations. Developing a consistent, accurate 
diagnostic method for determining the W-CIN status of patient tumors that is both 
practical and economical has the potential to contribute valuable information to predicted 
patient outcomes.                      
Exploitation of W-CIN for Anti-Cancer Therapies: 
 The low level of chromosome mis-segregation that is characteristic of W-CIN 
positive cancer cells is advantageous for continued proliferation and survival. However, 
severe aneuploidy is often not tolerated, and results in cell death. This opens up a 
therapeutic window, whereby the level of W-CIN in W-CIN positive cancer cells could be 
increased to a level that would force the cells into apoptosis. One potential therapeutic 
target that acts through this mechanism is the minus end-directed kinesin HSET. HSET 
is a kinesin-14 family member, and in normal cells is required for bundling microtubules 
[156]. In cells containing supernumerary centrosomes, HSET is required for centrosome 
clustering [157]. Studies show that depleting HSET from non-transformed cells by RNAi 
has no effect, but depleting HSET from cancer cells containing extra centrosomes 
prevents the cell from clustering these centrosomes, causing multi-polar cell division and 
subsequently cell death. For example, in the W-CIN positive mouse neuroblastoma cell 
line N1E-115, depletion of HSET increased multi-polar mitotic spindles by 88%, and 
reduced cell viability by greater than 90%. Similarly, in the human breast cancer cell line 
MDA-231, depletion of HSET increased multi-polar spindles by 45% and reduced cell 
viability by approximately 50%. In cancer cells that do not harbor supernumerary 
centrosomes, the effect of HSET depletion was insignificant [157]. Thus, HSET is a 
promising therapeutic target for W-CIN positive cancers containing supernumerary 
centrosomes. 
 Another study demonstrated that reducing the levels of checkpoint proteins 
BubR1 and Mps1 greatly increased cancer cell sensitivity to the chemotherapeutic 
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Taxol. Taxol acts by stabilizing microtubules, preventing them from disassembling. This 
prevents spindle formation during mitosis and activates the mitotic checkpoint, and 
prolonged activation of the mitotic checkpoint results in apoptosis. In two W-CIN positive 
cancer cells lines (U2OS cells and HeLa cells), partial, independent depletion of mitotic 
checkpoint proteins BubR1 and Mps1 had no significant effect on cell viability. Similarly, 
Taxol treatment alone had only marginal effects on cell viability. However, partial 
depletion of either BubR1 or Mps1 in combination with low, clinically relevant doses of 
Taxol dramatically reduced cell viability by 2- to 10-fold, which also correlated with an 
increase in the amount and severity of chromosome segregation errors [158]. Therefore, 
using small molecule inhibitors to inhibit these or other checkpoint proteins, in 
combination with current therapeutics like Taxol, may prevent mitotic checkpoint 
activation, leading to severe aneuploidy and tumor cell death. 
 In addition to increasing the severity of chromosome mis-segregation as a 
therapeutic strategy, the opposite approach may hold some promise. W-CIN results in 
tumor heterogeneity, which allows tumor cells to adapt to environmental pressures, 
including chemotherapeutics. Therefore, preventing chromosome mis-segregation may 
limit the cell’s ability to adapt, allowing chemotherapeutics to be more effective. For 
example, treating tumors with a compound that forces microtubule de-polymerization 
may suppress the incidence of lagging chromosomes in W-CIN positive cancers, in a 
manner similar to the way over-expression of the microtubule-depolymerizing kinesins 
Kif2b and MCAK do [99]. This would reduce chromosome mis-segregation, and limit W-
CIN.  
 
Conclusions 
The exploitation of W-CIN as a therapeutic target is in part limited by our current 
lack of understanding of the mechanisms that drive W-CIN in tumors. As mentioned, 
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disrupting the mechanisms that govern chromosome segregation can induce W-CIN, but 
whether these mechanisms are driving forces for transformation remains unknown. 
Further, many “CIN genes” have been identified (Table 1.1), but it is not known if 
mutations or changes in the level of gene expression for any of these genes are initiating 
events for cancer development. Additionally, W-CIN is extremely prevalent in cancers, 
and its association with poor patient prognosis makes W-CIN an important clinical factor. 
As such, there is an obvious need for research efforts to be put toward elucidating 
critical drivers of W-CIN in cancers. 
 One very important component that is often overlooked when discussing the 
mechanisms that govern chromosome segregation is the region of chromatin that many 
of those mechanisms are associated with, the centromere. The chromatin architecture of 
centromeres (discussed in detail in Chapter 2) must be maintained so that centromeres 
retain their ability to contribute to protecting cells against W-CIN. For example, the 
kinetochore assembles at centromeres, and without functional centromeres, kinetochore 
assembly is disrupted. Disrupted kinetochore assembly can result in issues with 
kinetochore-microtubule attachment, which can contribute to W-CIN, as discussed 
above. Similarly, because MCC proteins assemble at unattached kinetochores, 
disrupted kinetochores may prevent proper SAC signaling, allowing cells to exit mitosis 
with mal-attachments. Further, abnormalities in centromeric chromatin may weaken 
sister chromatid cohesion, allowing for precocious separation of sister chromatids. 
Chapters 4 and 5 reveal Sp1 as an important factor for maintaining centromere identity. 
The following chapter discusses centromere biology, and highlights the importance of 
maintaining centromere identity for proper chromosome segregation.      
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Figure 1.1: Acquired Capabilities of Cancer (Reprinted from [159] with permission 
Elsevier).  
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Figure 1.2: Genomic Instability. Most broadly definied, genomic instability is the failure 
of a cell to pass a complete and intact copy of its genome onto its daughter cells. 
Genomic aberations can occur on several different levels, including at the nucleotide 
level, the sub-chromosomal level (also referred to as structural/segmental CIN or S-
CIN), and with changes in the number of whole chromosomes per cell (also referred to 
as numerical/whole CIN or W-CIN).    
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Table 1.1: Proteins Associated with W-CIN (Reprinted from [160] with permission from 
Elsevier). 
  
Protein Alteration Putative mechanism(s) Reference 
APC Depletion, mutation Checkpoint defects, merotely [98, 161-166] 
Aurora A Overexpression Centrosome amplification, cytokinesis 
failure 
[167, 168] 
Aurora B Depletion, drug inhibition Checkpoint defects, merotely [90, 92, 169] 
β-catenin Mutation Dysregulation of cell-cycle proteins, 
merotely 
[165] 
BRCA1 Mutation Dysregulation of cell-cycle proteins, 
merotely 
[170] 
BRCA2 Mutation Dysregulation of cell-cycle proteins [170] 
Bub1 Heterozygous knockout, 
hypomorph, mutation 
Checkpoint defects [118, 171]  
Bub3 Heterozygous knockout Checkpoint defects [172, 173] 
BubR1 Knockout, mutation Checkpoint defect [114, 174-
176] 
CAML Knockout Cytokinesis failure, merotely [177] 
hCdc4/FBXW7 Depletion, knockout Dysregulation of cell-cycle proteins, 
merotely 
[178] 
Cdc20 Mutation Checkpoint defects [179] 
CENP-E Depletion, knockout Checkpoint defects, merotely [180-183] 
CENP-F Depletion Checkpoint defects, merotely [184, 185] 
CENP-H Overexpression Cytokinesis failure, merotely [186] 
CLASP Depletion Merotely [181, 187] 
Conductin/AXIN2 Overexpression Checkpoint defects, dysregulation of 
cell-cycle proteins 
[166] 
Cyclin E Overexpression Centrosome amplification, dysregulation 
of cell-cycle proteins, merotely 
[178, 188] 
EB1 Depletion Merotely [164] 
ECRG2 Depletion Centrosome amplification, checkpoint 
defects, dysregulation of cell-cycle 
proteins 
[189] 
Eg5 Overexpression Cytokinesis failure [190] 
FoxM1 Depletion, knockout Dysregulation of cell-cycle proteins [185] 
Hec1–NDC80 
complex 
Antibody inhibition, mutation, 
overexpression 
Cytokinesis failure, merotely [191-193] 
Hice-1 Depletion Cytokinesis failure, merotely [194] 
Id1 Overexpression Cytokinesis failure [195] 
Kif2a Depletion, with MCAK depletion Merotely [196] 
Kif2b Depletion Merotely [99] 
Kif4 Knockout Centrosome amplification, merotely [197] 
Kruppel-like 
factor 4 
Knockout Centrosome amplification, chromosome 
breakage 
[198] 
Mad1 Heterozygous knockout Checkpoint defects [199] 
Mad2 Depletion, heterozygous 
knockout, knockout, 
overexpression 
Checkpoint defects, merotely [120, 200-
203] 
MCAK Depletion Merotely [99, 204, 205] 
MCT-1 Overexpression Merotely [206] 
Mdm2 Overexpression Dysregulation of cell-cycle proteins [207] 
MdmX Knockout Centrosome amplification, cytokinesis 
failure multipolar anaphases 
[208] 
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Mps1 Mutation Checkpoint defects, merotely [209] 
p53 Knockout Dysregulation of cell-cycle proteins [206] 
PRP4 Depletion Checkpoint defects, merotely [210] 
Rad21/SCC1  Mutation Cohesion defects [71] 
Rae1 Heterozygous knockout Checkpoint defects [173] 
RanBP1 Depletion Merotely [211] 
Rb Depletion Centrosome amplification, dysregulation 
of mitosis proteins causing 
overactivation of checkpoint 
[202] 
REST Mutation Dysregulation of mitosis proteins 
causing checkpoint defects 
[212] 
SCC3  Mutation Cohesion defects [71] 
Securin Knockout, overexpression Cohesion defects [213, 214] 
Separase Knockout, overexpression Cohesion defects, cytokinesis failure [215, 216] 
SMC1  Depletion, mutation Cohesion defects, cytokinesis failure [71] 
SMC3 (cohesin 
subunit) 
Mutation Cohesion defects [71] 
Sgo1 Depletion Cohesion defects, cytokinesis failure [217] 
Sgo2/tripin Depletion Cohesion defects, merotely [218] 
TMAP/CKAP2 Depletion Merotely [219] 
Topoisomerase II Drug inhibition Catenation, merotely [220] 
Von Hippel 
Lindau 
Depletion Checkpoint defects [221] 
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Table 1.2: Clinical relevance of W-CIN (Reprinted from [8] with permission from John 
Wiley and Sons of EMBO Reports).  
 
Cancer Type 
Method for Measuring W-
CIN 
Associated Outcome Reference 
Lung Cancer 
  
  
  
  
FISH (n = 63) 
Poor prognosis (OS and 
DFS) 
[145] 
FISH (n = 47) Poor prognosis (OS) [147] 
FISH (n = 50) Poor prognosis (OS) [146] 
12-gene signature (n = 647) Poor prognosis (OS) [151] 
W-CIN70 signature (n = 62) Poor clinical outcome [148] 
Breast Cancer 
  
  
  
  
SSI (n = 890) Poor prognosis (OS) [222] 
SNP (n = 313) Poor prognosis (MFS) [223] 
12-gene signature (n = 469) 
Poor prognosis (DFS and 
RFS) 
[224] 
W-CIN70 signature (n = 
1866) 
Poor clinical outcome [148] 
FISH (n = 31) Lymph node metastasis [149] 
Myelodysplastic 
syndrome 
FISH (n = 65) Poor prognosis (DFS) [225] 
Endocrine 
pancreatic tumors 
CGH (n = 62) Metastasis [226] 
Colon cancer 
  
12-gene signature (n = 92) 
Recurrence of colon 
cancer 
[227] 
Flow cytometry/image 
cytometry (n = 10126) 
Poor prognosis 
Ovarian cancer 12-gene signature (n = 124) Poor prognosis (RFS) [151] 
Endometrial cancer SNP (n = 31) Poor prognosis (OS) [228] 
Synovial sarcoma CGH (n = 22) Poor prognosis (OS) [229] 
Oral cancer 
(SCCs) 
FISH (n = 77) 
Poor prognosis (OS and 
DFS) 
[153] 
FISH (n = 20) 
Regional tumour 
outgrowth 
[230] 
Diffuse large B-cell 
lymphoma 
Anaphase segregation 
errors (n = 54) 
Poor prognosis (RFS) [152] 
OS: Overall survival, DFS: Disease free survival, MFS: metastasis-free survival, RFS: relapse-
free survival, SCC: squamous cell carcinoma, SSI: Stem line scatter index, SNP: Single 
nucleotide polymorphisms.  
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Chapter 2: Centromere Biology 
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Introduction 
 
 Our work discussed in Chapters 4 and 5 demonstrate that Sp1 is an important 
factor for maintaining centromere identity. Sp1 regulates centromere epigenetics by 
maintaining centromeric histone modifications, transcription through the core 
centromere, and proper levels of important centromere-associated proteins like 
centromeric protein A (CENP-A), the histone H3 variant that defines centromeres, and 
centromeric protein C (CENP-C). To place our findings in the context of the current 
knowledge in the field, this chapter focuses on centromere biology and the importance of 
maintaining centromere identity for proper chromosome segregation.   
The centromere is a specialized region of chromatin that is critically important for 
faithful segregation of chromosomes during mitosis. Centromeres serve two major 
functions. First, the centromeric chromatin acts as a platform for assembly of the 
kinetochore. The kinetochore is a proteinaceous structure that serves as the interface 
between the mitotic chromatin and the mitotic spindle microtubules (Figure 2.1 and 
Figure 2.2). Inner kinetochore proteins are constitutively associated with centromeric 
DNA, and create a network of 16 proteins called the constitutive-centromere-associated 
network, or CCAN (Figure 2.2). CCAN proteins direct the assembly of outer kinetochore 
proteins when a cell enters mitosis, and these outer kinetochore proteins make 
connections with spindle microtubules. Thus, centromeres must maintain a specific 
chromatin architecture such that CCAN proteins recognize and assemble onto one and 
only one locus per chromosome. If this fails, resulting in more than one kinetochore per 
chromosome, that chromosome could be pulled in different directions during anaphase, 
resulting in fragmentation. Second, centromeres bind sister chromatid cohesion 
molecules, keeping sister chromatids together until they separate and move to opposite 
poles of the cell during anaphase. Defects in sister chromatid cohesion can result in 
premature chromosome segregation, and aneuploidy. Maintaining an active and 
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functioning centromere is essential for accurate chromosome segregation, as defects 
can lead to disruption or loss of genetic material during cell division, and pathological 
disease.    
 In 1882, the centromere was first observed using light microscopy simply as the 
attachment site for the mitotic spindle [231]. Since then, much effort has been directed 
toward understanding requirements for centromere identity and centromere function in 
many different species. Surprisingly, despite the importance and conservation of this 
region of chromatin, centromeres are highly divergent not only across species, but also 
on different chromosomes within a single organism [232]. The simplest centromere is the 
point centromere found in the budding yeast Saccharomyces cerevisiae. The point 
centromere is sequence specific, and exists on centromeric DNA that is organized into 
three domains, Centromere DNA Elements I, II, and III. A single nucleosome containing 
the centromere-specific histone H3 variant cenH3 wraps approximately 125 base pairs 
of centromeric DNA, and assembles onto Centromere DNA Element II [231, 233, 234]. 
More complexed centromeres in plants and animals contain several cenH3-containing 
nucleosomes, over a region of repetitive chromatin that spans several hundred kilobases 
to megabases in length, and are thus called regional centromeres [235-237]. 
Interestingly, there is a dramatic lack of homology between the repetitious centromeric 
sequences from different organisms [238, 239]. For example, Schizosaccharomyces 
pombe centromeres consist of a pair of repeated sequence arrays that are arranged in 
an inverted repeat around a central core sequence that is not conserved [240]. Oryza 
sativa (rice) centromeres contain a 155 base pair or 165 base pair satellite repeat called 
CentO, as well as the centromere-specific retrotransposon CRR (Centromeric 
Retrotransposon of Rice) that intermingles with CentO repeats, and spans 60 kilobases 
to 2 megabases, depending on the chromosome [241-243]. Drosophila melanogaster 
centromeres consist of short, 5 base pair repetitive sequences (AATAT and AAGAG) 
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interspersed with transposable elements [244], while chicken centromeres contain 
several hundred kilobases of repetitive arrays, where the repeat unit of each centromere 
is specific to each particular chromosome [245]. Mouse and human centromeres are 
composed of satellite DNA sequences. In mice, two types of repetitive DNA sequences 
are associated with centromeres, including major satellite repeats and minor satellite 
repeats. The major satellite sequences are located in the pericentromeric region, and 
encompass 6 megabases of 234 base pair repeat units [246]. The minor satellites 
encompass approximately 6 kilobases of 120 base pair repeat units [247]. Finally, 
human centromeres contain from 15,000 to more than 30,000 copies of a 171 base pair 
repeat, collectively called α-satellite (AS) DNA arrays, that span anywhere from 300 
base pairs to several megabases of DNA [183]. Interestingly, although the majority of 
human centromeres form on AS DNA arrays, the rare neocentromere forms on genomic 
DNA completely absent of AS DNA arrays, indicating that the underlying DNA sequence 
does not specify centromere formation [248]. Thus, although centromeres are necessary 
for faithful chromosome segregation, and although all species studied contain 
centromeres, this important chromatin region assembles on diverse types of DNA 
sequences rather than one that is evolutionarily conserved.    
 
Human Centromeric DNA 
 
Α-satellite (AS) DNA is thought to make up 2% to 3% of the human genome, with 
approximately 1 million copies of the 171 base pair repeat per diploid genome [249]. The 
highly repetitive nature of AS DNA arrays has made sequencing the human centromere 
extremely challenging. Currently, only a portion of the most distal AS DNA arrays that 
make up human centromeres have been annotated, and only on a few chromosomes. 
Other AS sequences have been identified, but have not been placed on a specific 
chromosome [250]. Human AS DNA is classified into two groups. The first group, 
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monomeric AS DNA, includes DNA containing several copies of the basic 171 base pair 
unit. The second group is higher-order (HOR) AS DNA, in which a block of multiple 171 
base pair units form a larger repeat unit [251-253]. Although a consensus sequence for 
the monomeric 171 base pair sequence has been described (Figure 2.3), there is a great 
deal of variation between monomeric sequences. For example, monomeric AS DNA 
sequences typically show identities of 70% to 90% to each other. Further, monomeric 
AS DNA sequences within a HOR array typically share about 95% identity with the 
monomeric AS DNA sequence at the same position in another HOR array. It appears as 
though HOR arrays are mostly found at core centromeres, and monomers are found in 
the distal regions, although a lack of complete centromere sequence information makes 
confirming this theory difficult [253, 254]. This does indicate, however, that the HOR 
arrays are more important than the monomeric AS DNA sequences, and where studied, 
have been found to be most critical for centromere function. For example, studies using 
the HOR array sequences known to be present at the primary constriction site of 
chromosome X, called DXZ1, indicate that DXZ1 alone, and not the monomeric AS 
sequences flanking DXZ1, is sufficient for accurate chromosome segregation [255]. 
Currently, there is no evidence for direct involvement of monomeric AS DNA sequences 
in centromere identity and function. 
 Pericentromeric heterochromatin lacking AS DNA surrounds mammalian 
centromeres. This region of heterochromatin is thought to have several functions, 
including sister chromatid cohesion, and recruitment of centromere-specific proteins to 
centromeres [256]. To date, no pericentromeric region has been genetically manipulated 
(deleted, reduced, or amplified), so the exact function of this region in mammals is still 
unclear. Like centromeric DNA, pericentromeric heterochromatin DNA sequence is not 
conserved between species, or even between chromosomes within the same species 
[257]. Also like centromeric DNA, pericentromeric heterochromatin is made up of tandem 
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repeats of satellite DNA, including satellites I, II, and III. These satellite repeats are much 
shorter than AS DNA, at approximately 5 base pairs [257].     
 
Defining Centromeres: Centromeric Protein A (CENP-A) 
 
Our work in Chapters 4 and 5 indicate that Sp1 regulates CENP-A deposition, as 
depletion of Sp1 by RNAi results in a decrease in CENP-A at centromeres. With the 
exception of budding yeast Saccharomyces cerevisiae, centromeres are not defined by 
DNA sequence. Instead, they are defined epigenetically, by the presence of 
nucleosomes containing the histone H3-like variant CENP-A (also referred to as CenH3 
in some species). CENP-A containing nucleosomes are interspersed between canonical 
histone H3-containing nucleosomes at core centromeres. The requirement for CENP-A 
is best exemplified in the case of neocentromeres, centromeres formed on genomic 
DNA devoid of the AS DNA arrays found at typical centromeres. Despite the lack of AS 
DNA, neocentromeres contain CENP-A and form functional kinetochores. CENP-A 
homologs have been identified in every active centromere studied, in both single-celled 
and multicellular organisms [239, 258]. This histone H3-varient directs the recruitment of 
CCAN proteins required for kinetochore formation, and thus for attachment of 
chromosomes to the mitotic spindle during mitosis [259]. As such, CENP-A is the most 
upstream component and single most important protein for centromere identity. 
Disruption in the amount of CENP-A protein at centromeres results in disrupted CCAN 
assembly and kinetochore formation, disrupted attachment of spindle microtubules, and 
chromosome segregation errors.    
The human CENP-A Gene and Protein: 
 
CENP-A is a 17 kilodalton protein that belongs to the histone H3 family, and is a 
histone H3-like variant found exclusively at the core centromere. Here, it replaces 
conventional histone H3 within the nucleosome. The CENP-A gene is located on 
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chromosome 2 at position 2p23.3 (26,987,157-27,023,935 forward strand), from which it 
produces 6 transcripts, including CENP-A-001 through CENP-A-006. Of these 
transcripts, only CENP-A-001 (Isoform 1) and CENP-A-006 (Isoform 2) are protein 
coding transcripts. CENP-A-005 produces a protein product that is subjected to 
nonsense mediated decay, and all other transcripts are non-coding [260]. 
The CENP-A-001 gene is 1452 base pairs in length, and produces a 140 amino 
acid protein, while the CENP-A-006 gene is 1299 base pairs in length, and produces a 
114 amino acid protein through alternative splicing [260]. CENP-A-006 lacks amino 
acids 71-96 [261]. CENP-A-001 is the functioning CENP-A molecule in the cell, while the 
function of CENP-A-006 is not yet clear.  
The transcribed CENP-A-001 protein (hereafter referred to as CENP-A) has 
several secondary structures, including four helices and two beta strands [262]. The 
CENP-A amino acid sequence shares significant homology with residues 48-135 in the 
C-terminus of histone H3. This region, which contains the histone fold domain, shares 
60% identity and 75% similarity to the CENP-A amino acid sequence [263]. Within 
CENP-A, this H3-like domain allows for CENP-A to incorporate into the nucleosome in 
place of histone H3. In addition, CENP-A contains a unique region required for targeting 
the histone variant to the centromere, called the CENP-A targeting domain (CATD) 
[264]. This region spans amino acids 75-116 [260], and contains the first loop and 
second alpha-helix of the protein. Replacement of the corresponding region of H3 with 
the CATD is sufficient to direct H3 to centromeres [259]. CENP-A mRNA and protein 
levels are maximal at the end of S phase [265]. Prior to assembly at centromeres, newly 
expressed CENP-A is sequestered for most of the cell cycle (late S-phase, G2, and most 
of mitosis) in a complex that contains its partner, H4, and its chaperone, HJURP 
(Holliday junction recognition protein) [266].  
The CENP-A Nucleosome: 
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 Genomic DNA is wrapped around a canonical histone octamer, containing two of 
each of histones H2A, H2B, H3, and H4. Each octameric unit contains an H3/H4 
tetramer, flanked by H2A/H2B dimers. DNA wraps around the histone octamer 1.7 times, 
or about 146 base pairs, in a left-handed orientation, a characteristic thought to be 
important for transcription, DNA replication, and DNA repair [267]. At centromeres, 
CENP-A replaces canonical histone H3 in a large fraction of the nucleosomes.  
Interestingly, the structure of CENP-A containing nucleosomes is currently a hotly 
debated topic, as several atypical nucleosome arrangements have been proposed. For 
example, in budding yeast, one study proposes that the H2A/H2B dimer is replaced with 
a non-histone protein, Scm3 (HJURP in mammalian cells), creating a hexameric 
nucleosome composed of two copies of the yeast CENP-A homolog Cse4, histone H4, 
and Scm3 [268]. Another study proposed that Cse4 containing nucleosomes form a 
hemisome, with only one copy of each of Cse4, H4, H2A, and H2B [269]. In both cases, 
it is thought that centromeric DNA may wrap around the budding yeast centromeric 
nucleosomes in a right-handed orientation, providing a specialized region of chromatin 
for centromere identification and kinetochore protein assembly [267]. This same 
hemisome model has been proposed in both Drosophila melanogaster [270], and in 
human cells [271]. Using atomic force microscopy, the latter study showed that CENP-A 
containing nucleosomes are one half the height of canonical octameric nucleosomes. 
Here, bulk chromatin octameric nucleosomes ranged in height from 2.5-4.5 nanometers, 
and 75% of CENP-A containing nucleosomes ranged in height from 1.4-2.0 nanometers. 
This study also used immunoelectron microscopy, a technique that permits mapping 
histones on chromatin at single molecule resolution [272], to support their claim that 
CENP-A containing nucleosomes contain only one copy of the CENP-A and H2B 
molecules [271]. Many other groups contest that CENP-A containing nucleosomes are 
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octasomes, like canonical nucleosomes. In vitro studies, including bacterially expressed 
nucleosomes reconstituted with palindromic DNA designed from human AS sequences, 
when crystalized, appear to reveal a histone octamer [273-275]. In vivo studies using a 
photobleaching-assisted copy-number counting technique [276] in HeLa cells stably 
expressing a CENP-A-YFP fusion protein supports these claims. This system, which 
allows direct visual analysis of CENP-A-YFP stoichiometry in native-assembled 
nucleosomes, showed that a majority of the complexes contained two molecules of 
CENP-A-YFP [275]. More recently, it has been proposed that CENP-A containing 
nucleosomes oscillate between octameric and tetrameric forms during cell-cycle 
progression in both human cells and budding yeast [277, 278]. In human cells, it appears 
as though CENP-A containing nucleosomes are tetrameric at early G1, convert to 
octamers at the G1 to S phase boundary, and then revert back to tetramers after 
replication. The tetrameric structure is then maintained for the remainder of the cell cycle 
[277]. Although this theory remains to be substantiated by other groups, it could explain 
the variability in CENP-A containing nucleosome structure observed experimentally.   
 Crystal structures of octameric CENP-A containing nucleosomes reveal other 
distinct differences between those and canonical histone H3-containing nucleosomes 
that may be vital for centromere identity and function. The CATD makes the CENP-A/H4 
tetramer more rigid than the H3/H4 tetramer [264]. It also causes the CENP-A/CENP-A 
protein interface to be rotated as compared to the H3/H3 interface [262]. Further, arrays 
of CENP-A containing nucleosomes are 30% more compact than arrays of canonical 
histone H3-containing nucleosomes [279], but with looser DNA at the entry and exit sites 
at the nucleosome boundaries [280]. Finally, post-translational modification of CENP-A 
can influence the conformation of CENP-A containing arrays. In most cases, NRMT (N-
terminal RCC1 methyltransferase) catalyzes the tri-methylation of glycine 1. Further, 
Serine 16 and 18 are phosphorylated, and these phosphorylated residues form a salt-
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bridged secondary structure within the N-terminus of the protein. This secondary 
structure allows for intermolecular and intramolecular interactions that influence the 
conformation of CENP-A containing nucleosome arrays [281]. CENP-A is also 
phosphorylated on serine 7, which is required for stabilization of CENP-A nucleosomes 
and for the interaction between CENP-A and the centromere associated protein CENP-C 
[282]. Recently, it was shown that CENP-A monoubiquitination on lysine (K) 124 is 
required for the interaction between CENP-A and the CENP-A specific chromatin 
assembly factor HJURP. This monoubiquitination is mediated by CUL4A-RBX1-COPS8 
E3 ligase [259]. Therefore, although the true composition of CENP-A containing 
nucleosomes is still unclear and currently under intense investigation, it is clear that 
CENP-A containing nucleosomes are distinct from canonical histone H3-containing 
nucleosomes, and that this distinction likely confers a specific identity to centromeric 
chromatin.  
CENP-A Deposition at Centromeres:     
 
 Canonical nucleosomes are assembled in S phase, as DNA is replicated. Newly 
synthesized histones form complexes with chromatin assembly factors, which mediate 
histone deposition onto new DNA and the assembly of DNA into nucleosomes [283]. 
Conversely, in vertebrate cells, new CENP-A molecules are deposited onto DNA after 
the cell exits mitosis, in early G1, when CDK1 activity has declined [284]. Thus, when 
cellular DNA is replicated, CENP-A containing nucleosomes are diluted across both 
strands of DNA, and cells proceed through mitosis with only half the maximal number of 
CENP-A containing nucleosomes [285]. Surprisingly, this is not true for all species. For 
example, during S phase, budding yeast first remove all existing Cse4 (the CENP-A 
homolog) before incorporating new Cse4 into centromeric DNA [286]. To date, several 
factors have been identified as regulators of CENP-A deposition, the major players of 
which include HJURP, the Mis18 complex, CENP-C, and CENP-I. Tight regulation of 
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CENP-A deposition is required, as deletion of CENP-A results in a mitotic lethal 
phenotype [284], and over-incorporation or mis-incorporation of CENP-A molecules is 
associated with chromosome segregation errors and cancer [287, 288].  
 Holliday junction recognition protein (HJURP): 
 
 HJURP was first identified in 2007 through a genome-wide expression profile 
analysis of non–small cell lung cancer (NSCLC) tissues, as a result of its having 5-fold or 
higher expression in cancer cells as compared to normal lung cells in more than 50% of 
the samples examined. In this study, HJURP was found to associate with hMSH5 and 
NBS1 in cancer cells, and also bound to a synthetic nucleotide with Holliday junction 
structure, hence the name. Depletion of HJURP by RNAi resulted in genomic instability, 
suggesting for the first time that HJURP is an indispensable factor for maintaining 
chromosomal stability [289]. Shortly after, HJURP was co-purified with CENP-A from 
chromosome-depleted extracts. This study showed that HJURP is required for CENP-A 
localization to centromeres, as HJURP depletion by RNAi reduced the intensity of 
CENP-A staining at centromeres. Further, adding the CATD to a canonical histone H3 
molecule (H3CATD) induced an interaction between H3CATD and HJURP that was 
otherwise nonexistent [290]. Several studies have followed that confirm HJURP as the 
centromere-specific assembly factor that directs the incorporation of CENP-A into 
nucleosomes [291-294], including a study that showed that targeting of HJURP to non-
centromeric locations results in CENP-A incorporation [292]. A recent study showed that 
the CENP-A/H4 tetramer is bound to HJURP for a majority of the cell cycle, including 
late S phase, G2, and mitosis [266]. 
 HJURP interacts with the CENP-A/H4 tetramer through its CENP-A binding 
domain (CBD), located within the first 80 amino acids of the HJURP protein. Within this 
region, HJURP contains a TLTY box (TLTYETPQ in humans), a novel amino acid 
sequence that is highly conserved across species and is required for the HJURP-CENP-
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A interaction, as deletion of the TLTY box alone abrogates HJURP binding to CENP-A. 
The HJURP CBD interacts with the CATD of CENP-A to stimulate CENP-A/H4 tetramer 
deposition [291]. The CENP-A/H4-HJURP complex localizes to centromeres in G1, 
consistent with new CENP-A incorporation [294]. Although HJURP was first identified as 
a protein that binds to Holliday junction structures, this DNA structure has not been 
identified as a requirement for CENP-A incorporation at centromeres [265].  
 The phosphorylation status of HJURP may regulate its association with 
centromeric DNA. Multiple serine residues are phosphorylated, including serine (S) 123, 
S140, S382, S412, S448, S472, S486, S557, S559, S595, and S686. Currently, the 
function of HJURP phosphorylation is only partially understood. One study showed that 
when HJURP is not associated with centromeres, it is most highly phosphorylated at 
S123, S412, and S557, suggesting these phosphorylation sites are important for 
preventing HJURP from localizing and thus loading CENP-A outside of G1 [266]. Another 
study showed that mutating S412, S448, and S472 resulted in premature loading of 
CENP-A [295], and thus must function to regulate the timing of HJURP association with 
centromeres as well.          
 The Mis18 Complex: 
 
 The Mis18 complex consists of 5 proteins, including Mis18α, Mis18β, 
Mis18BP1KNL2, RbAp48, and RbAp46 [265]. This complex localizes to centromeres in 
late anaphase and is required for recruitment of HJURP, as depletion of Mis18α and 
Mis18BP1KNL2 prevents localization [292]. Further, depletion of any one member of this 
complex prevents incorporation of new CENP-A [296, 297]. In mice, Mis18α deficiency 
leads to mislocalization of CENP-A in blastocysts, resulting in early embryonic lethality 
from severe chromosome mis-segregation [298]. Interestingly, despite the clear 
relationship between the Mis18 complex, HJURP, and CENP-A, no physical interaction 
between the Mis18 complex and HJURP, or the Mis18 complex and CENP-A, has been 
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observed [265]. Mis18 complex localization may also be regulated by CDK activity. One 
study showed that from cell cycle phase S through mitosis, when CDK activity is high, 
Mis18BP1KNL2 is unable to localize to centromeres. However, the sharp decrease in CDK 
activity at the exit of mitosis changes the phosphorylation status of Mis18BP1KNL2, 
allowing it to be recruited [299]. Then, in G1, centromere associated Plk1 binds to and 
phosphorylates Mis18BP1KNL2, also to promote its localization [300]. This CDK and Plk1-
dependent regulation of Mis18BP1KNL2 localization may help to restrict CENP-A 
incorporation to G1.     
Current models suggest that the Mis18 complex may function to recruit chromatin 
modifying factors to centromeres to create or maintain chromatin architecture 
permissible for CENP-A deposition. For example, a 2007 study showed that treating 
Mis18 complex-depleted cells with the histone deacetylase (HDAC) inhibitor trichostatin 
A (TSA) suppressed the loss of CENP-A at centromeres, suggesting that histone 
acetylation is required for CENP-A deposition [296]. In support of this, RbAp46 was 
previously shown to bind to histone H4 and the histone acetyltransferase Hat1 [301]. 
Additionally, another study showed that promoting centromeric histone acetylation by 
targeting histone acetyltransferases p300 and PCAF to synthetic AS DNA enhanced 
CENP-A assembly. This CENP-A assembly required HJURP, but did not require the 
Mis18 complex [302]. Further, Mis18BP1KNL2 contains a SANT domain (Swi3-Ada2-
NCoR-TFIIIB), a domain found in a variety of different chromatin remodelers [303], 
including histone acetyltransferases [304]. These data argue that the Mis18 complex 
may play a role in maintaining the histone acetylation status required for CENP-A 
deposition. This is perplexing, as centromeric nucleosomes are known to lack H3 and 
H4 acetylations typically found in euchromatin (H3K9 and H4K5, K8, K12 and K16) 
[104]. 
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In addition to a possible role in the maintenance of centromeric histone 
acetylation, the Mis18 complex may also affect histone methylation and DNA 
methylation at centromeres. In Mis18α-depleted mouse embryonic fibroblasts (MEFs), 
methylation levels of histone H3 lysine 9 (H3K9) and histone H3 lysine 4 (H3K4) were 
decreased. Further, recruitment of the histone methyltransferase Suv39h1 to 
centromeres, which has been shown to tri-methylate H3K9, was also reduced in Mis18α-
depleted MEFs. DNA methyltransferases DNMT3A and DNMT3B were shown to interact 
with Mis18α in mice, and depletion of Mis18α results in a decrease in DNA methylation 
[298]. Therefore, although the exact function of the Mis18 complex at centromeres is not 
clear, it is likely that this complex plays some role in centromeric chromatin maintenance 
vital for proper incorporation of CENP-A through recruitment of HJURP.          
 CENP-C and CENP-I: 
 
 CENP-C is one of several components of the CCAN, the network of proteins that 
associates with centromeric chromatin throughout the cell cycle. CENP-C is an important 
upstream factor for CENP-A deposition, as it binds to centromeric chromatin and recruits 
the Mis18 complex to this region. More specifically, the C-terminus of CENP-C interacts 
with the SANT domain of Mis18BP1KNL2, and knockdown of CENP-C results in 
decreased CENP-A at centromeres [305]. This has been demonstrated in several 
species, including Xenopus egg extracts [306], Drosophila melanogaster [307], and 
mouse cells [305]. Interestingly though, CENP-C appears to be recruited to centromeres 
through an interaction with CENP-A itself [308]. This suggests that CENP-C may be 
important for incorporation of CENP-A at existing centromeres, but not de novo 
incorporation of CENP-A. In support of this, targeting CENP-C to non-centromeric 
regions is not sufficient for CENP-A incorporation [309]. A recent study showed that 
CENP-I, also a component of the CCAN, can recruit Mis18BP1KNL2 to synthetic AS DNA. 
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In this study, depletion of CENP-C had no effect on the ability of CENP-I to recruit 
Mis18BP1KNL2, and vice versa [310].         
 
Other DNA Binding Proteins at Centromeres  
 In Chapters 4 and 5, we show by chromatin immunoprecipitation that Sp1 binds 
to both centromeres and pericentromeres during mitosis. Here, we review other proteins 
known to bind to centromeres, as well as how they contribute to preserving centromere 
identity and function.  
Centromeric Protein B (CENP-B): 
Of the proteins that bind to centromeric DNA, only one protein, centromeric 
protein B (CENP-B), has been identified as requiring a specific sequencing for binding. 
CENP-B is a highly conserved protein that binds to a 17 base pair sequence known as a 
CENP-B box (CTTCGTTGGAAACGGGA) [311]. In human centromeres, CENP-B boxes 
appear in every other monomeric AS sequence in higher-order (HOR) AS arrays, but not 
in clusters of AS monomers that do not form HOR repeats [312]. CENP-B is an 80 
kilodalton protein with a helix-loop-helix DNA-binding domain occupying the N-terminal 
125 amino acids of the protein [313]. CENP-B also contains a dimerization domain in the 
C-terminus, suggesting a model by which one molecule of CENP-B binds to HOR AS 
array and dimerizes with other DNA-bound CENP-B molecules to influence centromeric 
nucleosome positioning, and to establish higher order chromatin structures [314]. In 
studies using mammalian artificial chromosomes, CENP-B boxes are required for de 
novo centromere formation and assembly of some centromere associated proteins, 
including CENP-A [315]. However, mouse CENP-B knockout studies reveal that 
functional kinetochores are able to form in the absence of CENP-B [316]. Further, 
neocentromeres that lack AS DNA are also devoid of CENP-B boxes and thus CENP-B 
protein, yet form functional kinetochores [317], and CENP-B appears to be absent from 
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the Y chromosome all together [318]. A recent study showed that the amino-terminal tail 
of CENP-A binds to CENP-B, and that together, CENP-A and CENP-B are required for 
maintaining normal levels of CENP-C, an important chromatin and kinetochore assembly 
factor. This study also found that depletion of CENP-B yields a higher rate of 
chromosome mis-segregation [319]. Thus, a complete understanding of the function of 
this sequence-specific centromeric DNA binding protein is still needed.     
Centromeric Protein C (CENP-C): 
 CENP-C was one of the first centromere proteins identified [320]. It is a 
component of the CCAN, and thus constitutively localizes to centromeres throughout the 
cell cycle. The human CENP-C protein consists of 943 amino acids and contains several 
regions that are important for binding to AS DNA, as well as to other centromere and 
kinetochore proteins.  
The N-terminal region of CENP-C, consisting of amino acids 1-71, interacts with 
Mis12, a component the KMN network of proteins (including the Knl1 complex, the 
Mis12 complex, and the Ndc80 complex) of the outer kinetochore (Figure 2.2)  [321]. 
The KMN network is essential for kinetochore-microtubule interactions and is thus vitally 
important for chromosome segregation. In HeLa cells, expression of amino acids 1-71 
(CENP-C1-71) competed with endogenous CENP-C, and prevented recruitment of Mis12 
to kinetochores, as well as other KMN network proteins. Further, CENP-C1-71 expression 
prevented proper alignment of chromosomes along the metaphase plate, premature 
mitotic exit, and chromosomal instability [322]. As such, CENP-C serves as a bridge 
between CENP-A and the CCAN at the inner kinetochore, and the outer kinetochore and 
spindle microtubules. 
Amino acids 189 to approximately 400 are proline, glutamate, serine, and 
threonine rich, and are thus referred to as a “PEST rich” domain. Recently, this domain 
was found to be required for the interaction between CENP-C and the CENP-H-I-K-M 
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complex, a complex of centromere associated proteins consisting of CENP-H, CENP-I, 
CENP-K and CENP-M (Figure 2.2). The CENP-H-I-K-M complex appears to be a central 
complex in CCAN organization, as it interacts with several other CCAN proteins, 
including the CENP-T-W-S-X heterotetramer, also required for recruitment of the KMN 
network proteins (Figure 2.2) [323, 324]. Although amino acids 426-537 are only 
conserved among mammals, this portion of CENP-C is required for centromere 
localization, as it binds centromere AS DNA as well as CENP-A. More specifically, 
amino acids 482-508 include many positively charged amino acids that are likely to bind 
DNA, whereas amino acids 509-535 bind to CENP-A [325]. Amino acids 426-551, which 
contain a sequence homologous to the HP1 hinge domain, were also shown to bind AS-
derived long non-coding RNAs (lncRNA) [326].  
In contrast to the central domain, the C-terminus of CENP-C contains two distinct 
domains that are highly conserved from yeast to mammals. The first domain, located 
from amino acids 737–759, is called the Mif2p homology domain II (or the CENP-C 
domain). This domain is present in all homologs of CENP-C, and also binds AS DNA 
and centromeric nucleosomes. The second domain, located from amino acids 890 – 
943, is called the Mif2p homology domain III, and is required for CENP-C dimerization 
and/or oligomerization [327]. Both of these regions are required for the interaction 
between CENP-C and the Mis18 complex, an important upstream factor for CENP-A 
deposition (Figure 2.2) [305].  
Most recently, CENP-C was shown to influence the shape and dynamics of 
CENP-A containing nucleosomes. Using purified proteins and AS DNA sequences in 
vitro, Black and colleagues showed that in the absence of the CENP-C central domain 
(CENP-CCD), which binds CENP-A, the H2A/H2B dimers within CENP-A containing 
nucleosomes are approximately 5 angstroms farther apart than when reconstituted with 
the CENP-CCD. This increased distance between the H2A/H2B dimers is predicted to 
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weaken the physical connection between the H2A subunit on one face of the 
nucleosome, and the H4 subunit on the opposite face of the nucleosome. Thus, CENP-C 
functions to protect both the shape and the rigidity of CENP-A containing nucleosomes. 
This study also showed that CENP-C binding affects how tightly DNA is wrapped around 
CENP-A containing nucleosomes [328].    
The CENP-T-W-S-X Heterotetramer:  
 
 The CENP-T-W-S-X heterotetramer is composed of four CCAN proteins, CENP-
T, CENP-W, CENP-S, and CENP-X. This heterotetramer was discovered as two 
separate complexes, including the CENP-T-W complex and the CENP-S-X complex. 
CENP-T-W was first shown to be vital for kinetochore formation and function, and a 
detailed structural analysis of this complex revealed that CENP-T and CENP-W both 
contain histone fold domains, suggesting DNA-binding properties. Indeed, digested 
centromeric DNA immunoprecipitated with both CENP-T and CENP-W, and mutational 
analysis revealed that the histone fold domains are required for centromere targeting. 
Further, this complex was shown to associate with histone H3-containing nucleosomes, 
but not with CENP-A containing nucleosomes at centromeres [329]. A short time later, 
CENP-X was identified as an interacting partner with CENP-S, another CCAN protein 
containing a histone fold domain [330]. A detailed structural analysis of these complexes 
has revealed that CENP-T-W forms a dimer highly homologous to the structure of the 
histone H2A–H2B or H3–H4 dimers within the nucleosome, as does the CENP-S-X 
complex.  When these complexes were combined in equimolar ratios in solution, CENP-
S-X and CENP-T-W co-migrated and formed a single stoichiometric complex, 
suggesting that both dimers interact to form a heterotetramer. Further, the CENP-T-W-S-
X complex was shown to bind to approximately 100 base pairs of DNA as a (CENP-T-W-
S-X)2 structure, and although this complex is predicted to bend centromeric DNA in a 
manner similar to canonical histones, it is believed that the CENP-T-W-S-X complex 
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induces positive supercoils rather than negative coils, adding specificity to centromeric 
chromatin [331].  In this study, depletion of either the CENP-T-W or the CENP-S-X 
complex prevented formation of a functional kinetochore, suggesting that the CENP-T-
W-S-X heterotetramer contributes to the specialized chromatin architecture of this region 
[331, 332]. 
 In addition to epigenetically distinguishing the centromere from other genomic 
loci, the CENP-T-W-S-X complex contributes to faithful chromosome segregation by 
recruiting the KMN network to kinetochores. More specifically, the N-terminal tail of 
CENP-T interacts with KMN network component Ndc80, a key microtubule binding 
component of the outer kinetochore [333]. The CENP-T-W-S-X complex is interspersed 
between CENP-A containing and histone H3-containing nucleosomes at core 
centromeres.         
 
The Centrochromatin: Centromere-Specific Histone Modifications 
 In addition to the presence of CENP-A, it is becoming more and more evident 
that other centromere-specific histone modifications are just as important for centromere 
identity. The centromeric chromatin maintains a unique bivalent signature of histone 
modifications that are neither heterochromatic, nor euchromatic. Thus, because this 
region is neither typical heterochromatin nor typical euchromatin, it has been dubbed 
“centrochromatin” to reflect the uniqueness of the blended histone marks. While studies 
over the past fifteen years have shed light on the characteristics of the centrochromatin, 
it continues to be an area that is difficult to study because of the repetitiveness of the AS 
DNA sequences at centromeres. To circumvent this problem, many groups have 
examined extended chromatin fibers probed with specific antibodies to identify histone 
modifications present in CENP-A containing regions. We have used chromatin 
immunoprecipitation experiments to evaluate the effect of Sp1 depletion on histone 
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modifications at centromeres, and have found that Sp1 regulates several of them. Thus, 
this section focuses on our current understanding of histone modifications at core 
centromeres, as well as the enzymes that may maintain them.  
Histone Modifications at the Core Centromere: 
    
 As a result of its repetitive nature, centromeric DNA was long thought to be 
heterochromatic. Then, a landmark 2004 study identified histone modifications typically 
associated with active transcription in CENP-A containing regions. This study showed 
that centromeric histone H3-containing nucleosomes are di-methylated on lysine 4 
(H3K4me2) [334]. H3K4me2 is often enriched at promoters of active genes, as well as at 
promoters of genes that are primed for future gene expression during cell development. 
H3K4me2 can also exist in large domains over both the gene promoter and the gene 
body, indicating that it may be a mechanism for fine-tuning gene expression [335, 336]. 
A later study showed that H3K4me2 is required for HJURP-dependent incorporation of 
CENP-A, and also identified H3K36me2 and H3K36me3 at centromeres, both 
modifications associated with active transcription [337]. Recently, H4K20me1 was 
identified in CENP-A containing nucleosomes, and was found to be important for 
kinetochore assembly by promoting localization of CENP-T, a component of the CENP-
T-W-S-X complex [338]. In other areas of the genome, H4K20me1 is necessary for 
active elongation by facilitating the release of RNA Polymerase II [339]. Additionally, 
monoubiquitinated H2B (H2Bub1), a modification associated with active transcription of 
many genes, is present at centromeres during the G2-M transition [340]. Interestingly 
however, H3K4me3, a prominent histone mark associated with active genes, is absent 
from centromeres, as are histone H3 and H4 acetylations typically found in euchromatin 
(H3K9 and H4K5, K8, K12 and K16) [334]. Thus, although many euchromatic marks are 
maintained at centromeres, other prominent marks are conspicuously absent.  
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Despite an incomplete set of euchromatic marks, centromeres are not 
heterochromatic, as they mostly lack heterochromatic modifications like H3K9me2 and 
H3K9me3 [334], although some studies show that a small fraction of H3 histones are tri-
methylated on lysine 9 within the core centromere [302, 341]. Heavily 
heterochromatinizing centromeric DNA is devastating for centromere function. One study 
showed that targeting tTs (a powerful transcriptional repressor) to centromeres on 
human artificial chromosomes resulted in the accumulation H3K9me3 and HP1, a 
classic component of heterochromatin, and prevented kinetochore protein assembly 
[342]. Heterochromatin appears to be restricted to the pericentromeric region, as the 
surrounding pericentromeric DNA is enriched for H3K9me2/3, H3K27me2/3, and 
H4K20me3 (Figure 2.4) [343-345].  
Histone Modifiers: 
 
 While much effort has been directed toward identifying the enzymes responsible 
for adding, maintaining, or removing modifications from histones in genomic DNA over 
the years, the specific enzymes responsible for maintaining core centromere 
modifications specifically, have not been identified. It is attractive to assume that the 
same enzymes are responsible, but this remains to be determined. For example, the 
H3K4 methylases Set1 and Ash2 are required for inheritance of active transcriptional 
states in other genomic areas during mitosis [346], but have not been identified as being 
required for H3K4me2 at core centromeres. Similarly, methylases Set2 and WHSC1 
methylate H3K36, but have not been observed at centromeres [347]. Some histone 
modifiers, including p300/CBP, HDAC1, and DNMT1, have been shown to localize to 
metaphase centromeres, but the function of these factors at centromeres is not yet 
known [348]. At pericentromeres, Suv39h is responsible for H3K9me3, and also 
indirectly regulates H4K20me3 (Figure 2.4) [344, 349].  
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Transcription Through Core Centromeres 
 Centromeres are actively transcribed in several different organisms, including 
Saccharomyces cerevisiae [350], Schizosaccharomyces pombe [351], rice [352], mouse 
[353], tammar wallaby [354], and humans [326, 355-358]. While this region was once 
thought to be transcriptionally inactive in human cells [359], a landmark study in 2004 
identified histone modifications associated with active transcription [334]. Since then, 
much effort has been directed toward understanding the significance of the 
centrochromatin, including the significance of transcription through the core centromere. 
Accumulating evidence reveals that transcription through the core centromere in human 
cells produces lncRNAs. Core transcription and the lncRNA transcripts are required for 
the incorporation of new CENP-A molecules, as well as kinetochore assembly and 
stability, making transcription a critical process in maintaining centromere identity and 
function [360].  
Evidence for Transcription at Core Centromeres in Human Cells:  
 
 One of the first studies that examined transcription through core centromeres in 
human cells evaluated transcription at neocentromeres, active centromeres that form on 
genomic DNA instead of AS DNA. This study showed that neocentromere formation on 
genomic DNA had no effect on the expression of the genes within the region of 
neocentromere kinetochore assembly, despite the requirement for major chromatin 
remodeling at these sites [358]. Thus, although transcription through core centromeres 
formed on AS DNA had not yet been evaluated, this study demonstrated that despite the 
unique bivalent signature of centromeric chromatin that isn’t necessarily “active”, it is 
permissive to transcription machinery. Another study using the 10q25 neocentromere on 
the Mardel (10) chromosome showed that RNA transcribed from an L1 retrotransposon 
that resides within the CENP-A bound chromatin of this neocentromere (called FL-L1b) 
was directly incorporated into the neocentromeric chromatin, and knockdown of this 
59 
 
RNA transcript resulted in a reduction in CENP-A binding [356]. A later study showed 
that single-stranded RNA is directly transcribed from AS DNA, binds CENP-C, and is 
required for the association of kinetochore proteins with centromeres. Here, the authors 
used RNA-FISH with centromere specific AS RNA probes to show that AS-derived RNA 
is enriched at the nucleolus, along with centromere proteins CENP-C and INCENP. 
Electrophoretic mobility-shift assays using radioactive-labeled RNA probes confirmed 
that the AS-derived RNA binds CENP-C, and RNAse treatment abolished CENP-C 
localization to centromeres by immunofluorescence [326]. A recent study biochemically 
purified AS-derived lncRNA and used northern blotting to reveal that HeLa cells possess 
a unique centromeric RNA species that migrates at approximately 1.3 kilobases [361].  
Transcription Factors at Centromeres in Human Cells: 
  
 In 2012, an important study identified RNA Polymerase II as the polymerase 
responsible for transcribing core centromeres. By immunofluorescence, Chan, et al. 
[355] showed that RNA Polymerase II localizes to mitotic centromeres but not interphase 
centromeres in HeLa cells, as early as prometaphase. Using the same techniques, they 
also identified CTDP1 (carboxy-terminal domain, RNA polymerase II, polypeptide A 
phosphatase, subunit 1), a transcription factor specific to RNA Polymerase II required for 
transcription elongation, as well as SSRP1 (structure-specific recognition protein 1), 
another key component of the RNA Polymerase II machinery. SSRP1 is a component of 
the FACT complex (facilitates chromatin transcription), a complex previously identified 
as being required for CENP-A targeting to centromeres, along with the ATP-dependent 
chromatin remodeling factor CHD1 [362]. TBP (TATA-box binding protein) was also 
shown to localize to CENP-A containing regions [361].   
Timing of Core Centromere Transcription:  
 
To determine whether RNA Polymerase II actively transcribes at centromeres 
during mitosis, Chan, et al. used a transcription assay with Fluorescein-12-UTP to label 
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actively transcribed RNA, and found that discrete Fluorescein signals were visible at the 
kinetochore during mitosis, but not during interphase [355]. Quantitative real-time 
reverse transcriptase PCR (qRT-PCR) for AS-derived lncRNA confirmed mitotic 
transcription of core centromeres, and inhibition of RNA Polymerase II with α-amanitin 
resulted in a 68% reduction in these transcripts, as well as reduced CENP-C localization 
and chromosome segregation errors [355]. 
The exact timing of centromeric transcription is under debate. Many studies point 
to mitosis, and more specifically metaphase, as the point at which lncRNAs are 
transcribed. For example, RNA Polymerase II was not visible at centromeres in 
prophase cells, whereas a small subset of prometaphase cells showed localization by 
immunofluorescence. Localization was robust by metaphase [355]. However, another 
study indicates that centromeres are not transcribed until early G1. This study evaluated 
chromatin fibers from HeLa cells at different stages of the cell cycle for RNA Polymerase 
II and TBP binding by immunofluorescence. They were not able to detect these proteins 
at CENP-A containing regions until after mitosis, in early G1 [361]. Although it is widely 
accepted that centromeres are only transcribed during a short period of time between 
the onset of mitosis and late G1, the exact timing is still unclear.       
Human Artificial Chromosomes (HACs): 
    
 The generation of human artificial chromosomes (HACs) has been an important 
tool for studying human centromeres. The centromere and kinetochore structure within 
HACs mimic those within endogenous chromosomes, and are able to be manipulated 
through protein targeting without affecting endogenous centromeres [363]. The most 
commonly used HAC for studying centromeres is the synthetic alphoidtetO array. The 
basic repeating unit of the alphoidtetO array includes an AS monomer from chromosome 
17, followed by a CENP-B box, then a second consensus sequence AS monomer. In 
place of the CENP-B box in the AS monomer consensus sequence is a tetracycline 
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operator (tetO). This cassette was cloned head to tail to create an 8-mer, subjected to 
rolling circle amplification, and subsequently transfected into yeast with a YAC/BAC 
backbone. Recombination within the yeast generated a HAC with 1.1 megabases of AS 
DNA [364, 365]. The tetO sites are recognized by a tetracycline repressor (tetR) protein 
in a tetracycline-inducible manner. This allows for specific and inducible targeting of 
tetR-fusion proteins to the AS sequences on HACs, providing a powerful tool for 
studying centromere structure and dynamics. 
 HACs have been useful for determining the impact of certain histone 
modifications on centromeric transcription. In one study, centromeric H3K4me2 was 
depleted from the HAC centromere by targeting LSD1, an H3K4me2-specific 
demethylase, to the alphoidtetO array. Loss of H3K4me2 resulted in a decrease in 
transcription of the alphoidtetO array, as well as a decrease in HJURP recruitment and 
subsequent loss of CENP-A. The decrease in H3K4me2 was also paralleled by a 
decrease in H3K36me2 [337]. These data imply that centromeric transcription is an 
important upstream regulator in CENP-A deposition. Further, a later study showed that 
acetylating centromeric chromatin results in an increase in centromeric transcription, and 
a similar loss of CENP-A. Here, the authors tethered the p65 subunit of the NF-kB 
transcription factor complex (NF-kB-p65) to the alphoidtetO array by creating an NF-kB-
p65-tetR fusion protein. This resulted in increased H3K9 acetylation, and a 10 fold 
increase in transcription of the alphoidtetO arrays. They also tethered the herpes virus 
transcriptional activator protein VP16 to the alphoidtetO arrays using the same technique, 
which resulted in similar histone modifications and a 150-fold increase in transcription at 
the HAC core centromere. This increase in transcription was paralleled by a dramatic 
loss of CENP-A at the HAC centromere due to a defect in CENP-A loading [366]. Taken 
together, these two studies reinforce the notion that dysregulation of centromeric 
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transcription, whether it be an increase in transcription or a decrease, has detrimental 
effects on centromere identity and function.               
A Functional Requirement for Transcription at Core Centromeres: 
 
 In recent years, it has become clear that transcription through the core 
centromere is important for centromere function. Disrupting core centromere 
transcription has resulted in several different defects, including reduction or loss of 
kinetochore proteins, aberrant mitoses, and a decrease in CENP-A. However, the exact 
function of transcription is still unclear.  
 Some suggest that the act of transcription alone facilitates CENP-A deposition, 
as the general process of transcription requires chromatin and nucleosome remodeling. 
Passage of RNA Polymerase II through the region may initiate nucleosome remodeling 
that allows for HJURP-dependent deposition of CENP-A. Although this theory has not 
been substantiated, the presence of the FACT complex at centromeres allows for the 
possibility. During gene transcription, FACT aids in nucleosome disassembly prior to the 
passage of RNA Polymerase II, and then reassembles nucleosomes behind RNA 
Polymerase II, contributing to efficient transcription [367]. The FACT complex has been 
linked to CENP-A in several species, including humans. Although it has not been 
implicated specifically in CENP-A deposition in human cells, one study showed that 
knockdown of FACT subunit SSRP1 resulted in a decrease in CENP-A [362]. In yeast, 
FACT is capable of removing CENP-A from non-centromeric loci [368], and in flies, 
CENP-A assembly requires RNA Polymerase II-mediated transcription of the core 
centromere, and that transcription is dependent on FACT [369]. Thus, the movement of 
RNA Polymerase II through the centromere, and the accompanying chromatin 
modifications required, may facilitate CENP-A deposition independently of the transcripts 
that result.   
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 Studies do show that AS-derived lncRNA transcripts plays an important role in 
centromere function. Some centromere proteins have been shown to directly bind to 
lncRNA, and this RNA binding is required for their centromeric localization. For example, 
CENP-C contains a domain that is homologous to the HP1 (heterochromatin protein 1) 
hinge region (CENP-C amino acids 426–551), a region shown to have RNA-binding 
activity. This CENP-C domain binds AS-derived lncRNA by electrophoretic mobility-shift 
assay, and RNAse treatment abolishes CENP-C localization to centromeres by 
immunofluorescence [326]. This indicates that the centromere-derived transcript is 
required for CENP-C localization. As mentioned, CENP-C is a critical protein for 
maintaining centromere identity and function, as it is required for CENP-A deposition 
through the recruitment of the Mis18 complex, as well as for recruitment of outer 
kinetochore proteins. Thus, AS-derived lncRNA transcripts are indispensable for 
localization of these proteins as well. The same study showed that INCENP (inner 
centromere protein) and Survivin, both components of the CPC (chromosomal 
passenger complex), fail to localize to metaphase centromeres in cells treated with 
RNAseA, suggesting that an RNA component is required. Further, introduction of 
endogenous AS RNA restored localization of CENP-C and INCENP. Survivin was not 
evaluated [326]. Another study found that AS-derived lncRNA binds to Aurora B kinase, 
also a component of the CPC, and is required for its localization to metaphase 
centromeres [370].    
  A recent study showed that inhibition of transcription results in a decrease in 
CENP-A and HJURP recruitment to centromeres. Computational RNA-binding prediction 
algorithms suggest that both HJURP and CENP-A may bind RNA. To test if AS-derived 
lncRNAs bind to these proteins, HJURP and CENP-A were immunoprecipitated from 
both a soluble fraction and a chromatin fraction of HeLa cells. Then, RNA was purified 
from the immunoprecipitated proteins, and evaluated for AS-derived lncRNAs by 
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northern blot. Results showed that a 1.3 kilobase RNA species binds to CENP-A in both 
the soluble and the chromatin fraction, but only binds HJURP in the soluble fraction. 
Thus, lncRNA may bind to the HJURP/CENP-A complex prior to CENP-A loading, and 
may also bind CENP-A that has been incorporated into the centrochromatin. Abolishing 
AS-derived lncRNAs by RNAi prevented recruitment of both proteins to centromeres 
[361]. 
 The RNA transcripts themselves may hybridize to the centrochromatin from 
which they are transcribed, forming an RNA-DNA hybrid called an R-loop. An R-loop is a 
three-stranded nucleic acid structure generated by the act of transcription, and is formed 
by the RNA-DNA hybrid plus the displaced DNA strand identical to the RNA molecule 
[371]. Generally, these structures pose a threat to genomic integrity, as they cause an 
increase in spontaneous mutagenicity. R-loops are also a substrate for DNA modifying 
enzymes like AID (activation induced cytidine deaminase), an enzyme known to cause 
DNA double-strand-breaks during antibody gene diversification [372]. At centromeres, 
the repair of double-strand-breaks caused by R-loops could result in repair-coupled 
chromatin remodeling that facilitates CENP-A deposition [373]. Evidence for this has 
only been observed in Xenopus, where CENP-A assembly is modulated by the presence 
or absence of active DNA repair machinery at centromeres [374].           
Dysregulation of Centromeric Transcription: 
 
Many studies have shown that loss of AS-derived lncRNAs result in aberrant 
mitoses. In one study using HeLa cells, knockdown of AS-derived transcripts using 
antisense RNA/DNA chimeric oligonucleotides, which degrade annealed RNAs by 
endogenous RNase H activity, resulted in nuclei with an abnormal morphology. 
Immunofluroescence analysis revealed that the abnormal nuclei resulted from the 
inability of spindle microtubules to make connections with chromosomes, and as a 
result, chromosomes failed to align along the metaphase plate [370]. In another study, 
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depletion of AS-derived lncRNAs by RNAi resulted in 42.2% of cells having multipolar 
spindles and lagging chromosomes [361].  
While it is evident that depletion of AS-derived lncRNAs results in mitotic defects, 
the same appears to be true for an increase in expression of these lncRNAs. The 
tammar wallaby is a mammalian model system useful for studying centromeres because 
their centromeres are small (about 420 kilobases) and well characterized. One 
component of the tammar wallaby centromere is the kangaroo endogenous retrovirus 
(KERV) long terminal repeat (kLTR), a region of centromeric chromatin that produces 
RNA transcripts ranging in size from 34 to 42 nucleotides. These RNAs are termed 
centromere repeat-associated short interacting RNAs, or crasiRNAs. When crasiRNAs 
were over-expressed by transfection of kLTR sequences, cells failed to load newly 
transcribed CENP-A molecules at centromeres. Further, a range of mitotic defects 
resulted, including chromatin fragments and lagging chromosomes [375]. Studies in 
HACs showed a similar effect when transcription of HAC centromeres were upregulated. 
Acetylating centromeric chromatin resulted in an increase in centromeric transcription, 
and a similar loss of CENP-A [366]. Finally, ectopically expressing AS DNA in human 
mammary epithelial cells resulted in increased abnormal mitoses, including anaphase 
bridges, lagging chromosomes, and disorganization of chromosomes during metaphase 
[376].  
 
Conclusions 
 Centromere identity must be carefully maintained throughout the cell cycle so 
that the CCAN and the kinetochore complex properly associate and assemble onto one 
and only one locus per chromosome to avoid errors in chromosome segregation. As 
discussed above, it is clear that CENP-A is the most important factor for centromere 
identity. Deletion of CENP-A results in a mitotic lethal phenotype [284], and over-
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incorporation, under-incorporation, or mis-incorporation of CENP-A molecules is 
associated with chromosome segregation errors and cancer [287, 288]. This likely 
results from disrupted CCAN assembly and kinetochore formation, and subsequent 
spindle attachment errors. Current research suggest that CENP-A deposition depends 
on CCAN components CENP-C and CENP-I. These CCAN components recruit the 
Mis18 complex to centromeres, which in turn recruits HJURP to facilitate the exchange 
of canonical histone H3 for CENP-A, thereby maintaining CENP-A protein levels and 
centromere identity.     
Although the exact function of transcription through core centromeres is still 
unclear, recent work has indicated that transcription is an important regulatory 
component for CENP-A deposition. As discussed above, the transcription-coupled 
chromatin remodeling associated with core transcription may itself assist in CENP-A 
deposition. Additionally or alternatively, the lncRNA transcripts that result from core 
transcription bind to centromere associated proteins, including CENP-C, HJURP, and 
CENP-A, and act to recruit and/or stabilize these proteins at centromeres. Further, 
lncRNAs may bind to centromeres to create R-loops, and the chromatin remodeling 
associated with repair of R-loop-induced DNA double-strand-breaks could facilitate 
CENP-A deposition. Despite its emerging importance, very little is known about what 
regulates transcription through core centromeres. Our work discussed in Chapters 4 and 
5 demonstrates that Sp1 is a negative regulator of core transcription and is therefore an 
important upstream factor for CENP-A deposition. Sp1 likely regulates core transcription 
by maintaining histone modifications at this region, as these are also disrupted in Sp1-
depleted cells. Further, our work shows that Sp1 depletion causes a decrease in CENP-
C binding to centromeres, as well as a decrease in CENP-A deposition. Taken together, 
these data indicate that Sp1 is an important component of centromere biology, and as 
such contributes to faithful chromosome segregation.      
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Figure 2.1: Overview of Mitotic Chromatin. As a cell enters mitosis, chromatin 
condenses to form mitotic chromosomes. Sister chromatids remain joined at 
centromeres with the help of sister-chromatid-cohesin complexes that are loaded during 
DNA synthesis. Centromeres are defined by CENP-A-containing nucleosomes and are 
flanked on either side by pericentromeric heterochromatin. The constitutive-centromere-
associated network of proteins (CCAN) associates with CENP-A-containing regions 
throughout the cell cycle. During mitosis, the CCAN recruits outer kinetochore proteins, 
which interact with spindle microtubules emanating from centrosomes at opposite poles 
of the cells    
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Figure 2.2: The Constitutive-Centromere-Associated Network (CCAN) and the 
Kinetochore. The CCAN encompasses a network of 16 proteins that localize to 
centromeres throughout the cell cycle and serve as a bridge between the centromeric 
chromatin and the outer kinetochore and spindle microtubules. CCAN components can 
be broken down into five groups, including CENP-C, the CENP-L-N complex, the CENP-
H-I-K-M complex, the CENP‑O‑P‑Q‑U‑R complex, and the CENP‑T‑W‑S‑X complex. 
CENP-C is a key kinetochore assembly factor. It is recruited to centromeres by CENP-A 
and is also required for CENP-A loading at centromeres through recruitment of the 
Mis18 complex. CENP-C also recruits the CENP-H-I-K-M complex to centromeres, as 
well as outer kinetochore component Mis12. CENP-H-I-K-M interacts with several CCAN 
proteins, including CENP-T-W-S-X and CENP-C, and thus may function to stabilize 
these proteins. CENP-L-N interacts with both CENP-C and the CENP-H-I-K-M complex. 
The function of the CENP-O-P-Q-U-R is still unclear, as disruption of this complex by 
protein knockdown of CENP-O had no measurable effect on kinetochore assembly or 
function [377]. CENP-T-W-S-X binds centromeric DNA and is thought to induce positive 
supercoiling. It also interacts with KMN network protein Ndc80. The KMN network of the 
outer kinetochore makes attachments with spindle microtubules. Each centromere 
contains 20 to 25 kinetochores and attaches to the same number of microtubules.      
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Figure 2.3: Human A-satellite Consensus Sequence. The human α-satellite 
consensus sequence is 171 base pairs in length, with a high adenine and thymine 
content (62%) [378].     
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Figure 2.4: Histone Modifications at the Centrochromatin. Histone H3 is di-
methylated on lysine 4, and di- and tri-methylated on lysine 36. These modifications are 
known to be associated with active transcription. CENP-A is tri-methylated on glycine 1, 
catalyzed by NRMT. Serine 7 is phosphorylated, which is important for stabilization of 
the CENP-A nucleosome, as well as the interaction between CENP-A and CENP-C. 
CENP-A is also phosphorylated on serine 16 and 18, modifications that also influence 
the stability of the CENP-A nucleosome as well as the conformation of CENP-A 
containing nucleosome arrays. Finally, lysine 124 is monoubiquitinated by the CUL4A-
RBX1-COPS8  E3 ubiquitin ligase, required for the interaction between CENP-A and its 
assembly factor HJURP. The histone H4 within CENP-A containing nucleosomes is 
methylated on lysine 20, and promotes localization of CENP-T. H2B is 
monoubiquitinated (H2Bub1), although it is not known if this modification is restricted to 
CENP-A- or H3-containing nucleosomes. H2Bub1 is also associated with active 
transcription in other areas of the genome. Pericentromeric heterochromatin contains 
typical heterochromatin modifications, some of which are catalyzed by Suv39h1, 
including H3K9me3 and H4K20me3. Centromchromatin generally lacks histone H3 and 
H4 acetylation. p300/CBP, HDAC1, and DNMT1 have all been shown to localize to 
centromeres during mitosis, but the targets of these modifiers have not been identified.  
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Chapter 3: Specificity Protein 1 
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Introduction 
 Specificity Protein 1 (Sp1) was identified in the early 1980’s as a factor that has 
the ability to alter the activity of RNA Polymerase II so that it can recognize the SV40 
promoter and activate transcription of SV40 genes [379, 380]. In the last almost four 
decades, hundreds of studies have focused on attempting to gain a complete 
understanding of the transcriptional functions of Sp1. Initial studies suggested that Sp1 
was a general transcription factor required for basal transcription of housekeeping 
genes. This notion was supported by the fact that the GC-rich Sp1 binding sequence 5’-
(G/T)GGGCGG(G/A)(G/A)(G/T)-3’ is present in the promoters of many housekeeping 
genes [381] and that Sp1 was found to be required for the assembly of the RNA 
Polymerase II preinitiation complex (discussed below) [382, 383]. It is now clear that Sp1 
is not just a general transcription factor required for basal transcription but also has 
promoter-specific functions that include activating or repressing transcription of specific 
genes with TATA-less or TATA-containing promoters. Here, Sp1 functions to recruit 
transcriptional co-regulators such as chromatin remodeling complexes to promoters to 
influence gene transcription [382]. 
 In recent years, we have focused efforts on elucidating non-transcriptional roles 
for Sp1, adding another layer of complexity to a protein with a diversity of functions. The 
most well characterized non-transcriptional role is its facilitation of DNA double-strand-
break repair. Our studies have demonstrated that Sp1 is required for repair, as depletion 
of Sp1 by RNAi inhibits repair at site-specific DNA double-strand-breaks. Further, we 
have shown that Sp1 is phosphorylated by the DNA-damage sensory kinase ATM 
(ataxia telangiectasia mutated) in response to DNA double-strand-breaks and is rapidly 
recruited to regions immediately adjacent to sites of DNA damage [384]. Within this 
context, Sp1 appears to recruit the histone acetyltransferase p300 to break sites to 
facilitate chromatin remodeling required for repair (Guo, Beishline, Azizkhan-Clifford, 
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unpublished). In addition to its role in DNA double-strand-break repair, Sp1 also 
localizes to centrosomes and regulates centrosome number as depletion of Sp1 by RNAi 
results in centrosome amplification. Further, a deletion mutant of Sp1 lacking amino 
acids 1-182 does not localize to centrosomes or rescue the supernumerary centrosome 
phenotype in Sp1-depleted cells. Because this portion of the Sp1 protein has almost 
100% transcriptional activity on its own, these data suggest that regulation of 
centrosome number and function by Sp1 is non-transcriptional [7]. More recently, we 
have shown that amino acids 1-182 alone can localize to centrosomes and rescue the 
centrosome defects observed in Sp1-depleted cells, further supporting this notion 
(Flashner, Sowash, Azizkhan-Clifford, unpublished).  
In Chapters 4 and 5, I discuss a novel function for Sp1 in preserving centromere 
identity and function by regulating transcription through the core centromere during 
mitosis, likely through the recruitment of chromatin modifiers. As such, this chapter will 
introduce the Sp1 protein and review what is currently known about Sp1 during mitosis. 
It will also discuss chromatid modifiers known to interact with Sp1 at gene promoters to 
influence transcription; these modifiers may be recruited by Sp1 to centromeres to 
maintain the architecture of the centrochromatin.      
 
The Specificity Protein/Krüppel-like Factor (SP/KLF) Transcription Factor Family 
 Sp1 is a member of the Specificity Protein/Krüppel-like Factor (SP/KLF) 
transcription factor family [385]. In addition to Sp1, the Sp/KLF transcription factor family 
contains Sp2-4, Sp5-9, and a number of KLF transcription factors [386-388]. This family 
is united by the highly conserved Cys2His2-type zinc-finger, DNA-binding domain that 
consists of three adjacent zinc fingers close to the C-terminus of the proteins, which 
shares more than 65% sequence identity throughout [385]. Sp and KLF factors differ in 
the DNA sequences with which they preferentially bind. Sp factors bind with high affinity 
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to GC-boxes (GGGGCGGGG), whereas KLF factors bind to the related GT/CACCC-box 
(GGTGTGGGG) [389]. Of these family members, Sp1-4 are most similar. In addition to 
the DNA-binding domain, Sp1-4 also each contain transactivation domains that are 
serine/threonine-rich and are flanked by glutamine rich regions [388]. These and other 
domain features of Sp1-4 are illustrated in Figure 3.1. Sp1 and Sp3 are ubiquitously 
expressed in mammalian cells and are the most thoroughly studied. Sp2 is also 
expressed ubiquitously [390], but Sp2 does not bind to GC-boxes, significantly 
differentiating it from the other Sp proteins. Sp4 expression is mostly limited to the brain 
[391]. Because the data in Chapters 4 and 5 describe a novel function for Sp1, this 
section will focus solely on Sp1.  
 
The Sp1 Gene and Protein(s) 
 The Sp1 gene is located on chromosome 12 at position q13.1 (position 
53380195 in the current GRCh38.p2 assembly) and consists of 6 exons and 5 introns 
spanning 36 kilobases. There are three known isoforms of the Sp1 protein. Isoform 1, 
also known as Sp1a, is translated from a 2355 base pair transcript, creating a 785 amino 
acids protein that is 80.9 kilodaltons in the unmodified form. Isoform 2 (Sp1b) lacks the 
first 7 amino acids found in isoform 1, contains an alternative exon in the 5′ coding 
region, and is created using a second ATG start codon found at position +21 from the 
start codon used by isoform 1. The unmodified form of Sp1b is 778 amino acids and 80 
kilodaltons. A third isoform, Sp1c, is created through alternative splicing and results in a 
protein that lacks amino acids 54 through 101. The unmodified form of Sp1c is 737 
amino acids and 75.8 kilodaltons [392, 393]. Sp1a is the primary form of the protein and 
is ubiquitously expressed in all mammalian tissues. While Sp1a is likely one of the most 
well-characterized transcription factors to date, much less is known about Sp1b and 
Sp1c. One group showed that Sp1c is also ubiquitously expressed, although at very low 
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levels as compared to Sp1a [393]. The Sp1 protein is highly unstructured, with the 
exception of the DNA-binding domain. Sp1 is also highly post-translationally modified 
(discussed in more detail below). These two features allow the Sp1 protein to have 
multiple interacting partners, contributing to its functional diversity.  
 
Sp1 and Gene Regulation 
The promoters of genes contain a variety of different DNA elements that are 
recognized by both general and specific transcription factors. These transcription factors 
bind to promoter elements and function to control gene expression. It is predicted that 
there are over 12,000 Sp1 binding sites within the genome, indicating that Sp1 
transcriptionally regulates a vast amount of genes that are involved with almost all 
cellular processes [385]. Sp1 has been shown to act as a general transcription factor as 
well as both a transcriptional activator and transcriptional repressor. 
Sp1 as a General Transcription Factor: 
General transcription factors mark promoters that require RNA Polymerase II for 
gene transcription. To begin transcription, the TFIID protein complex binds to a short 
sequence of adenine and thymine nucleotides, called the TATA box, through the TFIID 
component TBP (TATA-binding protein). It is thought that binding of the TFIID complex 
causes a topological distortion in the DNA, which serves as a physical indicator of 
promoter activation. From there, other general transcription factors, as well as RNA 
Polymerase II, assemble to form the transcription-initiation complex. However, not all 
gene promoters contain TATA-boxes and require alternative means for recruiting and 
binding the TFIID complex. As a general transcription factor, Sp1 binds to Sp1 binding 
sites within gene promoters and interacts with components of the TFIID complex to 
recruit the complex to DNA. Sp1 interacts directly with TBP as well as TAFII130 (TBP-
associated factor) and TAFII55 to stimulate transcription initiation [394, 395]. Sp1 also 
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assists in the stable assembly of TFIIB and TFIIE [383] and may interact with TFIIA, 
although it is not clear if this interaction is direct [396].  
In addition to general transcription factors, eukaryotic genes bind other proteins 
to influence gene transcription, including mediator proteins, transcriptional activators and 
repressors, and chromatin modifying enzymes. Mediator proteins act as a bridge 
between general transcription factors and transcriptional activators and repressors that 
may be thousands of nucleotides away from the transcription-initiation complex. In some 
contexts, Sp1 interacts with the mediator protein CRSP (cofactor required for Sp1), as 
with the synergistic activation by Sp1 and SREBP-1a (sterol regulatory element-binding 
protein-1a) [397, 398]. Sp1 as a transcriptional activator and repressor is discussed 
below. 
Sp1 as a Specific Transcription Factor: 
In addition to aiding in the assembly of the preinitiation complex at RNA 
Polymerase II-dependent gene promoters, Sp1 acts as a transcriptional activator and 
transcriptional repressor at specific gene control regions. Transcriptional activators and 
repressors function to direct local alterations in chromatin structure to stimulate or 
repress transcription, respectively. This occurs through alterations in histone 
modifications and nucleosome architecture, which is accomplished though attracting 
histone modifying enzymes, chromatin remodeling complexes, and histone chaperones 
to DNA. 
Histone acetyltransferases function by transferring acetyl groups to lysine 
residues on histones, neutralizing the positive charge normally present on lysines. This 
reduces the affinity between the histones and the negatively charged DNA, making the 
DNA more accessible for transcription factors, thereby accelerating the rate of 
transcription. As a transcriptional activator, Sp1 binds directly to histone 
acetyltransferases like p300 and CBP (CREB-binding protein) and positions them at 
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promoters to stimulate transcription. For example, Sp1 recruits p300 to the promoter of 
the 12(S)-lipoxygenase gene to enhance its expression [399]. Similarly, in some 
contexts, Sp1 interacts with p300 to activate the p21 promoter and the p27 promoter 
[400, 401] and stimulates the histone acetyltransferase activity of CBP in vitro [402]. 
Histone deacetylases and DNA methyltransferases function to repress gene 
activity. Histone deacetylases remove acetyl groups from lysines, allowing for DNA to 
wrap more tightly around nucleosomes, thereby preventing access by transcription 
factors. DNA methyltransferases catalyze the transfer of methyl groups onto DNA, and 
when this occurs in promoter regions, DNA methylation typically acts to repress gene 
expression. Sp1 is known to bind to both histone deacetylases and DNA 
methyltransferases to negatively affect gene expression. For example, amino acids 619-
785 of Sp1 interact with HDAC1 (histone deacetylase 1) to facilitate repression of the 
p21 gene. Here, HDAC1 competes with p53 for Sp1 binding, and as such, Sp1 acts as a 
mediator of both positive (when associated with p53 or p300, as mentioned above) and 
negative (when associated with HDAC1) p21 expression, depending on the cellular 
context [403-405]. Sp1 is also required for HDAC1-dependent repression of SSeCKS 
(Src-suppressed C kinase substrate) as transcriptional repression of SSeCKS correlates 
with increased binding of Sp1 and increased recruitment of HDAC1 to the SSeCKS 
promoter [406]. Another study using the S-phase-specific mouse thymidine-kinase (TK) 
promoter as a model system showed that HDAC1 interacts with the C-terminus of Sp1 to 
repress transcription of TK expression. Here, HDAC1 competes with transcription factor 
E2F1 for Sp1 binding; the E2F1-Sp1 interaction relieves HDAC1-mediated repression 
[407]. Further, in normal human somatic cells, Sp1 is tightly associated with hTERT 
(human telomerase reverse transcriptase) gene promoters and recruits HDAC2 (histone 
deacetylase 2) to transcriptionally silence hTERT expression [408]. In HeLa cells, one 
study demonstrated that Sp1 recruits the DNA methyltransferase DMNT1 to the MAZ 
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(Myc-associated zinc-finger protein) promoter to repress transcription of the MAZ gene. 
Here, treatment with the methylation inhibitor 5-azacytidine reversed Sp1-dependent 
MAZ repression [409]. Finally, Sp1 interacts with a complex of proteins including 
HDAC1, HDAC2, and RbAp48 at the hLHR (human luteinizing hormone receptor) 
promoter to silence transcription of hLHR [410].  
ATP-dependent chromatin remodeling complexes can move, eject, or restructure 
nucleosomes in order to influence gene expression. Sp1 is known to interact with 
several of the components of the nucleosome remodeling complex SWI/SNF 
(SWItch/Sucrose Non-Fermentable) [382]. In particular, at the MMP-2 (matrix 
metalloproteinase 2) promoter, Sp1 interacts with BRG1, a component of the SWI/SNF 
complex, for constitutive expression of MMP-2 in tumor cells [411]. Further, an in vitro 
transcription assay showed that Sp1-dependent transcription required SWI/SNF 
component PBAF (polybromo- and BAF-containing complex) [412]. Finally, Sp1 interacts 
with and recruits SWI/SNF1 to human β-globin-gene promoters to activate transcription 
[413, 414]. In addition to the SWI/SNF complex, Sp1 interacts with HMGA1 and HMGA2 
(High Mobility Group A) proteins to enhance gene transcription. HMGA proteins can both 
positively and negatively regulate gene transcription and do so by binding to the minor 
groove of DNA, resulting in a change in the DNA structure, as well as by binding to a 
variety of transcription factors. Sp1 was found to associate with HMGA1 at the promoter 
of the IGF-I receptor gene to stimulate transcription [415] and interacts with HMGA2 at 
the hTERT promoter, thereby stimulating hTERT expression in HeLa cells [416]. Overall, 
Sp1 not only acts as a general transcription factor but also influences transcription of 
specific genes by interacting with a multitude of activators and repressors at gene 
control regions.      
 
Post-Translational Modifications (PTMs) for Sp1    
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Sp1 is a highly post-translationally modified protein. The unstructured nature of 
Sp1 allows for many different interacting partners, and as such, the PTMs of Sp1 likely 
confer specificity to those interactions. Sp1 is known to be phosphorylated, O-linked 
glycosylated, acetylated, SUMOylated, and ubiquitinylated. For a complete list of Sp1’s 
PTMs, including the enzyme responsible for the PTM and the consequence of the 
modification (when known), refer to Table 3.1. Mitosis-specific PTMs will be reviewed in 
this section. 
 An early study aimed at examining phosphorylation of the 5-amino-acid-linker 
sequence separating the zinc fingers in proteins containing Cys2His2-type zinc-finger, 
DNA-binding domains showed that the linker sequence in Sp1 is phosphorylated during 
mitosis as a potential mechanism for mitotic inactivation of the protein. The 
phosphorylated residues were identified as threonine 651 and threonine 681 [417]. While 
PKC-ζ (protein kinase C-ζ) has been shown to phosphorylate Sp1 at these residues in 
other contexts, mitotic-specific phosphorylation of Sp1 by PKC-ζ has not been 
demonstrated [418]. Sp1 was shown to be phosphorylated at serine 59 but the cell cycle 
timing of this particular phosphorylation is controversial. One study demonstrated that 
serine 59 is phosphorylated by CDK2/Cyclin A in late G1 and S phases of the cell cycle 
to enhance Sp1-mediated transcription [419]. Another study, however, showed that Sp1 
is phosphorylated at this residue during mitosis; in this study, the authors monitored 
phosphorylation of this residue in resting and dividing T lymphocytes using an antibody 
developed specifically against phospho-serine 59. They found that the phospho-serine-
59 signal is diminished in interphase cells but not in mitotic cells, suggesting that it is a 
mitotic phosphorylation. They also showed that the phospho-serine-59 signal could only 
be partly decreased by treatment with the CDK2 inhibitor roscovitine, suggesting that 
another kinase is also responsible for phosphorylation of this residue. Interestingly 
though, over-expression of the mitotic kinase CDK1/Cyclin B1 did not increase 
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phosphorylation status at serine 59, even when wild-type Sp1 was over-expressed [420]. 
Sp1 is phosphorylated by JNK1 (c-Jun NH(2)-terminal kinase 1) at threonines 278 and 
739 during mitosis and also on threonine 739 by CDK1/Cyclin B1 during mitosis, as 
discussed below.  
 
Sp1 and Mitosis 
 Studies have shown that during mitosis, as chromatin condenses into 
chromosomes, most transcription factors dissociate from chromatin and become 
dispersed throughout the cell. By telophase, these transcription factors are largely 
restored so that they are available for DNA binding as the chromatin decondenses at the 
exit of mitosis. Examples of transcription factors that follow this pattern include Oct-1, 
Fos-family transcription factors, and TFIIB [421, 422]. Other transcription factors have 
been shown to remain associated with mitotic chromatin throughout mitosis, including 
the transcription factor Runx1 (Runt-related transcription factor 1) [423] and AP2 
(activating protein 2) [421]. As such, it is difficult to predict the localization pattern of a 
particular transcription factor without careful evaluation. Our studies focus on the 
behavior of Sp1 during mitosis. Thus, this section summarizes how Sp1 is described 
during mitosis in the current literature.   
A handful of studies have shown that Sp1 is ejected from chromatin during 
mitosis. The first study, published in 1995, demonstrated that in mitotic extracts from 
HeLa cells Sp1 showed an approximately 5-fold reduction in specific DNA-binding 
activity, which was accompanied by a change in phosphorylation status [421]. Then, in 
2006, another group analyzed the spatial distribution of Sp1 in MCF-7 cells during 
mitosis and similarly found that Sp1 translocates away from chromatin during 
prometaphase and returns by telophase. This study additionally showed that Sp1 co-
localizes with F-actin microfilaments in the cytoplasm, likely to retain organization and to 
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stabilize the protein during cell division [424]. Importantly, a later study revealed that Sp1 
is phosphorylated by JNK1 (c-Jun NH(2)-terminal kinase 1) at two residues during 
mitosis, including threonine 278 and 739, and inhibition of JNK1 activity resulted in the 
ubiquitination and degradation of Sp1 [425]. Threonine 739 is close to the Sp1 DNA-
binding domain and thus likely facilitates Sp1’s eviction from the chromatin by sterically 
interfering with zinc-finger binding. The interaction between JNK1 and Sp1 is facilitated 
by Hsp90 (heat shock protein 90), which binds Sp1 primarily during mitosis [426]. A later 
study demonstrated that phosphorylation on threonine 739 also functions to stabilize 
Sp1 by preventing the interaction between Sp1 and the E3 ubiquitin ligase RNF4 [427]. 
Interestingly, Sp1 is also phosphorylated on threonine 739 by CDK1/Cyclin B1 during 
mitosis to suppress DNA binding. In this study, mutation of threonine 739 to alanine 
resulted in Sp1 remaining bound to chromatin. Mass spectrometry also revealed that 
Sp1 interacts with F-actin and myosin during mitosis, supporting earlier studies. This 
study also showed that Sp1 is dephosphorylated by PP2A (protein phosphatase 2A) 
upon mitotic exit to restore Sp1 DNA binding affinity [420, 428]. In contrast to what is 
reported in the literature, Chapters 4 and 5 describe our studies showing that a small 
pool of Sp1 remains at centromeres during mitosis and is involved with maintaining 
centromeric architecture through transcriptional regulation at this region.              
 
Sp1 and Whole Chromosomal Instability (W-CIN)      
The cell employs several surveillance systems to ensure that its genomic content 
is passed to its daughter cells with little genomic variation. As discussed in Chapter 1 
and 2, there are several mechanisms at centromeres and centrosomes that function to 
ensure proper chromosome segregation. These mechanisms can be disrupted in a 
number of different ways, resulting in chromosome segregation errors that can lead to 
whole chromosomal instability (W-CIN), aneuploidy, and cancer. The data presented in 
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Chapters 4 and 5 reveal a previously uncharacterized role for Sp1 in preserving 
chromosomal stability. Other known links between Sp1 and W-CIN are discussed below.   
Sp1 and Centrosome Regulation: 
In a previous study, we demonstrated that Sp1 depletion results in phenotypes 
that are consistent with W-CIN. Here, NHDF (normal human diploid fibroblast) cells 
depleted of Sp1 by RNAi showed a significant increase in the number of multi-nucleated 
cells as compared to control cells. Sp1 depletion also resulted in mis-alignment of 
metaphase chromosomes along the metaphase plate. In the W-CIN-negative mammary 
epithelial cell line MCF 10A, Sp1 depletion resulted in aneuploidy as Sp1-depleted cells 
showed a statistically significant increase in chromosome number as compared to 
control cells. The lack of tetraploid karyotypes suggested that this was not due to 
cytokinesis defects but rather from errors in chromosome segregation [7]. In addition to 
W-CIN, these studies also demonstrated that Sp1 depletion results in centrosome 
amplification. As discussed in Chapter 1, centrosome amplification can lead to improper 
attachment of microtubules to kinetochores and if not corrected, chromosome 
segregation errors. Further, this study showed that Sp1 localizes to centrosomes, and a 
deletion mutant of Sp1 lacking amino acids 1-182 did not localize to centrosomes or 
rescue the supernumerary centrosome phenotype in Sp1-depleted cells. Because this 
portion of the Sp1 protein has almost 100% transcriptional activity, these data suggest 
that regulation of centrosome number and function by Sp1 is non-transcriptional. More 
recently, we have found that a fragment of Sp1 comprising amino acids 1-182 can on its 
own localize to centrosomes and rescue the supernumerary centrosome phenotype 
(Flashner, Sowash, Azizkhan-Clifford, unpublished). Taken together, it is clear that Sp1 
maintains faithful chromosome segregation through centrosome regulation.      
Sp1 and Survivin: 
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 Survivin is a component of the CPC (chromosomal passenger complex) and 
functions to correct mal-attached microtubules through Aurora B kinase activity. This 
mitotic function for Survivin is evolutionally conserved and severe chromosome 
segregation defects have been found in Survivin-mutant yeast strains [429-432], 
Caenorhabditis elegans in which Survivin was knocked down by RNAi [433, 434], and 
Survivin-deficient mice [435]. Within this complex, Survivin dictates CPC localization by 
targeting it to centromeres through two aspartic acid residues in the BIR domain 
(discussed below) and is thus vital for CPC function [436, 437].   
In addition to functioning as a mitotic regulator, Survivin is also a member of the 
family of inhibitor of apoptosis proteins (IAPs) containing one baculovirus IAP repeat 
(BIR) domain [438]. IAPs function to inhibit apoptosis by directly binding to caspases, 
which prevents caspase cleavage and activation [439]. Survivin is dramatically over-
expressed in many tumors and fetal tissues [440], and the National Cancer Institute's 
cancer drug-screening program found that Survivin is expressed in all 60 human tumor 
lines that were tested with the highest levels in breast and lung cancer cells [441, 442]. 
Conversely, Survivin is expressed at very low levels or undetectable in normal healthy 
tissues. Over-expression of Survivin has been shown to inhibit apoptosis both through 
the extrinsic and the intrinsic apoptotic pathways. Here, Survivin binds to caspases 3, 7, 
and 9, disrupting the caspase-cleavage cascade required for apoptosis [443]. Further, 
Survivin was shown to inhibit cytochrome C and caspase 8 cleavage activity [444]. As 
such, in addition to being an important mitotic regulator, Survivin is also an integral 
component for apoptosis inhibition and cancer cell survival. Sp1 transcriptionally 
regulates Survivin gene expression. The Survivin promoter contains several Sp1 binding 
sites, and as such, perturbations in Sp1 expression affect Survivin-dependent apoptotic 
signaling [445].  
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Although it has not been carefully evaluated, changes in Sp1 protein levels likely 
also affect mitosis in a Survivin-dependent manner. Over-expression of Sp1 in tumors is 
correlated with increased Survivin expression [446, 447]. In a stomach adenocarcinoma 
cell line, over-expression of Survivin resulted in a decrease in cells that underwent 
mitotic slippage and subsequent cell death in response to treatment with the microtubule 
destabilizing drug monastrol. Here, over-expression of Survivin sustained mitotic arrest, 
potentially through increased CPC activity, thereby increasing viability of the cells and 
contributing to cell survival and continued proliferation [448]. Further studies are needed 
to evaluate the impact of Sp1-dependent changes in Survivin levels and CPC activity 
during mitosis.  
 
Sp1 and Cancer 
 In their 2000 paper entitled “Hallmarks of Cancer”, Hanahan and Weinberg 
described eight major “hallmarks” or characteristics that allow a transformed cell to 
survive, proliferate, and disseminate. These include sustained proliferative signaling, 
replicative immortality, resistance to cell death and avoidance of immune destruction, 
induction of angiogenesis, invasion and metastasis, and de-regulation of cellular 
energetics (Figure 1.1) [159]. Sp1 regulates genes whose products contribute to each of 
these characteristics, indicating that Sp1 could, and likely does, play a substantial role in 
cell transformation. A comprehensive list of cancer-related genes regulated by Sp1 can 
be found in Table 3.2. In support of this, Sp1 is over-expressed in several different types 
of cancers, including breast, gastric, pancreatic, lung, brain, and thyroid cancers, and 
increased Sp1 protein levels correlate with poor patient survival in several of these 
cancers [449-453]. Interestingly, Sp1 both activates and suppresses a number of 
oncogenes and tumor suppressor genes, respectively, and regulates both pro-survival 
genes and pro-apoptotic genes, underscoring its complexity as a transcription factor and 
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a contributor to tumorigenesis. Targeting Sp1 as an anti-cancer therapeutic is attractive 
because multiple pro-oncogenic pathways and genes would be affected [454]. However, 
the opposing functions of Sp1 also makes targeting Sp1 challenging, and a more 
complete mechanistic understanding of Sp1’s activities is required. We recently 
published an in-depth review addressing the role of Sp1 in cancer, including a thorough 
description of Sp1 target genes from each of the “hallmarks of cancer” [388].  
 
Conclusions  
 Although Sp1 is likely the most thoroughly studied transcription factor, a 
complete understanding of the diversity its functions is still lacking. Sp1 regulates a vast 
number of genes involved with almost all cellular processes. Further, it is dysregulated in 
many types of cancers and is associated with poor prognosis. In addition to its role as a 
general and gene-specific transcription factor, we have characterized non-transcriptional 
roles for Sp1, including its role in DNA double-strand-break repair and centrosome 
regulation. By regulating centrosome number and function, Sp1 contributes to faithful 
chromosome segregation, thereby preserving chromosome stability. While Sp1 appears 
to be a promising target for anti-cancer therapeutics, a more complete understanding of 
its diverse functions is required.    
Chapters 4 and 5 describe a novel function for Sp1 during mitosis. The current 
literature describes Sp1 as being evicted from chromatin during mitosis and stabilized in 
the cytoplasm (discussed above). Our work shows that a small pool or Sp1 remains 
associated with centromeres and functions to preserve centrochromatin architecture and 
centromeric transcription. This, in turn, allows for proper localization and assembly of 
centromere-associated proteins that are necessary for faithful chromosome segregation. 
Therefore, in addition to regulating centrosome number and function, Sp1 contributes to 
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maintaining chromosomal stability at centromeres, further diversifying the contributions 
of Sp1 to normal cell biology.       
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Figure 3.1: Domain Features of Sp1, Sp2, Sp3, and Sp4 (reprinted from [388] with 
permission from John Wiley and Sons and The FEBS Journal). The most significant 
features that unite Sp1–Sp4 include the highly conserved Cys2His2 zinc-finger, DNA-
binding domain as well as transactivation domains (TAD) indicated above. Sp1, Sp3, 
and Sp4 contain two TADs that are serine/threonine rich, and are flanked by regions that 
are glutamine rich. By contrast, Sp2 only contains one TAD. The zinc-finger, DNA-
binding domain consists of three adjacent zinc fingers, which share more than 65% 
sequence identity throughout the Sp/KLF transcription factor family. Each protein 
contains a Buttonhead (Btd) domain just N-terminal to the DNA-binding domain within a 
highly charged region of the proteins. The Btd domain is a conserved stretch of 11 
amino acids originally identified in the Drosophila melanogaster Sp1 homolog 
Buttonhead. Deletion of this domain reduces in vitro activity of Sp1 [387]. Sp1 also 
contains an N-terminal inhibitory domain as well as a C-terminal multimerization domain, 
which allows for formation of Sp1 tetramers, multiple stacked tetramers, and synergistic 
transcriptional activation [385, 388].   
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Table 3.1: Sp1 Post-Translational Modifications (reprinted from [388] with permission 
from John Wiley and Sons and The FEBS Journal).  
 
Residue Modification Enzyme Function References 
Ser2 
Phosphorylation; N–
acetylserine 
Unknown Unknown [455, 456] 
Ser7 Phosphorylation Unknown Stability [455-457] 
Lys16 
SUMOylation; 
ubiquitinylation 
RNF4 Stability 
[425, 427, 457, 
458] 
Ser56 Phosphorylation ATM/ATR Unknown [459] 
Ser59 Phosphorylation 
CDK2; ERK1/2; 
PP2A 
Stability, 
DNA binding 
[419, 420, 457, 
460, 461] 
Ser101 Phosphorylation ATM/ATR Unknown [459, 462, 463] 
Ser111-114 Glycosylation OGT Unknown Unpublished
b
 
Asp183 Cleavage Casp3 Unknown Unpublished
c
 
Ser220
a
 Phosphorylation DNA-PK Transcription [464] 
Thr278 Phosphorylation JNK1; ERK1/2 Stability [425] 
Ser301 Glycosylation OGT Unknown Unpublished
b
 
Thr355
a
 Phosphorylation ERK1/2; JNK1 Transcription [465] 
Thr453 Phosphorylation ERK1/2 Transcription [466-468] 
Ser491 Glycosylation OGT Transcription [469, 470] 
Ser535/540 Glycosylation OGT Unknown Unpublished
b
 
Asp584 Cleavage Casp3 Unknown [471] 
Ser612 
Phosphorylation; 
glycosylation 
OGT Localization [472] 
Thr640 
Phosphorylation; 
glycosylation 
OGT Localization [472] 
Ser641 
Phosphorylation; 
glycosylation 
PKCζ; OGT Transcription 
[472] 
[473] 
Thr651 Phosphorylation PKCζ   [474] 
Thr668
a
 Phosphorylation CKII; PPI; PKCζ DNA binding [472, 475, 476] 
Ser670 Phosphorylation PKCζ Unknown [476] 
Thr681 Phosphorylation PP2A; PKCζ Unknown [420, 476] 
Ser698 Glycosylation Unknown  Localization [472] 
Ser702 Glycosylation OGT Unknown [472] 
Lys703 Acetylation P300; HDAC1 Unknown [399, 477-479] 
Ser728 Phosphorylation GSK3β Degradation [480] 
Ser732 Phosphorylation GSK3β Degradation [480] 
Thr739 Phosphorylation Erk1/2, JNK1 
Transcription, 
stability 
[425, 427, 466, 
480] 
 
a Amino acid residue number is based on the full length 785 amino acid Sp1 protein. b 
Unpublished data from in vitro glycosylation assays (Beishline, Azizkhan-Clifford). c 
Unpulished data (Torabi, Azizkhan-Clifford). Paranthetic Numbers indicate amino acid 
number in original Sp1 sequence which lacks amino acids 1–89. 
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Table 3.2: Cancer-related genes regulated by Sp1 (reprinted from [388] with 
permission from John Wiley and Sons and The FEBS Journal). 
Gene References 
Sustained proliferation/immortality 
hTERT/hTERC [408, 416, 481-491] 
p53/MDM2 [492-497] 
p16 [498-500] 
p21 [501-504] 
IGF1R [415, 505-513] 
EGFR [514-519] 
EGF [520] 
FGF [521-524] 
IGF [525-530] 
Apoptosis 
Survivin [446, 482, 483, 531-537] 
Trail–R2 [538-540] 
Bcl–2 [477, 541] 
TRAIL [542] 
MCL–1 [534, 543] 
XIAP [544] 
Bak [477, 545] 
FasL [446, 546-548] 
Angiogenesis 
VEGF [467, 549-569] 
TSP–1 [570] 
PDGF [466, 571-575] 
uPA [576-578] 
DNA damage/stress response 
Brca1 [579, 580] 
ATM [581-583] 
MDC1 [584] 
Cdc25B [585, 586] 
RECQ4 [587] 
PARP [588, 589] 
XRCC1 [590, 591] 
BLM [592] 
CHEK2 [593, 594] 
XPC [595] 
XPB [596, 597] 
XPD [596] 
DDB1/2 [598] 
DNA–PK/Ku70/80 [599] 
XRCC5 [600] 
ERCC6 (CSB) [601] 
WRN [602] 
Invasion and metastasis 
MMP9 [468, 603] 
MT1–MMP [604, 605] 
RECK [468, 606-608] 
E–cadherin [609-614] 
Integrin α5 [615-617] 
MMP2 [411, 452, 603, 618-621] 
90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4: Transcription Factor Sp1 Regulates the Centrochromatin Landscape 
and Centromeric Transcription During Mitosis 
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Introduction 
The centromere is a unique region of chromatin that is vitally important for proper 
segregation of chromosomes during mitosis and meiosis. In most eukaryotes, the 
centromere is defined epigenetically by the presence of nucleosomes containing the 
histone H3 variant CENP-A interspersed between canonical H3-containing nucleosomes 
[320, 373, 622-626]. The centromere is vitally important for proper segregation of 
chromosomes because it serves as a platform for assembly of the multi-protein 
kinetochore complex, the proteinaceous interface between the mitotic spindle and the 
chromosomes. Proper assembly and function of kinetochores allows for error-free 
attachment of spindle microtubules to these structures and faithful chromosome 
segregation [627, 628]. Defects in chromosome segregation can lead to chromosome 
instability and thus can have significant negative consequences to the health of the 
organism [52, 629]. 
Sp1 is a ubiquitously expressed transcription factor that regulates genes involved 
with a variety of cellular processes, including cell proliferation, DNA repair, apoptosis, 
and senescence [386, 388]. Sp1 binds to the GC-rich Sp consensus sequence 5’-
(G/T)GGGCGG(G/A)(G/A)(G/T)-3’ in both proximal and distal gene promoters through 
its highly conserved Cys2His2-type zinc-finger, DNA-binding domain and functions to 
recruit general transcription factors and transcriptional co-regulators to promotors to 
influence transcription [382, 388, 630-633]. Sp1 is also important for maintaining 
chromosomal stability in human cells. Depletion of Sp1 by RNAi results in abnormal 
chromosome alignment along the metaphase plate, accumulation of micronucleated 
cells, and aneuploidy, all of which are phenotypes consistent with whole chromosomal 
instability (W-CIN) [7]. Based on our previous work showing that depletion of Sp1 by 
RNAi results in chromosome mis-segregation [7], we sought to gain a more detailed 
understanding of the localization and function of Sp1 during mitosis. In this section, we 
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show for the first time that Sp1 localizes and binds to centromeres of mitotic 
chromosomes where it functions to regulate the transcription of α-satellite (AS)-derived 
lncRNAs from core centromeres. Localization does not require the Sp1 DNA-binding 
domain but is dependent on ATM-kinase activity. Loss of Sp1 results in disrupted 
centrochromatin, including changes in histone modifications, and decreases in 
centromere-associated proteins including CENP-C and CENP-A. These data implicate 
Sp1, independent of its sequence-specific DNA-binding domain, as a factor that 
regulates AS-derived lncRNAs and maintains the structure, function, and identity of 
centromeres during mitosis, thereby preserving chromosomal stability. 
 
Sp1 Localizes to Centromeres in Mitotic Cells  
During mitosis, as the chromatin condenses into chromosomes, most 
transcription factors become dissociated from chromatin and are dispersed throughout 
the cell. However, others stay bound to chromatin. Therefore, it is difficult to predict the 
localization pattern of a particular transcription factor without careful evaluation. To gain 
a more detailed understanding of the localization and function of Sp1 during mitosis, we 
used the non-tumorigenic mammalian breast epithelial cell line MCF 10A to prepare 
chromosome spreads. Based on the overlap of Sp1 signal with that of CENP-A, 
immunofluorescence analysis (IF) showed that Sp1 was detected at centromeres during 
mitosis (Figures 4.1A and 4.1D). To verify that this was not an observation unique to 
MCF 10A cells, centromere localization of Sp1 was confirmed in chromosome spreads 
obtained from the osteosarcoma cell line Saos-2 as well as mouse embryonic fibroblasts 
(MEF) (Figures 4.1B, and 4.1C and E, respectively). We next examined Sp1 localization 
at different stages of mitosis (Figure 4.2) by fixing and staining untreated normal human 
diploid fibroblasts (NHDF) at various stages of mitosis. At interphase, there was no 
apparent localization of Sp1 to the centromeric region. Pro-metaphase was the earliest 
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point at which Sp1 was detected at centromeres, and by anaphase, much of the Sp1 
localized to centromeres was dissociated. Finally, by telophase, no Sp1 was detected at 
centromeres. Thus, Sp1 exhibited a dynamic localization pattern at centromeres in 
mitotic cells. 
 
Sp1 Binds to Centromeres and Pericentromeres in MCF 10A Cells 
The kinetochore is a multilayered structure composed of over 100 different 
proteins that assembles onto core centromeres. Several of these proteins bind directly to 
the centrochromatin, including CENP-A, CENP-B, CENP-C, CENP-N, and the CENP-T-
W-S-X complex [634, 635]. To determine if Sp1 binds directly to core centromeres, 
chromatin immunoprecipitation (ChIP) experiments were performed using MCF 10A 
cells. Sp1 binding to core centromeres was confirmed using SimpleChIP® Human α-
Satellite Repeat Primers. ChIP with a CENP-A antibody was performed as a positive 
control (Figure 4.3A). Careful examination of IF images revealed that Sp1 appeared to 
be localizing to both CENP-A containing regions as well as surrounding regions that 
were devoid of CENP-A (Figure 4.1D). To determine if Sp1 was also bound to 
surrounding pericentromeric heterochromatin, we designed primers that specifically 
amplified similar pericentromeric heterochromatin regions on chromosomes 9, 20, 21, 
and 22 (Table 4.1). Here, ChIP with a CENP-A antibody was performed as a negative 
control (Figure 4.3B). All results are presented as fold binding relative to the negative 
control, IgG. Results showed that Sp1 binds to AS arrays and pericentromeric 
heterochromatin in MCF 10A cells. 
 
Sp1 Binding to Centromeres is Not Dependent on the Sp1 Zinc-Finger, DNA-
Binding Domain  
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The Sp1 DNA-binding domain consists of three Cys2His2-type zinc fingers 
spanning amino acids 626-708, which bind directly to the very GC-rich consensus 
sequence 5’-(G/T)GGGCGG(G/A)(G/A)(G/T)-3’  [385]. The mammalian centromere is 
composed of several megabases of 171-bp AT-rich repetitive sequences, and does not 
appear to contain the Sp1 consensus sequence (Figure 2.3). Although a complete DNA 
sequence for centromeres is lacking, it seems unlikely that Sp1 localization and binding 
to centromeres is mediated by the zinc-finger domain. To test this, we prepared 
chromosome spreads from MEFs expressing full length Sp1 and from a MEF cell line 
that expressed a truncated form of Sp1, consisting of the 65 kilodalton intact N-terminal 
domain, and lacking the DNA-binding domain region in the C-terminus (hereafter 
referred to as Sp1-65) (Figure 4.4B and described in [636]). IF analysis of these spreads 
revealed that full length Sp1 (Figure 4.1C) and Sp1-65 localized to centromeres (Figure 
4.4A), suggesting that Sp1 binding to centromeres does not require the zinc-finger, 
DNA-binding domain. To more specifically determine the region of Sp1 that mediates 
localization to centromeres, we transfected MCF 10A cells with a plasmid expressing 
amino acids 1-182 of Sp1 (hereafter referred to as Sp11-182). IF analysis of chromosome 
spreads prepared from this cell line revealed that endogenous Sp1 and exogenous Sp11-
182 co-localized in a pattern consistent with centromeric localization (Figure 4.4C), 
confirming that the Sp1 DNA-binding domain was not required for localization of Sp1 to 
centromeres.  
 
ATM Activity Is Required for Rapid Sp1 Localization to Centromeres 
 Several studies have reported that Sp1 is phosphorylated during mitosis. The c-
Jun NH2-terminal kinase 1 (JNK1) phosphorylates Sp1 at threonine 278 and threonine 
739 [426, 637]. Additionally, Sp1 is a target of CDK1/Cyclin B1, which also 
phosphorylates Sp1 at threonine 739 [428]. These phosphorylation events decrease the 
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DNA binding affinity of Sp1 during mitosis as well as stabilize Sp1 in the cytoplasm by 
protecting it from RNF4-mediated degradation [421, 428, 638].    
Previously, we have shown that Sp1 is phosphorylated by the serine/threonine 
protein kinase ATM on serine 101 in response to DNA double-strand-breaks [384, 462]. 
Sp1 is also phosphorylated by ATM on serine 101 in response to viral infection [418, 
459]. ATM was recently shown to be phosphorylated and activated by Aurora B kinase 
during mitosis in a DNA damage-independent manner, resulting in the phosphorylation 
and activation of other centromere associated proteins, including Bub1 and Mad1 [639]. 
Therefore, we sought to determine if ATM activity is required for Sp1 localization to 
centromeres during mitosis. Here, we treated MCF 10A cells with the ATM-specific 
inhibitor KU-55933 [640] for 2 or 16 hours before preparing chromosome spreads. IF 
analysis revealed that 2 hours of KU-55933 treatment prevented Sp1 from localizing to 
centromeres (Figure 4.5A), suggesting that ATM activity was required for rapid 
localization. Sp1 re-appeared at centromeres after 16 hours (Figure 4.5A) when KU-
55933 was still active based on lack of phosphorylation of Chk2 as threonine 68 (Figure 
4.5B). To determine if serine 101 was the residue of Sp1 that was phosphorylated during 
mitosis, we used immunoblotting to probe interphase and mitotic lysates with a phospho-
serine 101 specific antibody (pSp1101) using untreated or Adriamycin treated cells as 
negative and positive controls, respectively (Figure 4.5C). Our results showed that within 
the context of mitosis, serine 101 remains unphosphorylated; however, it should be 
noted that there are several additional SQ/TQ sites clustered in Sp11-182, which are 
potential targets of ATM phosphorylation during mitosis.  
 
Sp1 Knockdown Results in a Decrease in CENP-A at Centromeres 
A commonly used technique for deducing the function of a particular protein is to 
eliminate that protein from a cell and examine the consequences. To better understand 
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the role of Sp1 during mitosis, we transduced MCF 10A cells with a control shRNA or an 
shRNA targeting the Sp1 transcript and then prepared chromosome spreads. 
Immunoblotting analysis was used to verify Sp1 protein knockdown (Figure 4.6B, left 
panel). IF analysis revealed two predominant phenotypes. First, metaphase stage cells 
lacking Sp1 showed a slight but significant increase in distance between the CENP-A 
signals on paired sister chromatids (measured using ImageJ), suggesting a centromeric 
or cohesion defect (Figure 4.6A, 4.6B right panel, and 4.6C). Second, the CENP-A 
signal intensity was significantly decreased by 15.9% in Sp1 knockdown cells, at 5181 ± 
86.05 rfu (relative fluorescent units) as compared to 6163 ± 99.58 rfu in control cells (rfu 
calculated as described in [641]), suggesting that Sp1 knockdown resulted in a decrease 
in CENP-A binding to centromeres (Figure 4.6D). To confirm our imaging data, ChIP 
experiments were performed using MCF 10A cells transduced with control shRNA or 
shRNA targeting the Sp1 transcript. Antibodies against CENP-A and H3 were used for 
immunoprecipitation and binding to core centromeres was determined using 
SimpleChIP® Human α-Satellite Repeat Primers. Comparison of the ratio of AS signal 
from CENP-A to H3 ChIP showed that in Sp1-depleted cells there was a 14.5% 
decrease in CENP-A binding to core centromeres as compared to control cells (Figure 
4.6E), corroborating the 15.9% decrease that we observed by IF. 
 
Decreased CENP-A at Centromeres is Not Due to Reduced Expression of CENP-A  
 CENP-A, like other histone proteins, is an exceptionally stable protein [642, 643]. 
Because of this, it was unlikely that the decrease in CENP-A protein levels at 
centromeres in Sp1-depleted cells was a result of Sp1-mediated transcriptional down-
regulation or normal CENP-A protein turnover. However, to explore this possibility, we 
first evaluated the distal and proximal CENP-A promoter regions for Sp1 binding sites. 
We found two Sp consensus sequences 2583 base pairs and 173 base pairs upstream 
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from the transcription start site (Figure 4.7A). ChIP experiments confirmed that Sp1 
binds to both regions, with more binding at the -173 site (Figure 4.7B, Table 4.1 for 
primers). Next, we transduced MCF 10A cells with control shRNA or shRNA targeting 
the Sp1 transcript exactly as performed for the experiments in Figure 4.6 and evaluated 
protein lysates for CENP-A protein levels. Protein densitometry measurements from 
three separate experiments revealed no difference in total CENP-A protein levels 
between Sp1-depleted and control cells (Figure 4.7C). Additionally, we evaluated CENP-
A mRNA transcript levels in both control and Sp1-depleted cells and found no significant 
difference in transcript levels (Figure 4.7D, Table 4.1 for primers). Thus, although Sp1 
binds to two Sp consensus sequences in the CENP-A promoter region, Sp1 does not 
appear to significantly alter CENP-A protein or mRNA levels within the timeframe of the 
experiments performed. These results showed that the decrease in CENP-A at 
centromeres in Sp1-depleted cells was not due to reduced expression of CENP-A.  
 
Sp1 Knockdown Results in a Decrease in CENP-C at Centromeres 
 CENP-C is an important upstream factor for CENP-A deposition. CENP-C is one 
of several components of the CCAN, the network of proteins that associates with 
centromeric chromatin throughout the cell cycle. CENP-C is an important upstream 
factor for CENP-A deposition because it binds to centromeric chromatin and recruits the 
Mis18 complex to this region. The Mis18 complex then recruits HJURP, the chaperone 
that facilitates the exchange of histone H3 for CENP-A. Knockdown of CENP-C results 
in decreased CENP-A levels at centromeres [305], which has been demonstrated in 
Xenopus egg extracts [306], Drosophila [307], and mouse cells [305]. In an attempt to 
gain a better understanding of why Sp1 knockdown resulted in a decrease in CENP-A at 
centromeres, we used ChIP to evaluate CENP-C binding to centromeres in MCF 10A 
cells transduced with a control shRNA or an shRNA targeting the Sp1 transcript (Table 
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4.1 for primers). Here, IgG was used as a negative control and binding of histone H2B to 
centromeres was used as a positive control. Two separate CENP-C antibodies were 
used. Results showed that Sp1 depletion resulted in a significant reduction in CENP-C 
binding to centromeres, likely contributing to the decrease in CENP-A at centromeres 
through a reduction in Mis18 complex and HJURP recruitment (Figure 4.8A). To confirm 
that the decrease in CENP-C at centromeres was not due to a decrease in total CENP-C 
protein levels in Sp1-depleted cells, we used immunoblotting to evaluate total cell 
lysates for CENP-C. Our results showed that depletion of Sp1 had no effect on total 
CENP-C levels (Figure 4.8B).  
 
Sp1 Contributes to Regulation of α-Satellite-Derived Long Non-Coding RNAs 
For many years, the core centromere was thought to be a purely heterochromatic 
region and thus transcriptionally inactive. However, several recent studies have shown 
that the core centromere is actively transcribed in a number of different species and that 
centromeric transcripts are important for maintaining the structure and function of 
centromeres and kinetochores [350, 352, 355, 358, 644]. Several studies have identified 
centromere-derived transcripts, including those in yeast [350, 368], rice [352, 645], mice 
[353], and humans [326, 355-358]. Consistent with these studies are those that have 
identified transcriptionally permissive epigenetic modifications at centromeres, including 
H3K4me1/2, H2Bub1, and H3K36me2 [337, 340, 646]. Although a complete 
understanding of the purpose of RNA Polymerase II-dependent transcription through this 
region, as well as the importance of centromere-derived transcripts, is still lacking, 
studies continue to demonstrate that this phenomenon plays a major role in maintaining 
active centromeres.  
In human cells, long non-coding RNAs (lncRNAs) derived from AS DNA are 
transcribed by RNA Polymerase II during mitosis, in conjunction with other general 
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transcription factors, including RNA polymerase II subunit A C-terminal domain 
phosphatase (CTDP1), structure-specific recognition protein 1 (SSRP1), and TATA-box 
binding protein (TBP) [355, 361]. These AS-derived lncRNAs have been shown to be 
present at mitotic centromeres to maintain the centrochromatin architecture as well as to 
facilitate the localization of centromere and kinetochore proteins, including CENP-A, 
CENP-C, Aurora B kinase, INCENP, and Survivin [326, 353, 361, 647]. In budding yeast 
and HeLa cells, both increases and decreases in centromeric transcription lead to 
chromosome segregation errors and W-CIN, a characteristic of many solid tumors and 
hematological malignancies [8, 350, 355].  However, how transcription of AS-derived 
lncRNAs is regulated is poorly understood. 
Because Sp1 is a transcription factor, we wanted to determine if Sp1 plays a role 
in the transcription of AS-derived lncRNAs at centromeres during mitosis. We 
transduced MCF 10A cells with a control shRNA or shRNA targeting the Sp1 transcript 
(Figure 4.9C) and evaluated each cell line for AS-derived lncRNAs by quantitative RT-
PCR (Table 4.1 for primers). Additionally, we transduced MCF 10A cells with retrovirus 
containing an Sp1 expression construct to over-express Sp1 in these cells (Figure 4.9D). 
Our results show that in response to Sp1 protein knockdown, AS-derived lncRNAs were 
increased approximately 3.5 fold (Figure 4.9A). For the Sp1 over-expressing MCF 10A 
cell line, AS-derived lncRNAs were decreased by 50% (Figure 4.9B). Here, because the 
AS sequences are highly repetitive, we chose to use two additional highly repetitive 
sequences as controls. First, we used 18S ribosomal RNA, an RNA polymerase I 
transcript that should not be impacted by changes in Sp1 protein levels [648, 649], and 
transcripts from Alu elements, a family of small interspersed elements (SINEs) widely 
distributed throughout the genome (Table 4.1 for primers). The transcription of Alu 
elements depends on both RNA Polymerase II and RNA Polymerase III, and because of 
their wide genomic distribution, changes in gene expression of individual proteins does 
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not influence expression of total Alu transcript levels [650-654]. Thus, Alu transcript 
levels should also remain unchanged in response to changes in total Sp1 protein levels. 
Indeed, our results show that in response to both Sp1 protein knockdown and Sp1 
protein over-expression, both 18S and Alu transcript levels remained unchanged. 
In support of these data, we used SimpleChIP® Human α-Satellite Repeat 
Primers to perform a ChIP experiment in MCF 10A cells that were transduced with 
control shRNA or shRNA targeting the Sp1 transcript and evaluated these cell lines for 
binding of RNA Polymerase II, phosphorylated on serine5 (RNA Polymerase IIpS5), at 
centromeres. RNA Polymeriase II becomes phorphorylated on serine 5 as the RNA 
Polymerase II pre-initiation complex transitions from pre-initiation to elongation. 
Therefore, RNA Polymerase IIpS5 is a measure of active transcription [655]. Our results 
showed an approximately 2-fold increase in RNA Polymerase IIpS5 binding at 
centromeres in Sp1-depleted cells, supporting an increase in transcription of AS-derived 
lncRNAs under these conditions (Figure 4.10A). To confirm that the increase in RNA 
Polymerase IIpS5 at centromeres was not due to an increase in total RNA Polymerase 
IIpS5 protein levels in Sp1-depleted cells, we used immunoblotting to evaluate total cell 
lysates for RNA Polymerase IIpS5. Our results showed that depletion of Sp1 had no effect 
on total RNA Polymerase IIpS5 levels (Figure 4.10B). Thus, changes in total Sp1 protein 
levels significantly alter AS-derived lncRNA transcription at centromeres. 
 
Over-Expression of Sp1 Results in a Decrease in CENP-A at Centromeres 
 We observed an increase in transcription through the core centromere in Sp1-
depleted cells as well as a decrease in CENP-A binding at centromeres. Further, Sp1 
over-expression resulted in a decrease in centromeric transcription. Studies have 
indicated that a perturbation in centromeric transcription in either direction prevents 
proper CENP-A deposition, resulting in a decrease in CENP-A binding. To determine if 
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over-expression of Sp1, and thus decreased centromeric transcription, prevents proper 
CENP-A deposition at centromeres, we used ChIP to evaluate CENP-A binding at 
centromeres in MCF 10A cells transduced with a control retrovirus and a retrovirus 
containing an Sp1 expression construct to over-express Sp1. Antibodies against CENP-
A and H3 were used for immunoprecipitation, and binding to core centromeres was 
determined using SimpleChIP® Human α-Satellite Repeat Primers. Immunoblotting was 
used to confirm over-expression of Sp1 and to ensure that over-expression of Sp1 had 
no effect on total CENP-A protein levels (Figure 4.11B). Comparison of the ratio of AS 
signal from CENP-A to H3 ChIP showed that in Sp1 over-expressing cells there was a 
slight but significant decrease in CENP-A at centromeres (Figure 4.11A).  
 
Sp1 Depletion Disrupts the Centrochromatin Landscape 
Within the context of transcriptional regulation, Sp1 directly or indirectly recruits 
several different factors to chromatin to modulate the chromatin landscape. Some of 
these factors include p300, HDAC1 and HDAC2, DNMT1, and the SWI/SNF complex 
[388, 408, 411, 498, 656, 657]. Therefore, we sought to determine if the increase in AS-
derived transcripts in Sp1-depleted cells was associated with changes in 
centrochromatin epigenetics, specifically in histone modifications. To address this, MCF 
10A cells were transduced with control shRNA or shRNA targeting the Sp1 transcript, 
followed by ChIP to evaluate changes in monoubiquitinated H2B (H2Bub1), a 
modification shown to be required for proper transcription of AS-derived lncRNAs [340]. 
Our results show that upon Sp1 depletion, there was a significant increase in the 
H2Bub1 to H2B ratio at centromeres as compared to our control cells (Figure 4.12A). 
We also used ChIP to evaluate H3K4me2 levels at centromeres, a modification 
associated with open but not active chromatin [335], as well as H3K36me2 levels at 
centromeres, associated with active transcription [337]. Interestingly, our results 
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revealed a significant decrease in the H3K4me2 to H3 ratios (Figure 4.12B) and the 
H3K36me2 to H3 ratios (Figure 4.12C), in Sp1-depleted cells as compared to control. 
Further, because HDAC1 has been shown to interact with Sp1 to facilitate deacetylation 
of H3K9 [658], we used ChIP to evaluated H3K9Ac levels at centromeres and found that 
Sp1 depletion resulted in a decrease in H3K9Ac levels at centromeres (Figure 4.12D). 
For these ChIP studies, binding was determined using SimpleChIP® Human α-Satellite 
Repeat Primers. Finally, studies have shown that changes in the pericentromeric 
heterochromatin can similarly affect transcription of core centromeres [659]. Because 
our studies showed that Sp1 binds to both core centromeres and pericentromeres 
(Figure 4.3B), we evaluated the prominent heterochromatic marks H3K9me2/3 at 
pericentromeres by ChIP. Our results showed that Sp1 depletion had no effect on this 
modification at pericentromeres (Figure 4.12E, Table 4.1 for primers). We used 
immunoblotting to confirm that Sp1 depletion alone had no effect on any of these histone 
modifications on a global level (Figure 4.13). This suggests that the changes in 
epigenetic modifications upon Sp1 depletion may be specific to centromeres. 
 
Conclusions 
With these experiments, we showed that transcription factor Sp1 localizes and 
binds to centromeres and pericentromeres during mitosis and that this interaction is not 
dependent upon the Sp1 zinc-finger, DNA-binding domain. Rapid localization required 
ATM activity, and knockdown of Sp1 protein resulted in a decrease in CENP-A and 
CENP-C at centromeres and a potential centromeric cohesion defect. Finally, 
knockdown of Sp1 protein disrupted the centrochromatin landscape. In a previous report 
[7], we demonstrated that Sp1 depletion resulted in chromosome mis-segregation and 
W-CIN. Taken together with the data presented in this chapter, we believe that although 
transcription factor Sp1 likely maintains chromosomal stability through numerous 
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mechanisms, maintaining centromere identity by regulating CENP-A levels, centromeric 
transcription, and the centrochromatin landscape are likely contributing factors. The 
implications of these findings are discussed in Chapter 6. 
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Figure 4.1: Sp1 Localizes to Centromeres in Mitotic Cells. (A) Chromosome spreads 
were prepared using MCF 10A cells treated with colcemid for 4 hours. Spreads where 
stained with antibodies against CENP-A and Sp1 and with DAPI for visualization of 
chromatin. Sp1 localized to CENP-A containing regions in metaphase stage cells. Inset 
is (D). (B) Chromosome spreads were prepared using a human osteosarcoma cell line 
Saos-2 treated with colcemid for 4 hours. Spreads where stained with antibodies against 
CENP-A and Sp1 and with DAPI for visualization of chromatin. Sp1 localized to CENP-A 
containing regions in metaphase Saos-2 cells. (C) Chromosome spreads were prepared 
using Sp1+/+ mouse embryonic fibroblasts treated with colcemid for 4 hours. Spreads 
B 
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were stained with antibodies against CREST and Sp1 and with DAPI for visualization of 
chromatin. Sp1 localized to centromeric regions in MEF cells. (D) Inset from (A) 
suggests that Sp1 localizes to both centromeric and pericentromeric regions. (E) Inset 
from (C), showing Sp1 (green) localized to CENP-A (red) containing regions of a 
metaphase chromosome. 
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Figure 4.2: Temporal Localization of Sp1 at Centromeres. Untreated, normal human 
diploid fibroblasts (NHDF) were fixed and stained using antibodies against Sp1 and 
CENP-A and with DAPI for visualization of chromatin. Cells at different stages of mitosis 
were examined for Sp1 localization at centromeres. Results showed that at interphase, 
there was no apparent localization of Sp1 to centromeres. Pro-metaphase was the 
earliest point at which Sp1 was detected at centromeres, and by anaphase, much of the 
Sp1 localized to the centromeres was dissociated. Finally, by telophase, no Sp1 was 
detected at centromeres.  
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Figure 4.3: Transcription Factor Sp1 Localizes and Binds to Centromeres and 
Pericentromeres in Mitotic Cells. (A) Untreated MCF 10A cells were collected, and 
SimpleChIP® Human α-Satellite Repeat Primers and ChIP were used to detect Sp1 
binding to AS arrays (A), or for Sp1 binding to pericentromeric heterochromatin regions 
(B), as described in methods. Normal rabbit IgG and CENP-A were used as controls. 
Immunoprecipitated chromatin was assessed by SYBR green quantitative PCR. All CT 
values were normalized to mock IgG control to show fold increase in Sp1 binding over 
control. Results confirmed Sp1 binding to core centromere and pericentromeric regions 
in untreated MCF 10A cells. * p<0.04. 
  
A B 
108 
 
 
 
Figure 4.4: Sp1 Binding to Centromeres is Not Dependent on the Sp1 Zinc-Finger, 
DNA-Binding Domain. (A) Chromosome spreads were prepared using Sp1-/- MEFs. 
This cell line is referred to as Sp1-/- because the Sp1 gene is truncated, resulting in the 
expression of a truncated form of Sp1, consisting of the 65 kDa intact N-terminal domain 
and lacking the DNA-binding domain region in the C-terminus (Sp1-65). The truncated 
Sp1 protein expressed in Sp1-/- MEFs localized to centromeres. (B) Western blot 
analysis of Sp1+/+ and Sp1-/- total cell lysates probed for Sp1. Actin was used as a 
loading control. Sp1+/+ cell lysates show wild-type Sp1 protein at approximately 100 
kilodalton as expected, whereas Sp1-/- cell lysates show truncated 65 kilodalton N-
terminal domain portion of Sp1 protein, as described in [636]. (C) Chromosome spreads 
were prepared using MCF 10A cells expressing LXSN-Sp11-182-HA then stained using 
antibodies against Sp1 (green), HA (red), and DAPI (blue). Sp1 and HA localized in a 
pattern consistent with centromeric localization, suggesting LXSN- Sp11-182-HA localized 
to centromeres. 
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Figure 4.5: ATM Activity Is Required for Rapid Sp1 Localization to Centromeres. 
(A) Chromosome spreads were prepared using MCF 10A cells treated with vehicle 
(DMSO) or 10 μM KU-55933 for 2 or 16 hours. Inhibition of ATM with KU-55933 
prevented Sp1 localization after 2 hours of treatment but not after 16 hours of treatment. 
(B) Western blot analysis of MCF 10A cell lysates after 1, 5, and 15 hours of KU-55933 
treatment plus 1 additional hour of KU-55933 treatment with 100 μM H2O2, for a total of 
2, 6, and 16 hours of KU-55933 treatment. Western blot was probed for phospho-Chk2 
as an indicator of ATM activity. ATM activity was inhibited by KU-55933 at all time 
points. (C) Western blot analysis of interphase and mitotic MCF 10A cell lysates from 2 
separate mechanical shake-off experiments were probed for pSp1101, total Sp1, and 
nucleolin as a loading control. Untreated MCF 10A cell lysates were used as a negative 
control (-), and Adriamycin treated MCF 10A cell lysates were used as a positive control 
(+). Sp1 was not phosphorylated on serine 101 during mitosis.  
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Figure 4.6: Sp1 Knockdown Results in a Decrease in CENP-A at Centromeres. (A) 
Chromosome spreads were prepared using MCF 10A cells transduced with control 
shRNA or shRNA targeting the Sp1 transcript and then stained using antibodies against 
Sp1 (green), CENP-A (red), and with DAPI (blue) for chromatin visualization. 
*background fluorescence.  (B) Left: Western blot analysis of MCF 10A cell lysates used 
in (A). Nucleolin was used as a loading control. Right: Insets from (A). (C) The distance 
between CENP-A signals from (A) were measured using ImageJ and plotted. For control 
shRNA, n = 399. For Sp1 shRNA, n = 389. p = 0.0008. (D) The CENP-A signal 
intensities from (A) were quantified using ImageJ and plotted. For control shRNA, n = 
259. For Sp1 shRNA, n = 279. p < 0.0001. (E) MCF 10A cells were transduced with 
control shRNA or shRNA targeting the Sp1 transcript. SimpleChIP® Human α-Satellite 
Repeat Primers and ChIP were used to evaluate binding of histone H3 and CENP-A to 
AS arrays, as described in methods. Normal rabbit IgG was used as a negative control. 
Immunoprecipitated chromatin was assessed by SYBR green quantitative PCR. CENP-
A to H3 ratios were determined using raw CT values, and those ratios were normalized 
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to mock IgG control. Results showed a decrease in the CENP-A to H3 ratio in Sp1-
depleted cells. n = 2, p = 0.01.  
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Figure 4.7: Sp1 Binds to CENP-A Promoter, but Does Not Influence CENP-A mRNA 
or Protein Levels Upon Knockdown. (A) Schematic of the CENP-A distal and proximal 
promoter regions showing Sp1 consensus sequences at 173 and 2583 nucleotides 
upstream from the transcriptional start site. (B) ChIP was performed using MCF 10A 
cells transduced with control shRNA or shRNA targeting the Sp1 transcript. 
Immunoprecipitated chromatin was evaluated for binding at the -173 locus and the -2583 
locus using primers described in Table 4.1. Immunoprecipitated chromatin was 
assessed by SYBR green quantitative PCR. All CT values were normalized to mock IgG 
control to show fold increase in Sp1 binding over control. Results confirm Sp1 binding to 
both the -173 and the -2583 loci. n=3, *p<0.04, **p<0.01. (C) MCF 10A cells were 
transduced with control shRNA or shRNA targeting Sp1 transcript. Protein lysates were 
collected and evaluated for Sp1 protein levels to confirm protein knockdown and CENP-
A levels to evaluate the effect of Sp1 knockdown on CENP-A protein. Left panel: 
Representative western blot. Right panel: CENP-A densitometry for all experimental 
replicates was plotted. Results show that Sp1 depletion did not significantly alter total 
CENP-A protein levels. n=3. (D) RNA was extracted from MCF 10A cells transduced 
with control shRNA or shRNA targeting Sp1 transcript. RNA extraction was performed 
using the Qiagen RNeasy® Mini Kit per manufacturer’s instructions. RNA was reverse 
transcribed using the qScriptTM cDNA Supermix, and CENP-A transcript levels were 
evaluated using primers described in methods. Results show that CENP-A transcript 
levels were not significantly altered in Sp1-depleted cells. n=3.  
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Figure 4.8: Sp1 Knockdown Results in a Decrease in CENP-C at Centromeres. (A) 
MCF 10A cells were transduced with control shRNA or shRNA targeting the Sp1 
transcript. SimpleChIP® Human α-Satellite Repeat Primers and ChIP were used to 
detect CENP-C binding to AS arrays, as described in methods. Normal rabbit IgG was 
used as a negative control, and histone H2B was used as a positive control. 
Immunoprecipitated chromatin was assessed by SYBR green quantitative PCR. Results 
showed a decrease in CENP-C binding to centromeres in Sp1-depleted cells. 1CENP-C 
antibody was purchased from abcam (ab193666). 2CENP-C antibody was a gracious gift 
from Dr. Andrea Musacchio [321]. n = 3. (B) MCF 10A cells were transduced with control 
shRNA or shRNA targeting the Sp1 transcript. Protein lysates were collected and 
evaluated for Sp1 protein levels to confirm protein depletion and for changes in CENP-C 
protein levels. Nucleolin was used as a loading control. Results showed Sp1 depletion 
had no effect on total CENP-C protein levels.  
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Figure 4.9: Sp1 Contributes to Regulation of α-Satellite-Derived Long Non-Coding 
RNAs. RNA was extracted from MCF 10A cells transduced with control shRNA or 
shRNA targeting the Sp1 transcript (A), or from MCF 10A cells transduced with empty 
pLXSN vector or pLXSN-Sp1-HA over-expression construct (B). RNA extraction was 
performed using the Qiagen RNeasy® Mini Kit. RNA was reverse transcribed using the 
qScriptTM cDNA Supermix, and transcripts were analyzed by quantitative PCR. 18S 
ribosomal RNA and Alu transcripts were used as controls. All results were normalized to 
nucleolin transcripts. Depletion of Sp1 resulted in an approximately 3.5 fold increase in 
AS-derived transcripts as compared to control, while Sp1 over-expression resulted in a 
50% decrease. n = 9. Protein lysates were collected and evaluated for Sp1 protein levels 
to confirm protein knockdown (C) and pLXSN-Sp1-HA over-expression (D). Nucleolin 
was used as a loading control.  
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Figure 4.10: Sp1 Depletion Results in an Increase in RNA Polymerase IIpS5 Binding 
at Centromeres. (A) MCF 10A cells were transduced with control or Sp1 targeted 
shRNA, and SimpleChIP® Human α-Satellite Repeat Primers and ChIP were used to 
detect RNA Polymerase IIpS5 binding at AS arrays. Results showed an increase in RNA 
Polymerase IIpS5 binding in Sp1-depleted cells. (B) MCF 10A cells were transduced with 
control shRNA or shRNA targeting the Sp1 transcript. Protein lysates were collected and 
evaluated for Sp1 protein levels to confirm protein depletion, and for changes in RNA 
Polymerase IIpS5. Nucleolin was used as a loading control. Results showed Sp1 
depletion had no effect on RNA Polymerase llpS5 protein levels. 
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Figure 4.11: Over-Expression of Sp1 Results in a Decrease in CENP-A at 
Centromeres (A) MCF 10A cells transduced with a control retrovirus (pLXSN empty 
vector) or a retrovirus containing an Sp1 expression construct to over-express Sp1 
(pLXSN-Sp1-HA). Antibodies against CENP-A and H3 were used for 
immunoprecipitation, and binding to core centromeres was determined using 
SimpleChIP® Human α-Satellite Repeat Primers. Results showed a slight but significant 
decrease in CENP-A binding at centromeres in Sp1 over-expressing cells. (B) MCF 10A 
cells were transduced with control retrovirus (pLXSN empty vector) or a retrovirus 
containing an Sp1 expression construct to over-express Sp1 (pLXSN-Sp1-HA). Protein 
lysates were collected and immunoblotting was used to evaluate lysates for total Sp1 
protein levels, exogenous Sp1 protein levels (HA), and total CENP-A levels. A-tubulin 
was used as a loading control. Results confirmed over-expression and that over-
expression of Sp1 had no effect on total CENP-A protein levels.  
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Figure 4.12: Sp1 Depletion Disrupts the Centrochromatin Landscape. (A) MCF 10A 
cells were transduced with control or Sp1 targeted shRNA, and SimpleChIP® Human α-
Satellite Repeat Primers and ChIP were used to detect H2Bub1 and H2B binding at AS 
arrays. Results showed an increase in the H2Bub1 to H2B ratio at centromeres in Sp1-
depleted cells. (B) MCF 10A cells were transduced with control or Sp1 targeted shRNA, 
and SimpleChIP® Human α-Satellite Repeat Primers and ChIP were used to detect 
H3K4me2 and H3 binding at AS arrays. Results showed a decrease in H3K4me2 to H3 
ratio in Sp1-depleted cells. (C) MCF 10A cells were transduced with control or Sp1 
targeted shRNA, and SimpleChIP® Human α-Satellite Repeat Primers and ChIP were 
used to detect H3K36me2 and H3 binding at AS arrays. Results showed a decrease in 
H3K36me2 to H3 ratio in Sp1-depleted cells. (D) MCF 10A cells were transduced with 
control or Sp1 targeted shRNA, and SimpleChIP® Human α-Satellite Repeat Primers 
and ChIP were used to detect H3K9Ac and H3 binding at AS arrays. Results showed a 
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decrease in H3K9Ac to H3 ratio in Sp1-depleted cells. (E) MCF 10A cells were 
transduced with control or Sp1 targeted shRNA, and ChIP was performed for 
H3K9me2/3 and H3 binding at the pericentromeric heterochromatin region. Results 
showed that Sp1 depletion had no effect on the H3K9me2/3 to H3 ratio. 
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Figure 4.13: Control Western Blots. MCF 10A cells were transduced with control 
shRNA or shRNA targeting the Sp1 transcript. Protein lysates were collected and 
evaluated for Sp1 protein levels to confirm protein depletion and for changes in H2Bub1 
(A), H3K4me2 (B), H3K36me2 (C), H3K9Ac (D), or H3K9me2/3 (E). α-tubulin was used 
as a loading control. Results showed Sp1 depletion had no effect on total H2Bub1, 
H2K4me2, H3K36me2, H3K9Ac, or H3K9me2/3 protein levels.  
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Table 4.1: Primers Used in Described Experiments. 
 
Oligonucleotides Sequence 
α-Satellites ChIP - DNA 
SimpleChIP® Human α-Satellite Repeat Primers (Cell 
Signaling 4486) 
Pericentromeric Heterochromatin Regions 
on Chromosomes 9, 20, 21, and 22 
forward 5’-AGCTCGGGCAAAGAGTTCAA-3’,  
reverse 5’-TTTGGGGGAAATTCCTGCA-3’ 
CENP-A -173 Locus 
forward 5’-AGTCGCTGGATTCGGGTTTT-3’,  
reverse 5’-CTCACATGAGCCGGTGCTT-3’ 
CENP-A -2583 Locus 
forward 5’-AATAGTGCAAGACCCGGTTG-3’,  
reverse 5’-AGGTGGGGAGTTTTAGTTTGA 
CENP-A Transcripts 
forward 5’-CTTAGGCGCTTCCTCCCATC-3’,  
reverse 5’-AGAGGTGTGTGCTCTTCTGA-3’ 
α-Satellite Transcripts - RNA 
forward 5’-CATCACAAAGAAGTTTCTGAGAATGCTTC-3’  
reverse 5’-TGCATTCAACTCACAGAGTTGAACCTTCC-3’ 
18S Control Transcripts 
forward 5’-GTAACCCGTTGAACCCCATT-3’,  
reverse 5’-CCATCCAATCGGTAGTAGCG-3’ 
Alu Control Transcripts 
forward 5'-CATGGTGAAACCCCGTCTCTA-3'  
reverse 5'-GCCTCAGCCTCCCGAGTAG-3' 
C23 Control Transcripts 
forward 5'-CTCGCGAAGGCAGGTAAAAAT-3'  
reverse 5'-CAGCAGCCTTCTTGCCTTTC-3' 
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Chapter 5: Sp11-182 May Be Sufficient for Functional Centromeres 
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Introduction 
 In addition to being regulated by various post-translational modifications, Sp1 is 
also regulated through proteolytic cleavage. For example, when cellular glucose levels 
are low, Sp1 is specifically rapidly degraded by the proteasome, likely in an effort to 
conserve cellular resources by down-regulating Sp1-mediated transcription [660]. Using 
an in vitro system to further analyze this degradation, it was determined that Sp1 
contains a proteolytic cleavage site between leucine 56 and 57 and that this cleavage is 
required for proteasome-dependent degradation [661]. Sp1 has also been shown to be 
cleaved by caspases during apoptosis. This was first observed during retinoid-induced 
apoptosis, in which Sp1 was specifically cleaved, likely by caspase 2 [662]. Further, in 
the human Burkitt lymphoma cell line BL60, Sp1 is cleaved by caspase 3 during anti-
IgM-induced apoptosis. This study identified a caspase 3 cleavage site (AQPQAGR) 
directly after aspartic acid 584 of Sp1b (or 590 of Sp1a), suggesting that cleavage of 
Sp1 plays a role in anti-IgM-induced apoptosis [471]. 
 We previously demonstrated that Sp1 is cleaved by caspase 3 at aspartic acid 
183 of Sp1a during DNA damage- or TRAIL-induced apoptosis. Cleavage at aspartic 
acid 183 produces a 70 kilodalton fragment comprising the DNA-binding domain and 
trans-activation domains (herein referred to as Sp1183-785), as well as a 30 kilodalton 
fragment containing the N-terminal 182 amino acids (herein referred to as Sp11-182). 
Although it is not clear why Sp1 is cleaved, our data suggest that this cleavage is 
actively involved with apoptosis; mutating aspartic acid 183 to alanine protects cells 
against ultraviolet-induced apoptosis (Torabi, Azizkhan-Clifford, unpublished). It is 
attractive to speculate that genes are differentially regulated by cleaved Sp1183-785 as 
compared to full-length Sp1. Although there is currently no evidence to suggest that this 
is the case, we continue to investigate this possibility. 
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Interestingly, new evidence indicates that Sp1 may be cleaved at aspartic acid 
183 to stabilize the Sp1183-785 cleavage product. Studies have shown that SUMOylation of 
Sp1 on lysine 16 facilitates Sp1 degradation through the recruitment of RNF4, a SUMO-
targeted ubiquitin ligase (STUbL). RNF4 interacts with the C-terminus of Sp1, at amino 
acids 619 – 785 [427]. Therefore, both the N-terminus (lysine 16) and the C-terminus of 
Sp1 (amino acids 619 – 785) are required for RNF4-dependent degradation. If Sp1 is 
involved with transcriptional induction of apoptosis, cleavage of Sp1 at aspartic acid 183 
may function to prevent RNF4-mediated degradation by physically separating the N-
terminus of the protein from the C-terminus of the protein, thereby allowing the C-
terminus of the protein to function as a transcriptional regulator. To determine if this is 
the case, we created three cell lines expressing exogenous full-length Sp1 (pLXSN-Sp1-
HA), Sp1 in which aspartic acid 183 is mutated to alanine (pLXSN-Sp1-D183A-HA), and 
cleavage product Sp1183-785 (pLXSN-Sp1183-785-HA). These cell lines were treated with the 
DNA damaging agent Adriamycin to induce apoptosis, and the stability of each of the 
exogenously expressed proteins was monitored over time. Results show that at 12 and 
24 hours post treatment, Sp1-D183A, which cannot be cleaved, was more quickly 
degraded as compared to full-length Sp1 and Sp1183-785. Full-length Sp1 and Sp1183-785 
showed comparable stability at both time points (Figure 5.1). These data suggest that 
cleavage of Sp1 at aspartic acid 183 stabilizes the Sp1183-785 cleavage product, 
potentially allowing for Sp1183-785-dependent transcriptional regulation during apoptosis. 
In addition to a likely pro-apoptotic role for the Sp1183-785 cleavage product, we 
have demonstrated that the N-terminal cleavage product, Sp11-182, functions 
independently from the C-terminal cleavage product in a number of cellular pathways, 
including DNA double-strand-break repair and centrosome regulation (both discussed 
below).  Further, Sp11-183 localizes to centromeres and rescues centromere defects 
observed in Sp1-depleted cells. As such, this chapter reviews the established functions 
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for Sp11-182, as well as presents evidence indicating that Sp11-182 may be sufficient for 
maintaining centromere identity and function.            
 
Sp11-182 Is Sufficient for DNA Double-Strand-Break Repair 
 Recently, we showed that Sp1 is required for efficient site-specific DNA double-
strand-break repair. In response to ionizing radiation-induced DNA damage, Sp1 is 
phosphorylated by the DNA damage sensory kinase ATM at serine 101 and co-localizes 
with γH2AX (i.e. histone H2AX phosphorylated at serine 139 at sites of DNA damage) 
[384]. H2AX is a variant of histone H2A that is phosphorylated early by damage sensory 
kinases in response to DNA damage and is thus commonly used as a DNA damage 
marker. We demonstrated that depletion of Sp1 by RNAi inhibits repair of DNA double-
strand-breaks, similar to the effect of depletion of the MRN complex component Nbs1, 
demonstrating an important role for Sp1 in break repair. Interestingly, Sp11-182 alone 
localized to sites of DNA damage and appeared to be sufficient for rescuing the repair 
defect observed in Sp1-depleted cells [384].  
Current studies indicate that Sp1 modulates the chromatin surrounding break 
sites to allow for efficient repair. Depletion of Sp1 by RNAi resulted in loss of H4K18 
acetylation and an increase in H4K16 acetylation at break sites; these modifications are 
essential for double-strand-break repair by non-homologous end joining (NHEJ). This 
Sp1-mediated chromatin modulation was accomplished, at least in part, through Sp1-
dependent recruitment of the histone acetyltransferase p300 and HDACs to break sites. 
Remarkably, expression of Sp11-183 rescued the changes in histone modifications 
observed in Sp1-depleted cells and was sufficient for recruitment of p300 (Guo, 
Beishline, Azizkhan-Clifford, unpublished).   
 
Sp11-182 Is Sufficient for Centrosome Regulation 
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Centrosome amplification can lead to improper attachment of microtubules to 
kinetochores, and if not properly corrected, chromosome segregation errors. We 
previously showed that Sp1 localized to centrosomes and regulated centrosome 
number, as depletion of Sp1 by RNAi resulted in centrosome amplification. Sp1183-785 did 
not localize to centrosomes or rescue the supernumerary centrosome phenotype in Sp1-
depleted cells [7]. Recently, new data showed that Sp11-182 can localize to centrosomes 
and rescue the centrosome defects observed in Sp1-depleted cells (Flashner, Sowash, 
Azizkhan-Clifford, unpublished). The function of Sp1 at centrosomes is still not clear and 
requires further investigation.   
 
Sp11-182 Rescues Centromere Distance Phenotype  
 We have presented data showing that Sp11-182 localized to centromeres (Figure 
4.4C). To determine if Sp11-182 is functional at centromeres, we created four cell lines, 
including MCF 10A cells transduced with: control shRNA with pLXSN empty expression 
vector (cell line A), shRNA targeting the Sp1 transcript with pLXSN empty expression 
vector (cell line B), control shRNA with pLXSN-SP11-182-HA over-expression vector (cell 
line C), and shRNA targeting the Sp1 transcript with pLXSN-SP11-182-HA over-expression 
vector (cell line D). Immunoblotting was used to verify Sp1 protein knockdown and/or 
Sp11-182 over-expression in each cell line (Figure 5.2A). We next prepared chromosome 
spreads and evaluated metaphase stage cells for the centromere distance phenotype 
previously observed in Sp1-depleted cells (Figures 4.6A, 4.6B, and 4.6C). As expected, 
we observed a small but significant increase in the distance between CENP-A signals in 
cell line B as compared to cell line A. Over-expression of Sp11-182 alone did not affect the 
distance between CENP-A signals (cell line C compared to cell line A). Remarkably, 
Sp11-182 rescued the CENP-A distance phenotype observed in Sp1-depleted cells (cell 
126 
 
line D compared to cell line A) (Figure 5.2B and 5.2C). Thus, Sp11-182 localized to 
centromeres and was sufficient for the function of Sp1 at this region.       
 
Sp11-182 Rescues CENP-A Intensity Phenotype by Immunofluorescence Imaging 
 In addition to causing an increased distance between CENP-A signals, Sp1 
depletion also resulted in a decrease in CENP-A at centromeres (Figures 4.6D and 
4.6E). To determine if Sp11-182 is capable of rescuing this phenotype, the intensity of the 
centromeric CENP-A signals from the cell lines in Figure 5.2A were quantified using 
ImageJ. As expected, Sp1 depletion resulted in a decrease in CENP-A signal (cell line B 
compared to cell line A). Over-expression of Sp11-182 alone did not affect the intensity of 
the CENP-A signals (cell line C compared to cell line A). Remarkably, Sp11-182 rescued 
the CENP-A signal intensity phenotype observed in Sp1-depleted cells (cell line D 
compared to cell line A) (Figure 5.3). Thus, Sp11-182 localized to centromeres and was 
sufficient for function of Sp1 at this region.          
 
Sp11-182 Partially Rescues CENP-A Binding by Chromatin Immunoprecipitation 
To confirm the imaging data presented in Figures 5.2 and 5.3, chromatin 
immunoprecipitation experiments were performed using cell lines A, B and D. Antibodies 
against CENP-A and H3 were used for immunoprecipitation, and binding to core 
centromeres was determined using SimpleChIP® Human α-Satellite Repeat Primers. 
Comparison of the ratio of AS signal from CENP-A to H3 ChIP showed that there was a 
decrease in CENP-A binding to core centromeres in cell line B as compared to cell line 
A. Further, the decrease in CENP-A binding at centromeres was rescued by expression 
of Sp11-182 in cell line D as compared to cell line B (Figure 5.4). These data are 
preliminary, and experiments need to be repeated to confirm rescue and establish 
significance.   
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Conclusion 
 Within the context of DNA double-strand-break repair, Sp11-182 was capable of 
recruiting p300 to break sites to facilitate the chromatin remodeling required for efficient 
repair. Further, although the function of Sp1 at centrosomes is still unclear, Sp11-182 
localized to centrosomes and rescued the centrosomal defects observed in Sp1-
depleted cells. With the data presented in Chapters 4 and 5, we have shown that Sp11-
182 localized to centromeres (Figure 4.4) and partially rescued centromeric defects 
observed in Sp1-depleted cells. Implications of these findings are discussed in Chapter 
6.  
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Figure 5.1: Cleavage of Sp1 at Aspartic Acid 183 Stabilizes Sp1183-785. MCF 10A 
cells were transduced with full-length Sp1 (pLXSN-Sp1-HA), Sp1 in which aspartic acid 
is mutated to alanine (pLXSN-Sp1-D183A-HA), and the C-terminal cleavage product 
(pLXSN-Sp1183-785-HA). Then, cells were treated with 10 μM Adraimycin to induce DNA 
damage, and total cell lysates were collected at 12, 24, and 48 hours post treatment. 
The signal intensity of the HA tag from each cell line was quantified using ImageJ and 
normalized to α-tubulin loading control. Results suggested that non-cleavage Sp1 was 
less stable than full-length Sp1 and Sp1183-785.    
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Figure 5.2: Sp11-182 Rescues Centromere Distance Phenotype. (A) MCF 10A cells 
were transduced with: control shRNA with pLXSN empty vector (cell line A), shRNA 
targeting the Sp1 transcript with pLXSN empty vector (cell line B), control shRNA with 
pLXSN-SP11-182-HA over-expression vector (cell line C), and shRNA targeting the Sp1 
transcription with pLXSN-SP11-182-HA over-expression vector (cell line D). 
Immunoblotting was used to verify Sp1 protein knockdown and/or Sp11-182 over-
expression in each cell line. (B) The distance between CENP-A signals from (A) were 
measured using ImageJ and plotted. (C) Representative images from each cell line from 
(A).   
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Figure 5.3: Sp11-182 Rescues CENP-A Intensity Phenotype by Immunofluorescence 
Imaging. Intensity of the centromeric CENP-A signals from the cell lines in Figure 5.2A 
were quantified using ImageJ. As expected, Sp1 depletion resulted in a decrease in 
CENP-A signal (cell line A compared to cell line B). Over-expression of Sp11-182 alone did 
not affect the intensity of the CENP-A signals (cell line A compared to cell line C). 
Remarkably, Sp11-182 rescued the CENP-A signal intensity phenotype observed in Sp1-
depleted cells (cell line A compared to cell line D). 
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Figure 5.4: Sp11-182 Partially Rescues CENP-A Binding by Chromatin 
Immunoprecipitation. Chromatin immunoprecipitation experiments were performed 
using cell lines A, B, and D. Antibodies against CENP-A and H3 were used for 
immunoprecipitation, and binding to core centromeres was determined using 
SimpleChIP® Human α-Satellite Repeat Primers. Comparison of the ratio of AS signal 
from CENP-A to H3 ChIP show that there was a decrease in CENP-A binding to core 
centromeres in cell line B as compared to cell line A. Further, the decrease in CENP-A 
binding at centromeres was rescued by expression of Sp11-182 in cell line D as compared 
to cell line B. Normal rabbit IgG was used as a negative control.  
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Chapter 6: Discussion and Future Directions 
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Introduction 
The experiments presented in Chapter 4 demonstrate that transcription factor 
Sp1 localizes and binds to centromeres and pericentromeres during mitosis and that this 
interaction is not dependent upon the Sp1 zinc-finger, DNA-binding domain. This 
localization requires ATM activity, and knockdown of Sp1 protein results in a decrease in 
CENP-A and CENP-C at centromeres, as well as a potential centromeric cohesion 
defect. Finally, knockdown of Sp1 protein significantly changes histone modifications 
and the centrochromatin landscape. In a previous report [7], we demonstrated that Sp1 
depletion results in chromosome mis-segregation and W-CIN. Taken together with this 
newly identified function for Sp1, we believe that although transcription factor Sp1 likely 
maintains chromosomal stability through numerous mechanisms, maintaining 
centromere identity by regulating CENP-A deposition, centromeric transcription, and the 
centrochromatin landscape are likely contributing factors. The implications of these 
findings are discussed below. 
Within the context of DNA double-strand-break repair, the first 182 amino acids 
of Sp1 (Sp11-182) are capable of recruiting p300 to break sites to facilitate the chromatin 
remodeling required for efficient repair (Guo, Beishline, Azizkhan-Clifford, unpublished). 
Further, although the function of Sp1 at centrosomes is still unclear, Sp11-182 localizes to 
centrosomes and rescues the centrosomal defects observed in Sp1-depleted cells 
(Flashner, Sowash, Azizkhan-Clifford, unpublished). With the data presented in Chapter 
5, we shown that Sp11-182 localizes to centromeres and rescues some of the centromeric 
defects observed in Sp1-depleted cells. The implications of these findings are also 
discussed below. 
 
Discussion of Presented Results 
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Transcription Factor Sp1 Regulates the Centrochromatin Landscape and Centromeric 
Transcription During Mitosis: 
We show by immunofluorescence that Sp1 is absent from centromeres during 
interphase but transiently localizes and binds to centromeres during mitosis. More 
specifically, Sp1 localizes to all CENP-A containing regions by pro-metaphase, partially 
dissociating by anaphase, and completely dissociating by late anaphase or early 
telophase (Figure 4.1 and Figure 4.2); the timing is consistent with transcription through 
the core centromere [355]. Our cytological data is supported by ChIP experiments where 
we confirm that Sp1 binds to both AS DNA as well as surrounding pericentromeric 
heterochromatin (Figure 4.3A and 4.3B). Sp1 localizes to centromeres in all cell types 
examined, including several different human cell types and in mouse cells, illustrating 
that this phenomenon is conserved across different cell lines and may be conserved 
across species (Figure 4.1). This level of conservation indicates that Sp1 has an 
important function at centromeres during mitosis.   
The localization of Sp1 to centromeres is not dependent on its zinc-finger, DNA-
binding domain, which, within the context of gene transcription, binds to GC-rich Sp 
consensus sequences (Figure 4.4). This observation is consistent with the properties of 
the core centromere, composed of AT-rich repetitive AS arrays (Figure 2.3). Although it 
is not yet clear how Sp1 localizes to centromeres during mitosis, our data suggest that 
Sp1 is likely recruited as a component of a complex, where complex formation requires 
only Sp11-182 as this fragment alone is capable of localizing to centromeres. Additionally, 
ATM activity is required for rapid Sp1 localization, at least initially (Figure 4.5). ATM is 
best known for its role as a sensor for detecting DNA double-strand-breaks and 
subsequent activation of the DNA damage response [663]. In humans, loss of ATM 
causes Ataxia-Telangiectasia (A-T). Lymphoblastoid cells from A-T patients have 
defective spindle checkpoints as well as increased incidence of aneuploidy, suggesting a 
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role for ATM during mitosis [664-666]. It was recently shown that ATM is phosphorylated 
and activated by Aurora B kinase in a DNA damage-independent manner during mitosis, 
resulting in the phosphorylation and activation of other centromere associated proteins, 
including Bub1 and Mad1 [639]. We have not identified Sp1 as a direct target of ATM 
during mitosis, nor have we identified a phospho-residue required for Sp1 localization to 
centromeres. We confirmed that during mitosis Sp1 is not phosphorylated at serine 101 
(Figure 4.5C), an ATM-dependent modification that we and others have shown to be 
important for the repair of DNA double-strand-breaks [459, 462]. As ATM is an important 
signaling kinase in this and other cellular contexts, it will be interesting to determine if 
Sp1 is a direct target of ATM during mitosis or if ATM targets another signaling factor(s) 
required for Sp1 localization. 
Cells depleted of Sp1 protein by RNAi show a decrease in CENP-A at 
centromeres and a potential cohesion defect (Figure 4.6). When cellular DNA is 
replicated, CENP-A containing nucleosomes are diluted across both strands of DNA, 
and cells proceed through mitosis with only half the maximal number of CENP-A 
containing nucleosomes [285]. Then, new CENP-A is incorporated into centrochromatin 
in early G1, after CDK1 activity declines [667], a process vitally important for maintaining 
centromere identity and function. This is exemplified in studies demonstrating that 
depletion of CENP-A by RNAi results in centromere inactivation and chromosome mis-
segregation [668, 669]. Further, CENP-A over-expression is associated with several 
different types of cancer, including hepatocellular carcinoma [670], colorectal cancer 
[287], and lung adenocarcinoma [671]. These data suggest that CENP-A protein levels 
must be carefully regulated to maintain centromere identity in normally dividing cells. 
Upon Sp1 depletion, there is a 15.9% decrease in CENP-A signal intensity at 
centromeres in Sp1-depleted cells as quantified using ImageJ (Figure 4.6D). These 
cytological data are supported by ChIP experiments showing a similar decrease in 
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CENP-A binding to core centromeres in response to Sp1 depletion (Figure 4.6E). 
Although we identified two Sp binding sites within the distal and proximal promoter of the 
CENP-A gene, and confirmed that Sp1 binds to both of these sites (Figure 4.7A and 
4.7B), our CENP-A protein and CENP-A gene transcript studies in Sp1-depleted cells fail 
to show a significant decrease in total CENP-A protein levels and total CENP-A gene 
transcript levels, respectively, as compared to controls (Figure 4.7C and 4.7D). This 
confirms that the decrease in CENP-A at centromeres is not due to decreased CENP-A 
gene transcription as a result of Sp1 depletion within the time frame of our experiments. 
Additionally, CENP-A is an exceptionally stable protein, and thus the decrease at 
centromeres is unlikely due to normal protein turnover [642, 643]. Therefore, Sp1 
maintains CENP-A protein levels at centromeres, emerging as an important factor for 
preserving centromere identity and function.  
Recently, studies have shown that precise regulation of centromere-associated 
transcription is required for proper CENP-A deposition in G1 [337, 366]. Current models 
for CENP-A nucleosome assembly suggest that the centromere binding protein CENP-C 
recruits components of the Mis18 complex to centromeres, which in turn recruits the 
CENP-A chaperone protein HJURP to facilitate the exchange of H3 for CENP-A [306]. 
Core centromere-derived transcripts interact directly with CENP-C, HJURP, and CENP-
A, and loss of these transcripts prevents centromeric recruitment of these proteins. This 
results in loss of centromere identity, at least in part due to a decrease in CENP-A 
deposition, and chromosome mis-segregation [306, 361]. Studies have also shown that 
an increase in centromeric transcription can result in decreased CENP-A deposition at 
the centromere. Using human artificial chromosomes (HACs), one group showed that 
forcing a more open HAC centrochromatin conformation through histone acetylation 
resulted in an increase in centromeric transcription, coupled with a decrease in CENP-A 
loading and loss of kinetochore function [366]. In the tammer wallaby, hypermorphic 
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expression of centromeric RNAs also led to decreased CENP-A loading at centromeres 
[375], and in budding yeast, both increases and decreases in centromeric-derived 
transcripts results in chromosome mis-segregation [350]. These combined data suggest 
that precise regulation of centromere-derived transcription is required for proper CENP-A 
loading, centromere identity, and kinetochore function, and perturbations in transcript 
levels in either direction has detrimental effects on chromosome segregation. Here, we 
show that depletion of Sp1 by RNAi results in an increase in AS-derived lncRNAs and a 
concomitant increased binding of active RNA Polymerase IIpS5 at centromeres (Figure 
4.9A and 4.9C, and Figure 4.10, respectively). Over-expression of Sp1 has the opposite 
effect on transcription, resulting in a decrease in AS derived lncRNAs and a similar 
decrease in CENP-A binding at centromeres (Figure 4.9B and 4.9D, and Figure 4.11, 
respectively). Thus, Sp1 acts as a negative regulator of AS-derived lncRNAs during 
mitosis. As such, the increase in AS-derived lncRNAs in Sp1-depleted cells likely 
contributes to decreased CENP-C binding to centromeres (Figure 4.8) resulting in 
decreased CENP-A loading at centromeres (Figure 4.6E), implicating Sp1 as a critically 
important factor for regulating centromeric transcripts and thus downstream loading of 
CENP-A molecules in G1. This decrease in CENP-A at centromeres likely contributes to 
chromosome segregation errors in Sp1-depleted cells [7]. 
Centromeric histone modifications, or centrochromatin architecture, is also 
significantly altered in Sp1-depleted cells (Figure 4.12). During gene transcription, Sp1 
collaborates with and recruits chromatin modifiers and remodelers to gene promoters. 
Here, these enzymes modify histones to alter the chromatin structure, resulting in both 
positive and negative changes to gene transcription, depending on the context [388]. 
Thus, it is likely that Sp1 is acting to recruit enzymes to centromeres to down-regulate 
centromeric transcription. In other areas of the genome, Sp1 and HDAC1/2 interact to 
down-regulate genes, including SSeCKS (Src-suppressed C kinase substrate), hLHR 
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(human luteinizing hormone receptor), and hTERT (telomerase reverse transcriptase) 
[406, 410, 481]. Further, Sp1 interacts with DNMT1 to down-regulate expression of the 
MAZ (Myc-associated zinc-finger protein) gene [409]. HDAC1, HDAC2 (as a component 
of the mSin3 complex), and DNMT1 have all been shown to localize to metaphase 
centromeres. With the exception of mSin3 (discussed below), the function of these 
factors at centromeres is not yet determined [348]. We predict that Sp1 interacts with or 
recruits these or other chromatin remodeling/modifying factors to mitotic centromeres to 
regulate histone modifications and subsequently influence transcription of core 
centromeres.   
Our current understanding of the centrochromatin architecture indicates that the 
centrochromatin maintains a unique bivalent signature consisting of both 
heterochromatic modifications and transcription-coupled modifications. For example, the 
centrochromatin is enriched for H3K4me2 and H3K36me2, both modifications 
associated with transcription. H3K4me2 is often enriched at promoters of active genes, 
as well as at promoters of genes that are primed for future gene expression during cell 
development. H3K4me2 can also exist in large domains over both the gene promoter 
and the gene body, indicating that it may be a mechanism for fine-tuning gene 
expression [335]. H3K36me2 is highly enriched 3’ to open reading frames, and 
methylation of H3K36 is carried out by Set2, a conserved histone methyltransferase that 
specifically associates with elongating RNA Polymerase II [672, 673]. Although it is 
widely accepted that H3K36me2 is associated with active transcription, the mechanisms 
behind H3K36me2-dependent activation remain largely obscure [674-676]. Additionally, 
H2Bub1, a modification associated with active transcription of many genes, is associated 
with centromeres during the G2-M transition [340]. Conversely, the centrochromatin does 
not display other histone modifications typically associated with active transcription, 
including H3K4me3, acetylated H3K9, and acetylated H4K5, H4K8, H4K12, and H4K16 
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[334], indicating that the pattern of modification at this region is less clear and may not 
necessarily conform to “active” or “inactive” marks. We show that some of these histone 
modifications are disrupted in Sp1-depleted cells, supporting the notion that Sp1 may 
interact with chromatin remodeling/modifying factors to maintain centrochromatin 
epigenetics during mitosis. We observe an increase in the H2Bub1 to H2B ratio at 
centromeres (Figure 4.12A) and a decrease in the H3K4me2 to H3 ratio and H3K36me2 
to H3 ratio at centromeres (Figure 4.12B and Figure 4.12C, respectively) in Sp1-
depleted cells. The increase in the ratio of H2Bub1 to H2B may contribute to the 
increase in centromeric transcripts as this modification is associated with active 
transcription. The decrease in the ratio of H3K4me2 to H3 and H3K36me2 to H3 is 
surprising as this would typically indicate more tightly packed centrochromatin in the 
absence of Sp1 and thus a decrease in core centromere transcription. As our data 
shows the opposite effect, we believe these data highlight the complexity of histone 
modifications such as H3K4me2 and H3K36me2 at the centrochromatin.  
In an attempt to explain the increase in transcription in Sp1-depleted cells despite 
changes in histone modifications that might indicate the opposite effect, we evaluated 
centromeres for acetylated histones, and found a significant decrease in histone 3 
acetylated on lysine 9 (H3K9Ac) in Sp1-depleted cells (Figure 4.12D). Because 
centromeres are hypo-acetylated in normal cells, this specific change may not have a 
significant impact on centromere function. However, how changes in centrochromatin 
histone modifications affect transcription at centromeres has not been fully elucidated 
nor has how changes in some histone modifications may affect others. More information 
on the acetylation status of centromeric histones in Sp1-depleted cells will help to 
determine if Sp1 negatively regulates centromeric transcription though histone 
deacetylation.  
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The surrounding pericentromeric DNA is enriched for heterochromatic marks, 
including H3K9me2/3, H3K27me2/3, and H4K20me3 [343-345]. We did not see a 
change in the pericentromeric mark H3K9me2/3 (Figure 4.12E). This is consistent with 
Sp1 functioning primarily at the core centromere rather than at the surrounding 
pericentromeric region. However, because disrupted pericentromeric heterochromatin 
can affect centromere architecture and function [677], we plan to more thoroughly 
analyze pericentromeric heterochromatin marks in the context of Sp1 depletion.  
Taken together, the data presented in Chapter 4 indicate that Sp1 likely interacts 
with chromatin remodeling/modifying factors to modulate histone modifications and the 
centrochromatin architecture at centromeres, subsequently regulating transcription 
through this region. The resulting lncRNA transcripts maintain centromere identity and 
function by regulating the recruitment of centromere-associated proteins including 
CENP-C and CENP-A, both of which are vital for maintaining centromere identity. 
Disrupted centromere identity contributes to chromosome segregation errors and W-CIN 
(see our model in Figure 6.1). A more complete understanding of centrochromatin 
epigenetics, as well as what factors influence centrochromatin architecture, is required to 
confirm our model. 
Sp11-182 May Be Sufficient for Functional Centromeres: 
As discussed above, we hypothesize that Sp1 regulates the centrochromatin 
histone code, subsequently acting as a negative regulator of core centromeric 
transcription, thereby maintaining centromere identity and function. This is likely 
accomplished through Sp1-dependent recruitment of chromatin modifiers and/or 
remodelers to centromeres, although a specific enzyme(s) has not been identified. The 
data presented in Chapter 5 indicate that the N-terminal 182 amino acids may be 
sufficient for function of Sp1 at this region. This information may help us identify 
centromere-specific Sp1 interacting partners because it potentially limits candidate 
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enzymes to those that interact with Sp1 at its N-terminus. For example, HDAC1 has 
been shown to localize to centromeres, although its function at this region has not been 
characterized [348]. HDAC1 also interacts with Sp1 at promoters of a number of genes 
to deacetylate histones and down-regulate transcription [403-407], making HDAC1 an 
attractive candidate for an Sp1-dependent chromatin modifier at centromeres. However, 
HDAC1 reportedly interacts with the C-terminus of Sp1 in these cases and therefore 
may not interact with Sp11-182 directly [403]. This does not rule out the possibility that Sp1 
may interact with HDAC1 indirectly as a component of a larger complex of proteins 
where complex formation only requires amino acids 1-182. HDAC2, for example, 
interacts with Sp1 transactivation domains and therefore may interact with Sp11-182. 
HDAC2 is often found in complex with HDAC1, including in three major co-repressor 
complexes, Sin3, NuRD (nucleosome remodeling and deacetylation), and CoREST (co-
repressor for element-1-silencing transcription factor) [678]. Interestingly, in fission 
yeast, the Sin3 co-repressor Pst1p was shown to localize to centromeres and is required 
for maintaining low levels of acetylation at this region. Pst1p mutant cells show 
centromeric and chromosome segregation defects, including hyperacetylation, lagging 
chromosomes, and defects in sister chromatid cohesion [679]. The mammalian Sin3 
complex, mSin3, includes HDAC1, HDAC2, and RbAp48, among other proteins. Sp1 
was shown to direct the localization of the mSin3 complex to the hLHR promoter through 
its interaction with HDAC2 [410]. Further, although the mSin3 complex has not been 
identified as being targeted to centromeres, deletion of the mSin3 component mSds3 
results in defects in pericentromeric histone modifications and chromosome segregation 
errors [680]. Thus, although it is unlikely that Sp1 interacts with HDAC1 directly at 
centromeres, it may do so indirectly, possibly through HDAC2 and the mSin3 complex. 
Taken together, the data presented in Chapter 5 provide valuable information that can 
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be used for identifying potential Sp1 interacting partners at centromeres in an effort to 
gain a full understanding of its function at centromeres during mitosis.     
Current Model: 
  To ensure that chromosomes segregate faithfully during mitosis, CCAN proteins 
and kinetochore complexes must assemble properly at centromeres for correct 
attachment of chromosomes to spindle microtubules. Centromeres are identified by 
CENP-A containing nucleosomes, and defects in CENP-A deposition can result in 
disrupted CCAN and kinetochore assembly. CENP-A deposition is dependent on 
lncRNAs transcribed from core centromeres, and transcription through core centromeres 
is regulated by the centrochromatin architecture. The data presented in Chapters 4 and 
5 suggest that Sp1 regulates the centrochromatin architecture during mitosis, thereby 
regulating centromeric transcription,  subsequent assembly of the CCAN protein CENP-
C, and finally deposition of CENP-A at centromeres. This identifies Sp1 as an important 
upstream factor for centromere identity and function. This information is summarized in 
our model in Figure 6.1. 
 
Future Directions 
 Although the data presented in this body of work makes a strong case for Sp1-
dependent regulation of centromeric transcription, and therefore downstream deposition 
of CENP-A for maintaining centromere identity and function, there are significant 
unknowns in our model. Further, additional information is required to conclusively link 
the function of Sp1 at centromeres to chromosome instability as well as to implicate this 
function of Sp1 in cell transformation and cancer development. This section discusses 
future directions for this area of study, with the goal of filling these gaps and gaining a 
more complete understanding of the function of Sp1 at centromeres during mitosis.  
Identifying Sp1 Interacting Partners at Centromeres: 
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 Our studies indicate that Sp1 is a negative regulator of centromeric transcription 
during mitosis. We show that depletion of Sp1 results in a dramatic increase in 
centromere-derived lncRNAs (Figure 4.9A and 4.9C) as well as an increase in RNA 
Polymerase II, phosphorylated on serine 5, an indicator of active transcription (Figure 
4.10). Further, over-expression of Sp1 has the opposite effect, decreasing lncRNA 
expression (Figure 4.9B and 4.9D). It is well established that centromeres are 
transcribed during mitosis, although the timing of this transcription is slightly 
controversial (see review in Chapter 2). Some studies suggest that transcription of core 
centromeres peaks during metaphase, the stage at which Sp1 localizes to centromeres. 
Thus, though Sp1 appears to be acting as a negative regulator of transcription, it does 
not completely repress transcription, but may fine-tune expression, preventing over-
expression and reduced expression of lncRNAs, both of which are detrimental to proper 
mitoses. 
How Sp1 negatively regulates transcription at core centromeres is not clear. Sp1 
is most commonly known as a transcriptional activator. However, there are examples of 
Sp1 acting as a transcriptional repressor at other locations within the genome by 
recruiting histone deacetylases and DNA methyltransferases to gene promoters 
(discussed in Chapter 3). To understand Sp1 as a negative regulator of centromeric 
transcription, it will be necessary to identify the Sp1-dependent enzyme or enzymes 
required for this regulation. One potential candidate is the mammalian transcriptional co-
repressor mSin3. As discussed above, the Sin3 co-repressor Pst1p was shown to 
localize to centromeres in fission yeast and is required for maintaining low levels of 
acetylation at this region [679]. In mammalian cells, deletion of the mSin3 component 
mSds3 results in failure of pericentric histones to be deacetylated, thereby preventing 
the cascade of histone modification events required for the establishment of a functional 
pericentric heterochromatin structure [680]. mSin3 may act at both centromeres and 
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pericentromeres in an Sp1-dependent manner and merits further investigation. 
Alternatively, immunoprecipitation of Sp1 from an exclusively mitotic population of cells, 
coupled with mass spectrometry, could identify chromatin remodelers or modifiers that 
interact with Sp1 during mitosis and could therefore be candidate enzymes for regulators 
of Sp1-dependent histone modifications at centromeres. Once candidate interacting 
partners are identified, it must be shown that these factors localize to centromeres in a 
manner that is both spatially and temporally consistent with being recruited by Sp1 and 
also show that Sp1 knockdown prevents localization of these proteins. An experiment 
designed such that a candidate protein is artificially tethered to centromeres in the 
absence of Sp1, perhaps through creating a fusion protein with the CENP-B DNA-
binding domain, may add strength to these data, with the anticipation that artificial 
tethering will rescue phenotypes observed in Sp1-depleted cells.     
Linking Histone Modifications to Transcription: 
Although Sp1 depletion results in an increase in centromeric transcription, the 
alterations in histone modifications observed in Sp1-depleted cells do not align with 
transcriptional upregulation. For example, H3K4me2 and H3K36me2 are both histone 
modifications associated with active transcription. In Sp1-depleted cells, however, both 
of these modifications are decreased, which is what might be expected if Sp1 were 
acting as a positive regulator of centromeric transcription. Continuing to evaluate histone 
modifications in Sp1-depleted cells with the goal of identifying the aberrant 
modification(s) that contributes to up-regulation of centromeric transcription may help 
identify the enzymes responsible for normal maintenance of these modifications. For 
example, centromeres are hypo-acetylated, and an increase in histone acetylation in 
response to Sp1 depletion may explain the increase in transcription. Although we 
observed a decrease in H3K9Ac, investigating other acetylated residues by ChIP, such 
as those known to be low or absent at centromeres (see Figure 2.4), may provide 
145 
 
valuable information to this end. Studies in human artificial chromosomes have shown 
that increased acetylation results in an increase in core transcription and a coupled 
decrease in CENP-A assembly [366]. Further, studies in fission yeast have shown that 
treatment with the histone deacetylase inhibitor Trichostatin A (TSA) increases histone 
H3 and H4 acetylation at centromeres and causes chromosome segregation defects 
[681]. Within the context of DNA damage, Sp1 depletion results in an increase in 
H4K16Ac at DNA double-strand-breaks, and may have a similar effect at centromeres. 
Thus, a closer look at the acetylation status of centromeres in response to Sp1 depletion 
may help to determine the mechanism behind negative regulation of centromeric 
transcription by Sp1 as well as aid in identifying the Sp1-dependent enzymes 
responsible for maintaining the centrochromatin.  
Demonstrating a Decrease in CENP-A Over Time:  
 Our model suggests that Sp1 is required for downstream loading of new CENP-A 
molecules at centromeres after cells exit mitosis (Figure 6.1). Therefore, after Sp1 has 
been depleted, cells must continue to cycle through mitosis and into G1 in order to show 
the CENP-A phenotype. As such, for each subsequent cell cycle, centromeres will show 
a progressive decrease in CENP-A, as the cell continuously fails to load new CENP-A 
molecules. For experiments in which CENP-A levels were evaluated in Sp1-depleted 
cells, samples were collected 96 hours post infection. Although we have not specifically 
evaluated the cell cycle after lentivirus infection, it is likely that within this timeframe, 
cells cycle a very limited number of times. To support our model, it will be important to 
evaluate CENP-A levels at centromeres over an extended timeframe to see this 
expected progressive decrease in CENP-A at centromeres. Such an experiment will 
confirm our hypothesis that Sp1 is required for loading of new CENP-A molecules in G1.         
Completing the Sp11-182 Story: 
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The data presented in Chapter 5 indicate that Sp11-182 may be capable of 
rescuing some of the centromere phenotypes observed in Sp1-depleted cells. These 
phenotypes include the centromere distance phenotype (Figure 5.2) as well as the 
decrease in CENP-A at centromeres (Figure 5.3 and 5.4). These data indicate that the 
first 182 amino acids may be sufficient for function. Though meaningful, much work is 
needed to make these data relevant. First, the experiment presented in Figure 5.4 
requires repeating in order to establish significance. Next, the first 182 amino acids of 
Sp1 do not contain the sequence-specific DNA-binding domain. Therefore, how full 
length or Sp11-182 localizes to centromeres remains undetermined. One could postulate 
that Sp1 is recruited to this region as part of a larger complex, where complex formation 
requires only amino acids 1-182. Co-immunoprecipitation experiments using Sp11-182, 
coupled with mass spectrometry may provide clues as to how this occurs. Next, any 
centromere-specific chromatin modifiers or remodeling complexes identified as being 
Sp1-dependent should interact with and be recruited to centromeres by Sp11-182, either 
directly or indirectly. To conclusively determine that Sp11-182 is functional at centromeres, 
it will be important to show that Sp11-182 is capable of rescuing the changes in 
centromeric transcription observed in Sp1-depleted cells as well as binding of CENP-C 
and all aberrant histone modifications that result from Sp1 knockdown.   
Linking the Function of Sp1 at Centromeres to Chromosomal Instability: 
Throughout this body of work, we have linked the function of Sp1 at centromeres 
to W-CIN. We previously demonstrated that Sp1 depletion results in phenotypes 
consistent with W-CIN [7]. Here, we showed that Sp1 depletion results in decreased 
CENP-A loading at centromeres (Figure 4.6), which has been shown in other studies to 
cause segregation defects and W-CIN (discussed in Chapter 2). However, we have not 
directly shown an Sp1 depletion-dependent inactivation of centromeres as a result of 
decreased CENP-A loading and subsequent chromosome segregation errors. To 
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accomplish this, we would need to measure centromeric function directly within the 
context of Sp1 knockdown. This could be done by evaluating kinetochore assembly and 
the attachment of microtubules to kinetochores. Kinetochore assembly is often 
measured by evaluating the localization of outer kinetochore proteins using 
immunofluorescence, as the outer kinetochore assembles during mitosis. Defects in 
kinetochore assembly in Sp1-depleted cells would be identifiable by changes in the 
staining pattern of these proteins as compared to control cells. Further, attachment of 
microtubules to kinetochores could similarly be measured by immunofluorescence. Cells 
in which end-on kinetochore-microtubule attachments are disrupted would show fewer 
attachments as compared to control cells. W-CIN could be measured by fixing control 
and Sp1-depleted cells in anaphase and evaluating those cells for evidence of 
chromosome mis-segregation. To confirm that these defects are caused by loss of Sp1 
specifically at centromeres, and not from changes in Sp1-dependent transcription of 
other proteins, we would need to show that Sp11-182, or a DNA binding-deficient mutant 
of Sp1, is capable of rescuing kinetochore assembly errors, microtubule attachment 
errors, and W-CIN. Finally, as both increases and decreases in transcription of core 
centromeres is associated with chromosome segregation errors and W-CIN, a study 
correlating the rate of transcription of core centromeres in W-CIN positive and W-CIN 
negative cell lines with total Sp1 protein levels may provide important data in support of 
our model.  
Identifying Post-Translational Modifications Required for Localization:    
Sp1 is phosphorylated on several residues during mitosis, including serine 59 
(controversially; see Chapter 3), threonine 278, threonine 651, threonine 681, and 
threonine 739.  Threonine 651, 681, and 739 phosphorylation events likely decrease the 
DNA-binding affinity of Sp1 and stabilize Sp1 by preventing ubiquitination and 
degradation (discussed in Chapter 3). Interestingly, our data show that ATM kinase 
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activity is required for rapid Sp1 recruitment to centromeres, as specific inhibition of ATM 
by the small molecule inhibitor KU-55933 prevents localization (Figure 4.5). ATM is best 
known for its role in DNA double-strand-break repair, where it phosphorylates a variety 
of proteins involved in the DNA damage response [682]. Recently, ATM was shown to 
be activated by Aurora B kinase in a DNA-damage independent context during mitosis 
(discussed above). ATM preferentially phosphorylates substrates on serine or threonine 
residues that are followed by glutamine residues, called SQ/TQ, or S/TQ motifs [683]. 
Sp1 has 15 SQ/TQ motifs in total, 7 of which are immediately preceded by a 
hydrophobic residue, which is the preferred ATM phosphorylation site (Table 6.1) [683]. 
None of the residues identified as being phosphorylated during mitosis are SQ/TQ sites 
and thus are not likely phosphorylated by ATM. Of the 15 SQ/TQ sites, only serine 56 
and serine 101 have been identified as being phosphorylated by ATM (Table 3.1), and 
our data shows that Sp1 is not phosphorylated on serine 101 during mitosis (Figure 4.5). 
Although serine 56 is phosphorylated by ATM, we have not evaluated mitotic cells for 
this post-translational modification. Because ATM directly phosphorylates other 
centromere-associated proteins for localization to centromeres, it is possible that ATM 
phosphorylates Sp1 at serine 56 for recruitment to centromeres. This hypothesis has not 
yet been tested nor have we evaluated any other SQ/TQ sites, although this could be 
accomplished through mutagenesis. Additionally, although the data in Figure 4.5 are 
compelling, an experiment showing that ATM depletion by RNAi abrogates Sp1 
localization to centromeres, or the same study in ATM-null cells, would strengthen our 
conclusion.    
Effects of Sp1 Knockdown on the Chromosomal Passenger Complex: 
 The Chromosomal Passenger Complex (CPC) is a complex of proteins 
consisting of Aurora B kinase, INCENP (inner centromere protein), Borealin, and 
Survivin. During early stages of mitosis, the CPC localizes to chromosome arms and 
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centromeres as Aurora B kinase together with Plk1 phosphorylates arm sister-
chromatid-cohesin (SCC) complexes to allow for their dissociation from chromosomes. 
As the cell progresses into metaphase, localization is restricted to centromeres, where 
the CPC is thought to assist in recruiting other centromere-associated proteins (like SAC 
proteins [87] and Sgo1 [88]) as well as to assist in destabilizing incorrectly attached 
microtubules. When CPC function is compromised, a cell fails to detach incorrectly 
attached microtubules, resulting in an increased persistence of merotelic attachments 
and chromosome segregation errors. Failed CPC function also likely affects SCC at both 
chromosome arms and at centromeres. Sp1 transcriptionally regulates Survivin gene 
expression, and although it has not been specifically evaluated, changes in Sp1 protein 
levels likely also affect mitosis in a Survivin-dependent manner. Additional studies are 
needed to evaluate the impact of Sp1-dependent changes in Survivin levels on CPC 
activity during mitosis.  
Understanding the Centromeric Cohesion Defect in Sp1-depleted Cells: 
 One apparent phenotype upon Sp1 depletion is an increased distance between 
CENP-A signals as analyzed by IF (Figure 4.6C and Figure 5.2). These data suggest 
that Sp1 may be an important factor for maintaining centromeric sister chromatid 
cohesion at centromeres. In an attempt to begin to understand the relationship between 
Sp1 and SCC complexes, we have evaluated Scc1, Smc1, and Smc3 protein levels in 
Sp1-depleted cells to determine if Sp1 depletion results in a decrease in total cellular 
levels of SCC complex components. If so, this could explain the decrease in sister 
chromatin cohesion observed upon Sp1 depletion. Our data from a single experiment 
suggests that Scc1, Smc1, and Smc3 protein levels do not change significantly in Sp1-
depleted cells (Figure 6.2A). SA1/SA2 levels have not been evaluated. Additional 
experiments evaluating the effect of Sp1 depletion on SCC complex components is 
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necessary to conclusively determine if Sp1 depletion affects SCC complex component 
protein levels and thus SCC itself.  
 SCC complexes are known to play a role in transcriptional regulation by enabling 
the DNA-binding protein CTCF (CCCTC-binding factor) to protect gene promoters from 
distal enhancers, thereby acting as a transcriptional insulator [684]. Additionally, SCC 
complexes are also required for efficient repair of DNA double stranded breaks [685, 
686]. Further, SCC complexes are thought to maintain the connection between the two 
centrioles of a centrosome, and our previous work shows that Sp1 depletion results in an 
increase in the distance between centrioles as measured by IF [7], a phenotype similar 
to that seen at centromeres in Sp1-depleted cells. Because Sp1 is an integral 
component of both transcriptional regulation and efficient DNA double-strand-break 
repair, and because Sp1 localizes to both centrosomes and centromeres, it is possible 
that Sp1 regulates the localization and/or function of SCC complexes through a physical 
interaction. To begin to evaluate this possibility, we isolated mitotic cells by mechanical 
shake-off (Figure 6.2B) and used co-immunoprecipitation (Co-IP) to determine if Sp1 
interacts with Smc3 during mitosis. Our data show that Sp1 does not pull down Smc3, 
nor does Smc3 pull down Sp1 (Figure 6.2C). It would be compelling to determine if Sp1 
interacts with other SCC complex components during mitosis.  
Much about how SCC complexes are loaded and established at mammalian 
centromeres remains unclear. However, studies in yeast have indicated that the 
epigenetic state of centromeric and pericentromeric chromatin may play an important 
role. Fission yeast Swi6 (HP1) is required for heterochromatin formation at 
pericentromeres, as well as promoting sister chromatin cohesion, as Swi6 deficiency 
specifically disrupts cohesion at centromeres but not along chromosome arms [687-689]. 
Similarly, Sp1-dependent centrochromatin regulation may be required for proper 
establishment and/or maintenance of centromeric cohesion. The changes in histone 
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modifications observed in Sp1-depleted cells may prevent proper loading and/or 
establishment of sister chromatid cohesion and merits further investigation.   
During mitosis, sister chromatid cohesion is maintained at centromeres largely in 
part by phosphatase activity of the Sgo1-PP2A complex. Chromosome arm SCC 
complexes are removed at the beginning of mitosis by Plk1 and Aurora B kinase-
mediated phosphorylation; Sgo1-PP2A complexes maintain a hypo-phosphorylated state 
at centromeres, preventing premature SCC dissociation [70]. Centromeric localization of 
Sgo1 depends on histone H2A phosphorylation mediated by kinase Bub1 [690], as well 
as CPC localization [88]. As such, evaluating cells for Sp1 depletion-dependent changes 
Bub1 kinase localization, histone H2B phosphorylation status, and/or Sgo1 localization 
and function may reveal defects that contribute to the sister chromatid cohesion 
phenotype observed in Sp1-depleted cells.          
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Figure 6.1: Model. During mitosis, Sp1 localizes to centromeres and pericentromeres in 
a sequence independent manner. The mechanism by which Sp1 localizes to 
centromeres and pericentromeres is not known. Because binding at this region is not 
sequence dependent, Sp1 is likely either recruited to this region by an unknown factor 
(A,1a) or is recruited as a component of a complex that has yet to be identified (A,1b). 
At centromeres, Sp1 likely recruits chromatin modifiers or remodelers (A, 2) to maintain 
the histone modifications (A, 3) necessary for RNA Polymerase II-dependent 
transcription of core centromeres (B, 4). The lncRNA transcripts generated from RNA 
Polymerase II-dependent transcription (B, 5) ensure proper assembly of CCAN proteins 
like CENP-C (B,6), which is required for recruitment of the Mis18 complex (C, 7). The 
Mis18 complex recruits the CENP-A chaperone HJURP to centromeres (C, 8), which 
facilitates the exchange of histone H3 for CENP-A (D, 9), thereby maintain proper levels 
of CENP-A at centromeres, and thus centromere identity, preventing the chromosome 
mis-segregation events that lead to W-CIN (D, 10).   
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Figure 6.2: Understanding the Centromeric Cohesion Defect in Sp1-depleted Cells. 
(A) MCF 10A cells were transduced with control shRNA or shRNA targeting the Sp1 
transcript. Protein lysates were collected and evaluated for Sp1 protein levels to confirm 
protein knockdown, and for changes in Scc1, Smc1, and Smc3. Nucleolin was used as a 
loading control. Results show that Sp1 depletion has no effect on Scc1, Smc1, or Smc3 
protein levels. (B) Mitotic cells were isolated by mechanical shake-off. Both the mitotic 
population and the remaining interphase population of cells were lysed, and protein 
lysates were evaluated for cyclins to ensure the mitotic population of cells contained no 
interphase cells. (C) Mitotic lysates from (B) were used for co-immunoprecipitation, using 
Sp1 Ab581, Sp1 conjugated beads (Santa Cruz sc-59 AC) and Smc3 for pull-down. 
Immunoprecipitated lysates were analyzed by immunoblotting using Sp1 Ab581 and 
Smc3. Here, normal rabbit IgG was used as a negative control. Results show that Sp1 
does not co-immunoprecipitate with Smc3 in the mitotic population and vice versa.   
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Table 6.1: Sp1 SQ/TQ Sites. 
 
Sp1 SQ/TQ Site 
Residue with Preceding and Proceeding 
Amino Acids 
Serine 36 Phenylalanine-Serine-Glutamine 
Serine 56 Glutamic Acid-Serine-Glutamine 
Serine 81 Asparagine-Serine-Glutamine 
Serine 85 Proline-Serine-Glutamine 
Threonine 98 Alanine-Threonine-Glutamine 
Serine 101 Leucine-Serine-Glutamine 
Threonine 250 Glutamine-Threonine-Glutamine 
Serine 281 Serine-Serine-Glutamine 
Serine 291 Glycine-Serine-Glutamine 
Serine 296 Glycine-Serine-Glutamine 
Serine 313 Serine-Serine-Glutamine 
Serine 351 Asparagine-Serine-Glutamine 
Threonine 394 Glutamine-Threonine-Glutamine 
Threonine 427 Threonine-Threonine-Glutamine 
Serine 431 Isoleucine-Serine-Glutamine 
 
Residues highlighted in green are preferred ATM sites; the serine or threonine is directly 
preceded by a hydrophobic residue.  
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Chapter 7: Experimental Procedures 
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Cell Lines and Culture Conditions: MCF 10As (ATCC) were cultured in Dulbecco's 
Modified of Eagle's Medium/Ham's F-12 50:50 Mix (Cellgrow, Mediatech, Inc) 
supplemented with 5% fetal bovine serum (FBS; Gemini), 10 μg recombinant human 
epidermal growth factor (EGF; PeproTech), 250 ug hydrocortisone (Sigma), 5 mg insulin 
from bovine pancreas (Sigma), 50 μg Cholera Toxin from Vibrio cholera (Sigma), 100 
mg penicillin, and 60 mg streptomycin (Pen-Strep; Sigma). Sp1+/+ and Sp1-/- mouse 
embryonic fibroblasts (MEFs) have been previously described [636] and were kindly 
provided by Dr. G.Suske. MEFs, Normal Human Diploid Fibroblasts (NHDFs; ATCC), 
and human osteosarcoma cell line Saos-2 (ATCC), were cultured in Dulbecco's 
Modification of Eagle's Medium (DMEM; Cellgrow, Mediatech, Inc) supplemented with 
10% FBS. The retroviral packaging cell line 293-GPG (VSV-G) was maintained in 
DMEM supplemented with 10% heat-inactivated FBS, Pen-Strep, 1 μg/mL tetracycline, 2 
μg/mL puromycin, and 0.3 mg/mL G418. During production of lentiviruses, 293T cells 
were maintained in DMEM supplemented with 10% heat-inactivated FBS and Pen-Strep. 
All cells were maintained in a 37ᵒC humidified atmosphere with 5% CO2.   
 
Plasmids and Viral Infections: All vectors, including pLKO-shRNA control vector, 
pLKO-shRNA vector for Sp1, pLXSN empty vector, pLXSN-Sp1-HA, and pLXSN-Sp11-
182-HA (also known as pLXSN-Sp1-damage response domain), pLXSN-Sp1183-785-HA, 
and pLXSN-Sp1-D183A-HA were previously described [384]. Viral packaging vectors, 
pCMV-VSV-G, pRSV-Rev, and pMDLg/pRRE, were generously provided by M. Reginato 
(Drexel University College of Medicine, Philadelphia, PA). For lentivirus production, 293T 
cells were co-transfected for 6 h with 6 μg of pLKO vectors containing the shRNA 
sequences, along with 2 μg of each viral packaging component. Virus was collected 48 
and 72 hours post-transfection, and stored at -80ᵒC. For retrovirus production, 293-GPG 
cells were transfected with 10 μg pLXSN empty vector, pLXSN-Sp1-HA, or pLXSN-Sp11-
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182-HA plasmid using Gendrill transfection reagent (Bamagin) per manufacturer’s 
instructions. Virus was collected on days 6, 7, and 8 post-transfection, and stored at -
80ᵒC.  
 
Transduction of MCF 10A Cells: For protein knockdown or expression vectors: MCF 
10A cells were plated and treated with pLKO-shRNA control lentivirus, pLKO-Sp1 
shRNA lentivirus, pLXSN empty vector retrovirus, pLXSN-Sp11-182-HA retrovirus, pLXSN-
Sp1183-785-HA retrovirus, or pLXSN-Sp1-D183A-HA retrovirus at a concentration of 4 μL 
of virus per cell plated. A complete medium change was performed 16 hours post 
infection, and cells were used for experiments 96 hours post infection. For rescue 
experiments: MCF 10A cells were first treated with retroviral vectors as described above. 
24 hours after post infection, cells were infected with lentivirus as described above. Cells 
were used for experiments 72 hours post lentivirus infection.    
 
DNA Spreads and Immunofluorescence: Cells were treated with 100 mg/mL Colcemid 
(Sigma) for 4 hours, harvested, and pelleted at a concentration of 80,000 cells/mL. Then, 
cell pellets were resuspended in hypotonic solution (10 mM Hepes pH 7.3; 2% FBS; 30 
mM Glycerol; 1.0 mM CaCl2; 0.8 mM MgCl2) and incubated at 4ᵒC for 15 minutes. DNA 
spreads were prepared using a Shandon Cytospin 3 (2000 rpm for 20 minutes at room 
temperature), and fixed in 100% methanol for 30 minutes at -20ᵒC, rehydrated in 
acetone for 30 seconds at -20ᵒC, then dried at room temperature. For 
immunofluorescence: dried DNA spreads were rehydrated in 1xPBS with 0.01% sodium 
azide for 5 minutes. Slides were washed 3 times for 1 minute each in TTB solution (1.0 
mM Triethanolamine:HCl pH 8.5; 0.2 mM Na-EDTA; 25 mM NaCl; 0.1% Triton-X 100; 
0.1% BSA, Gemini), then incubated with primary antibodies diluted in TTB solution for 30 
minutes at 37ᵒC. Slides were washed for 2, 5, then 3 minutes with 1xKB solution (10 mM 
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Tris:HCl pH 7.7; 0.15 M NaCl; 0.1% BSA), then incubated with secondary antibodies 
diluted in 1xKB solution for 30 minutes at 37ᵒC. Slides were washed with 1xKB solution 
for 5 minutes, then with 1xPBS solution for 5 minutes. Coverslips were applied using 
VectaMountTM AQ (Vector Laboratories, Inc). Images were collected using an Olympus 
AX-70 compound microscope, and iVisionTM Scientific Image Process software by 
BioVision Technologies. For KU-55933 treatment: MCF 10A cells were incubated with 
KU-55933 (Tocris) or DMSO (Sigma) for indicated time. Primary antibodies: Sp1 H225 
(Santa Cruz sc-14027, 1:200), CENP-A (Abcam ab13939, 1:200), CREST 
(ImmunoVision HCT-0100, 1:200), HA (Cell Signaling 2367, 1:500). Secondary 
antibodies: Donkey anti-Rabbit IgG (H+L) Secondary Antibody, Alexa Fluor® 488 
conjugate (A21206, 1:1000), Donkey anti-Mouse IgG (H+L) Secondary Antibody, Alexa 
Fluor® 594 conjugate (A21203, 1:1000). DNA stain: DAPI (Sigma). 
 
Western Blotting: For Western blot analysis, cells were directly lysed in 2x SDS sample 
buffer (12.5 mMTris pH 6.8; 20% glycerol; 4% SDS). Proteins were separated by 
traditional SDS-PAGE, transferred to a polyvinylidene difluoride (PVDF) membrane, and 
analyzed by immunoblotting with the following antibodies, diluted in TBST with 5% BSA: 
Sp1 Ab581, (1:500 [381]), Sp1p101 (1:500, [384]), Sp1 H225 (Santa Cruz sc-14027, 
1:200), Sp1 pre-conjugated beads (Santa Cruz sc-59 AC),  CENP-A (Abcam ab13939, 
1:1000), CENP-C (Abcam ab196666, 1:1000), H2Bub1 (Cell Signaling 5546, 1:1000), 
H3K36me2 (Abcam 9049, 1:1000), H3K9me2/3 (Cell Signaling 5327, 1:1000), H3K4me2 
(NeoBioLab A2356, 1:500), H3K9Ac (Cell Signaling 9649, 1:1000), HA (Cell Signaling 
3724, 1:1000), pChk2 Thr68 (Cell Signaling 2661,1:1000), Chk2 (Cell Signaling 3440, 
1:1000), Cyclin-B1 (Santa Cruz sc-245, 1:500), Cyclin-D (Santa Cruz sc-753, 1:500), 
Cyclin-E (Santa Cruz sc-198, 1:500), Cyclin-A (Santa Cruz sc-239, 1:500), Scc1 (Abcam 
ab992, 1:500), Smc1 (Bethyl A300-055A, 1:500), Smc3 (Bethyl A300-060A, 1:500), actin 
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(Santa Cruz sc-1615, 1:2500) α-tubulin (GeneTex GTX27291, 1:3000), Nucleolin (Santa 
Cruz sc-8031, 1:500) 
 
Chromatin Immunoprecipitation: Cells were cross-linked with 1% formaldehyde while 
rocking for 15 minutes. Reaction was quenched by the addition of 125 mM glycine for 5 
minutes, cells were then scraped and collected in 1xPBS with protease and 
phosphatase inhibitors. Cell pellets were lysed in 1 mL cell lysis buffer (5 mM PIPES, pH 
8.0; 85 mM KCl; 0.5% NP-40; plus protease and phosphatase inhibitors), then in 1 mL 
nuclei lysis buffer (50 mM Tris-HCl pH 8.0; 10 mM EDTA; 1% SDS; plus protease and 
phosphatase inhibitors). Chromatin was sheared by sonication using a Branson 
sonicator at 50% duty for a total of 30 seconds at pulsed intervals. Protein was 
quantified using a standard bicinchoninic acid (BCA) assay. A total of 5% of the lysate 
was reserved, and genomic DNA was isolated as input. Equal amounts of the remaining 
lysate was aliquoted and used for immunoprecipitation with CENP-A (Abcam ab13939), 
CENP-C (Abcam 196666 and a gift from Dr. Andrea Musacchio, Ph.D [321]), H3 (Cell 
Signaling 2650), H2Bub1 (Cell Signaling 5546), H2B (Millipore 07-371), H3K4me2 
(NeoBioLab A2356), H3K36me2 (Abcam 9049), H3K9me2/3 (Cell Signaling 5327), 
H3K9Ac (Cell Signaling 9649), RNA Polymerase II pCTD Ser5 (Abcam ab5095) and IgG 
(Abcam ab46540) antibodies. Antibodies were pre-incubated with protein A/G agarose 
beads (Santa Cruz sc-2003). All beads were pre-blocked with 1 mg/mL low IgG BSA and 
1 mg/mL tRNA (Sigma) prior to immunoprecipitation. Immunoprecipitated chromatin was 
isolated overnight, then beads were washed 4 times in high salt wash buffer (50 mM 
HEPES pH 7.9; 250 mM NaCl; 1 mM EDTA; 0.1% SDS; 1% Triton X-100; 0.1% 
Deoxycholate; plus protease and phosphatase inhibitors). DNA was treated with 10% 
Chelex resin (BioRad), 10 mg/mL RNAse A (Qiagen), and 20 μg/mL Proteinase K 
(Ambion), then collected. Input chromatin was treated with 10% Chelex resin, 10 mg/mL 
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RNAse A, and 20 ug/mL Proteinase K, then precipitated using 100% ethanol. Dry pellets 
were resuspended clean water. Analysis of protein binding at specific locations was 
assessed by SYBR green (Bio-Rad) quantitative PCR (qPCR) using a Bio-Rad CFX-96 
real-time PCR detection system.  Refer to Table 1 for primer information. 
 
Co-Immunoprecipitation: Mitotic MCF 10A cells were isolated by mechanical shake-off 
as described in [691]. Then, cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.4; 
1% NP-40; 120 mM NaCl; 0.25% Deoxycholic Acid; 1 mM EDTA; plus protease and 
phosphatase inhibitors). Cell lysates were pre-cleared by incubation with a 50% protein 
A/G agarose bead slurry (Santa Cruz sc-2003) for 2 hours with rotation at 4C. Pre-
cleared samples were centrifuged, and cell lysate supernatants were transferred to a 
fresh tube. After quantifying lysates by BCA assay, a portion of the total sample was set 
aside to be used as the input control, then equal amounts of the sample were incubated 
with the appropriate antibody for 2 hours with rotation at 4C to allow antibody-antigen 
complex formation. Antibody concentrations used were based on manufacturer’s 
recommendation. Then, a 60% protein A/G agarose bead slurry was added to each 
sample, and incubated for 4 hours with rotation at 4C to allow the antibody-antigen 
complex to conjugate to the beads. Beads were washed twice with a wash buffer (50 
mM Tris-HCl, pH 7.4; 1% NP-40; 1% Triton-X; 250 mM NaCl; 0.25% Deoxycholic Acid;  
1 mM EDTA; plus protease and phosphatase inhibitors), then resuspended in 70 μL of 
2x SDS sample buffer (12.5 mMTris pH 6.8; 20% glycerol; 4% SDS). Samples were 
boiled at 100C for 5 minutes, then cooled at 4C for 5 minutes, then loaded onto an SDS-
PAGE gel for analysis by western blot, along with a 10% input control. Antibodies used: 
Sp1 Ab581, Sp1 pre-conjugated beads (Santa Cruz sc-59 AC), Smc3 (Bethyl A300-
060A) and IgG (Abcam ab46540). 
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RNA Isolation, cDNA Synthesis and Quantitative PCR: RNA was extracted from MCF 
10A cells using the Qiagen RNeasy® Mini Kit, per manufacturer’s instructions. RNA was 
reverse transcribed using the qScriptTM cDNA Supermix (Quanta Biosciences). PCR was 
performed using SYBR green (Bio-Rad) quantitative PCR (qPCR) using a Bio-Rad CFX-
96 real-time PCR detection system. Refer to Table 1 for primer information.   
 
Sp1183-785 Stabilization Experiment: MCF 10A cells were plated and infected with 
pLXSN empty vector retrovirus, pLXSN-Sp11-182-HA retrovirus, pLXSN-Sp1183-785-HA 
retrovirus, or pLXSN-Sp1-D183A-HA retrovirus as described above. Treated each cell 
line with 10 μM Adriamycin, then collected cell lysates in 2x SDS sample buffer at 12, 
24, and 48 hours post treatment. Proteins were separated by traditional SDS-PAGE, 
transferred to a polyvinylidene difluoride (PVDF) membrane, and analyzed by 
immunoblotting with the following antibodies, diluted in TBST with 5% BSA: Sp1 Ab581, 
HA, and α-tubulin. The HA signal and the α-tubulin signal from each cell line were 
quantified using ImageJ, and the change in HA signal over time was determine as a ratio 
of HA to α-tubulin control. Then, results were normalized to ratios from untreated 
controls.       
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